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Abstract 
Cancer is uncontrolled cellular proliferation devoid of normal biological regulatory 
mechanisms.  Therapeutic treatment of cancers relies on overcoming such proliferation, 
to allow cytotoxic destruction of cancer cells.  Many of the recent therapeutic 
breakthroughs have been in the targeting of various blood cancers: eg imatinib has 
effectively eradicated chronic myeloid leukaemia (CML) morbidity.  However, acute 
myeloid leukaemia (AML) remains essentially incurable for the vast majority of patients.  
The current gold-standard treatment for AML has remained relatively unchanged for 
decades, consisting of the antimetabolite cytarabine (ara-C) and the anthracycline 
cytotoxic antibiotic daunorubicin (DNR). The cytoprotective gene haem oxygenase-1 
(HO-1) has been found regulated in various forms of cancers (including AML) and 
implicated in chemotherapeutic drug-resistance. HO-1 protects AML cells from induced 
apoptosis via its transcription factor nuclear factor erythroid-derived 2-like 2 (Nrf2). We 
show a role for HO-1 in regulating apoptosis in AML cells in response to ara-C and DNR. 
HO-1 expression was increased in response to both cytotoxic agents.  Upon micro RNA 
(miRNA) silencing of HO-1 expression, both ara-C and DNR stimulated greater apoptotic 
responses in these silenced AML cells. A concurrent induction in reactive oxygen 
species (ROS) generation was observed. Studies with ara-C-resistant AML cell lines 
(THP1araC(1)) showed there to be significantly suppressed levels of Nrf2 and HO-1.  A 
miRNA screen in these resistant cells revealed reduced basal miR-196a expression.  
One of miR-196a’s targets is the Nrf2-inhibitory protein Bach1 (BTB and CNC homology 
1), which was found to be elevated in these cells.  Exogenous replacement of miR-196a 
with the introduction of a miR-mimic, suppressed the Bach1 overexpression, elevated 
HO-1 expression, and reintroduced sensitivity towards ara-C. These findings suggest 
HO-1 inhibition in conjunction with chemotherapy would improve the number of cases 
who reach complete remission (CR).   
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Chapter 1: Introduction  
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1.1 Cancer Biology 
Cancer affects approximately one in three people living in the United Kingdom (UK) at 
some point during their life time. There are approximately 200 different types, of which 
breast, lung, colorectal and prostate account for over half of all cases reported in the 
clinic [1].  It is a genetic disease which results from a number of genetic alternations 
leading to uncontrollable cell proliferation.  
 
1.2 Blood cancer 
There are three main general types of blood cancer, namely leukaemia, lymphoma and 
myeloma – each of these depends on the stage of development of the haematopoietic 
stem cell (HSC) at which the cancerous phenotype emerges [2]. Lymphomas are 
characterised by the lymphoid cancerous cell residing in the lymphatic system and 
lymph glands. Myelomas are characterised as cancerous white blood cells that are 
plasma cells in nature.  These plasma cells are the active B-cells which are the antibody-
producing cells found in the normal immune system. Leukaemia’s are the remainder of 
blood cancers where the primary cancerous tumour resides in the bone marrow stem 
cell niche environment. Leukaemia’s are divided into myeloid and lymphoid types (see 
Figure 1.1), of which both are further subdivided into subtypes dependent on the 
aggressiveness of the condition. There are acute and chronic types which indicate the 
indolence of the disease progression and the severity and aggressiveness of the 
cancerous cell type. The general symptom profile of these blood cancers is that the 
cancerous cell phenotype, overwhelms the normal immune system profile, and leads to 
gradually reduced immune system function.  The inability to elicit a normal physiological 
immune response means that tissue damage remains unrepaired and infection becomes 
far more life threatening. 
  
1.2.1 Lymphoma 
Lymphomas are a large range of individual cancers that affect the lymphatic system and 
resultant immune responses.  The lymphoid nature of the cancer cell usually resides in 
the lymph nodes, but can affect other parts of the body including the spleen and bone 
marrow.  Fever, lethargy, weight loss and night sweats are common symptoms of 
lymphoma diseases.  The major classes of lymphomas are Hodgkin’s lymphoma and 
Non-Hodgkin’s lymphoma, although follicular, mantle cell, and diffuse large B-cell 
lymphomas are other major types.  The treatment of lymphomas has improved of late by 
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the introduction of the CD20 antigenic monoclonal antibody, rituximab.  Lymphomas 
generally respond well to chemotherapies. 
 
 
 
 
Figure 1.1. Production of blood cells by the bone marrow. The appearance of each 
precursor is the same for simplicity. The undifferentiated Pluripotent Hematopoietic Stem 
Cells are able to give rise to precursors of each of the blood cells. The first division 
results in either Lymphoid or Myeloid Stem Cells. Which become further differentiated 
upon division. Diagram adapted from Widmaier et al (2006) [3]. 
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1.2.2 Myeloma 
Myeloma starts in the bone marrow, but ultimately affects the plasma B-cells responsible 
for antibody generation. The main types of myeloma are plasmacytoma, localised 
myeloma and extramedullary myeloma, however over 90% of all myeloma cases are of 
multiple myeloma (MM), meaning that it affects more than one location in the body. 
 
1.2.2.1 Multiple Myeloma 
Multiple Myeloma (MM) is a B-cell malignancy which is the second biggest blood cancer 
accounting for 1% of all cancers diagnosed.  Currently there is no treatment that can 
cure MM. It is characterised by the presence of excess monotypic plasma cells in the 
bone marrow and excess monoclonal protein in the patients’ serum or urine. Even with 
high dose chemotherapy, MM remains relatively incurable due to acquired drug 
resistance [4]. When high dose chemotherapy or stem cell transplantation is deemed 
inappropriate, an immunomdulating drug such as thalidomide or its newer analogue 
lenalidomide, in combination with an alkylating agent for example melphalan and a 
corticosteroid usually dexamethasone (which suppress the corticotrophin secretions [5] 
are first-line treatment options. If thalidomide is not appropriate then the proteasome 
inhibitor bortezomib can be used instead [6].  
 
1.2.3 Leukaemia 
Leukaemia is a term used to encompasses both cancers of the bone marrow and blood 
which can be characterised by an increase in leukocyte cell proliferation and failed pro-
apoptotic responses to abnormal cells [7]. It is then clinically divided into ‘acute’ and 
‘chronic’. Further sub division is dependent on the hematopoietic lineage affected usually 
myeloid or lymphoblastic [8]. The four key types of leukaemia are Chronic Lymphoblastic 
Leukaemia, Acute Lymphoblastic Leukaemia, Chronic Myeloid Leukaemia and Acute 
Myeloid Leukaemia.   
  
1.2.3.1 Chronic Lymphoblastic Leukaemia 
Chronic Lymphoblastic Leukaemia (CLL) is the most common type of leukaemia 
although it is highly indolent and often sufferers remain without severe symptoms for 
many years.  Many of those with CLL will be monitored without treatment. However, if 
the disease progresses, first-line treatment consists of rituximab in combination with both 
fludarabine and cyclophosphamide if deemed appropriate. Rituximab a chimeric 
5 
 
monoclonal antibody binds to the CD20 antigen expressed on the cell surface of mature 
B lymphocytes and tumour cells [9]. Rituximab is also used in relapsed or refractory CLL 
[10].  
 
1.2.3.2. Acute Lymphoblastic Leukaemia 
Acute Lymphoblastic Leukaemia (ALL) is the most common form of cancer found in 
children.  The majority of people with ALL are juveniles and as such, can tolerate high 
dose chemotherapeutic regimes that lead to good disease eradication.  Many of the 
most dangerous types of childhood cancer cases are of AML type origin or of mixed 
lineage.  Adults with ALL fair worse than juveniles with ALL, purely due to a juvenile’s 
ability to withstand very toxic high dose treatments. 
 
1.2.3.3 Chronic Myeloid Leukaemia 
95% of Chronic Myeloid Leukaemia (CML) cases are characterised by the presence of 
the BCR-ABL fusion gene which is due to a reciprocal translocation between 
chromosomes 9 and 22, producing the cytogenetically shortened chromosome 22 also 
known as the Philadelphia chromosome [11]. The Philadelphia chromosome is present 
in 95% of CML patients, a third of ALL patients and occasionally present in AML patients 
[12]. The resultant BCR-ABL protein possess increased tyrosine kinase activity which 
results in either increased proliferation or decreased apoptosis of haematopoietic stem 
cells or progenitor cells which eventually results in increased myeloid cells, premature 
release of immature myeloid cells and genetic instability which results in CML disease 
progression. The Tyrosine Kinase Inhibitor (TKI) imatinib, inhibits the BCR-ABL tyrosine 
kinase. Imatinib has significantly improved long term survival in CML patients and is 
used as a first line treatment for chronic phase Philadelphia-chromosome positive CML 
or an option for patients presenting with either accelerated or blast phase CML [13]. 
However a number of patients have developed resistant to imatinib thus paving the way 
for more potent TKI development [14]. Even though the mechanisms of action behind 
imatinib resistance are not fully understood, 66% of imatinib-resistant patients possess 
mutated BCR-ABL sequences [15]. The BCR-ABL Philadelphia chromosome is 
composed of an ATP-binding P-loop and another larger activating loop. Two thirds of 
imatinib resistant patients possess mutations in the ATP binding portion of the BCR-ABL 
Philadelphia chromosome [15]. Treatment options include an allogeneic haematopoietic 
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stem cell transplant [16] or a secondary generation TKI for example dasatinib or nilotinib 
depending on the mutation present [14].  
 
 
 
Figure 1.2. Philadelphia chromosome (Bcr-Abl). (A) Diagrammatic representation of 
the domains of BCR-ABL including the domains: OLI (oligomerization); S/TK 
(serine/threonine kinase); CAP (myristoylated (Myr) site found in normal ABL that binds 
the kinase domain to confer auto-inhibition – this region is truncated and replaced by 
BCR in the Philadelphia chromosome); SH2 (phosphotyrosine-binding); SH3 (Pro-X-X-
Pro –binding motif for protein-protein interactions); DNA- and actin-binding motifs (DB 
and AB respectively) and nuclear localization sequences (NLS). Expanded region shows 
the P-, C- and A (activation)-loops and SH2-binding motifs.  Indicated by the arrows are 
the commonly found mutations of BCR-ABL identified in the clinic; the most common of 
which are highlighted in bold (*) and their position is also indicated on the 3-dimensional 
representation (B).  This diagram also shows the kinase active site and the molecular 
sites on BCR-ABL that are targeted by CML treatments. 
 
1.2.3.4 Acute Myeloid Leukaemia  
Acute Myeloid Leukaemia (AML) accounts for approximately 1% of all cancer deaths, it 
is a malignancy of the haematopoietic progenitor cells [7]. AML incidence is increasing 
with age, particularly with an aging population therefore the number of new cases is 
expected to increase. The median age at diagnosis is 66 years [17]. Risk factors for AML 
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include exposure to ionising radiation, benzene and cytotoxic chemotherapy. Between 
10 and 15 % of AML patients have previously received cytotoxic chemotherapy [7]. 
However less than 10% of patients over 60 are expected to survive the intense 
treatment regime. 
 
An induction regime aims to reduce the tumour burden thus allowing the patient to reach 
Complete Remission (CR) [18].  CR is defined as less than 5% leukemic blast cells in 
the patient’s bone marrow and normalisation of peripheral blood counts [18]. Currently 
the standard induction treatment for younger fitter patients consists of the antimetabolite 
cytarabine (ara-C; 100mg/m2) administered via intravenous infusion over seven days 
plus the anthracycline antibiotic daunorubicin (DNR; 45-60mg/m2/d) administered 
intravenously for three days [5, 19, 20].  
 
Patients who go into remission would normally receive consolidation therapy with either 
high dose ara-C or an allogeneic stem cell transplant dependant on their 
clinicopathological characteristics. Despite these intensive treatment strategies, a 
significant number of patients relapse and only approximately 50% of younger fitter 
patients can be cured. Patient treatment outcomes are dependent on a variety of clinical 
and biological factors including cytogenetics, age and drug-resistance [19, 21-23].  
 
Table 1.1: Treatment strategies used in AML treatment. Table adapted from Tallman 
et al (2005) [19] 
 
Stage  Treatment Options 
Induction   Ara-C 100mg/m2  infused over 7 days  
                              +  
 DNR 45-60mg/m2 daily for three days 
Remission 
 
 
Consolidation 
Therapy 
 High dose ara-C 
 Allogeneic stem cell transplant 
Relapsed 
or 
Refractory 
AML 
  Chemotherapy 
 Allogeneic transplantation 
 Autologous transplantation 
 Palliative care 
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Palliative care is provided when advanced progressive disease is present. It 
encompasses management of a patients pain and any other symptoms which they may 
be experiencing for example constipation, depression, xerostomia or nausea and 
vomiting and also providing psychological, social and spiritual support [24].   
 
1.2.3.4.1 Acute Promyelocytic Leukaemia  
The AML subtype, Acute Promyelocytic leukaemia (APL) is at current the most curable 
form of AML. It is identified by a t(15;17) translocation causing a fusion transcript, known 
as the promyelocytic leukaemia retinoic acid receptor α (PML-RARX). Current treatment 
for APL consists of targeting the above genetic mutation using all-trans retinoic acid [19, 
25, 26]. 
 
1.3.1 AML Treatments 
AML 17 trial sponsored by Cardiff University is suitable for the inclusion of AML and high 
risk Myelodysplastic syndrome patients between the ages of 18 and 60 years. Patients 
over the age of 60 can also be included if intensive therapy is deemed appropriate. AML 
17 is a randomised, controlled, open label phase III trial. There are two distinct sections; 
(A) Patients with AML or high risk myelodysplasia and (B) Patients with APL. The trial 
aims to explore (A) Five different induction chemotherapy schedules (B) CEP-701 a 
FLT3 inhibitor and its benefit in treating patients with Fms-Like Tyrosine Kinease (FLT3) 
activating mutation (C) mTOR inhibition in patients negative for either the FLT3 mutation 
or Core Binding Leukaemia (CBF) And  high risk patients (D)  Comparing the number of 
treatment course (three verse four) and (E) High risk patients (1) benefit of DNR/ 
Clofarabine versus standard FLAG-ida; composed of idarubicin, fludarabine, ara-C and 
granulocyte-colony stimulating factor (2) allogeneic stem cell transplantation [27].    
 
There are two type of FLT3 activating mutation present which have been identified.  
CBF leukaemia possess either a t(8;21) or inv(16)/t(16;16) balance chromosomal re-
arrangement which results in the production of a fusion transcript either called AML1-
ETO or CBFβ-MYHII [27]. 
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1.3.1.1 Cytarabine  
Cytarabine (ara-C) its chemical name 1-β-D-arabinofuranosylcytosine and also known as 
cytosine arabinoside, cytarabine hydrochloride and arabinofuranosyl. It is usually 
administrated alongside the anthracycline antibiotic, daunorubicin (DNR) in AML 
treatment. It is administered to the patient either subcutaneously, intravenously or 
intrathecally. As with any drug, cytarabine has a number of associated side effects which 
are also common to other chemotherapeutic agents. These are oral mucositis, tumour 
lysis syndrome, hyperuricaemia, local tissue necrosis if ara-C leaks into the 
extravascular compartment whilst being administered, nausea and vomiting, alopecia, 
bone marrow suppression and thromboembolism [5]. 
 
After rapid IV injection ara-C plasma concentration declines in a biphasic manner. 
During the initial phase its half-life is 10 mins and then increases to between 1-3 h in the 
terminal phase. However, when ara-C is administered intrathecally its half-life is 
increased to approximately 2 h. It is predominately excreted by the liver and to a lesser 
extent the kidneys, gastro intestinal mucosa and granulocytes where it is converted into 
ara-U and eventually excreted in the urine of which 10% remains unchanged. Between 
70 and 80% of the original ara-C dose is excreted within 24 hours of administration [28, 
29]. 
 
Ara-C is a antimetabolite analogue of cytidine, which possess an arabinose sugar 
moiety. Allowing it to compete with cytidine, for incorporation into DNA. Due to the 
sterical hindrance from the arabinose sugar, DNA replication is inhibited during S phase 
[30] thus it is known as a S phase specific drug,[31] which eventually leads to chromatid 
breakage [32]. Ara-C is phosphorylated into ara-C triphosphate (ara-CTP) its active 
metabolite, by deoxycytidine kinase (dCK) [33]. Which goes onto to inhibit DNA 
replication [34] by inhibiting cytidine disphosphate [35]. ara-C monophosphate (ara-
CMP) is further phosphorylated by pyrimidine nucleoside monophosphate into ara-CDP 
and then subsequently phosphorylated into ara-CTP by diphosphate kinases [36]. ara-
CTP is metabolised  into its inactive form, uracil arabinoside (ara-U) by cytidine 
deaminase (CDA)  [37, 38].  
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Figure 1.3. Cytarabine (ara-C) metabolism. Initally ara-C is transported into the cell, 
dCK phosphorylates ara-C into ara-CMP. dCK is controlled by a negative feed back 
mechanism involing dTTP and dCTP. Ara-CMP is subsequently phosphorylated into ara-
CTP and then incorprated into the cellular DNA. Ara-C is also deaminated by CDA into 
ara-U, whilst ara-CMP is deaminated by dCMPDA into ara-UMP. Diagram adapted from 
Y. Ge. et al (2004) [39]. Ara-CMP = cytarabine monophosphate, ara-CTP = cyarabine- 
triphosphate, ara-U = uracil arabinoside, CDA = cytidine deaminase, dCK = 
deoxycytidine kinase, dTTP = deoxythymidine triphosphate, dCTP = deoxycytidine 
triphosphae  and  CdCMPDA = deoxycytidylate deaminase. 
 
1.3.1.2 Ara-C Resistance 
A number of mechanisms have been proposed to contribute towards drug resistance in 
AML patients. Which include the cell failing to undergo apoptosis in response to the 
chemotherapy agent, drugs failing to reach their intracellular targets or being removed 
by the ABC membrane transport protein, P-glycoprotein (Pgp). Pgp is an efflux 
transporter, present within the cells plasma membrane, its expression in AML patients 
has been reported to be relatively low, however an increase in its expression after drug 
treatment and during relapse have been noted [40]. Galmarini et al have shown that high 
levels of 5’-nucleotidase (5NT) [41], which is involved in DNA repair and membrane 
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transport, is related to the poor prognosis and patient outcomes in AML patients. Both 
expression and enzyme activity of 5NT has been shown to be higher in cytarabine 
resistant cells compared to that of non-resistant cells. Human equilibrative nucleoside 
transporter 1 (hENTI) expression was found to be widely expressed by patients suffering 
from AML at the point of diagnosis. hENTI is also known to be the main transporter of 
ara-C. Suggesting 5NT expression and hENTI deficiency could be involved in ara-C 
resistance in AML patients [42]. These studies suggest that AML cells have evolved to 
regulate pathways that provide protection against toxic chemotherapeutic agents. 
 
A number of ara-C, DNR and Bortezomib resistant cells lines have been established 
over the last 10 years by various groups [43]. Funato developed  a  ara-C resistant K562 
(K562/AC) cell line by increasing ara-C doses over a 3 month period  to examine the 
differences between them and ara-C sensitive K562 cells [44].  
 
 
1.3.1.3 Daunorubicin 
Daunorubicin (DNR) part of the anthracycline antibiotics family and is indicated in the 
treatment of acute leukaemia and is administered via intravenous infusion. It is also 
licensed for use in AIDs-related Kaposi’s sarcoma. Side effects include bone marrow 
suppression, hyperuricaemia, alopecia, extravasation of intravenous drugs, oral 
mucositis, tumour lysis syndrome and nausea and vomiting [5]. DNR functions by 
forming a complex with cellular DNA and thus intercalating between the base pairs 
which allows it to inhibit Topoisomerase II by stabilising the complex between the 
enzyme and DNA. Which results in both single and double DNA stranded breaks [45]. 
 
1.3.1.4 Etoposide 
Etoposide an anti-neoplastic, is indicated for the treatment of small cell carcinoma of the 
bronchus, lymphomas and testicular cancer; it is either administered orally or via slow 
intravenous infusion. The same side effects as for DNR can be expected [5]. 
 
1.3.1.5 Amsacrine 
Amsacrine is occasionally used to treat AML, it is administered via intravenous infusion, 
patients could experience myelosuppression along with the side effects listed for DNR 
[5]. 
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1.3.1.6 Proteasome Inhibitors 
Bortezomib is a proteasome inhibitor licensed to treat multiple myeloma which has 
progressed even though it has been treated with at least one other chemotherapeutic 
agent, the patient has already had or is unable tolerate a bone marrow transplant [5]. We 
have previously shown HO-1 up-regulation in response to bortezomib and lenalidomide 
exposure in MM cell lines. HO-1 expression was also explored in the lenalidomide 
resistant MM cell line and shown to be up regulated [46]. Bortezomib use in AML 
treatment has revealed disappointing results. We have previously shown AML cell lines 
are less sensitive to bortezomib than their control non-cancerous cells. [47]  
 
1.3.1.7 Mitoxantrone 
Mitoxantrone an anthracycline derivative is licensed for use to treat metastatic Breast 
cancer, Non-Hodgkin’s Lymphoma, Adult Non-Lymphocytic Leukaemia and Non-
Resectable Primary Hepatocellular Carcinoma treatment. It is administered 
intravenously however both myelosuppression and dose-related cardio toxicity can occur 
[5].  
 
1.4 World Health Organisation (WHO)  
WHO AML classification of AML subtypes supersedes the previous classification based 
around the French-American-British (FAB) system based on HSC differentiation status. 
The above classification takes into account genetics, both biological and clinical features 
as well as morphological results during AML subtype diagnosis.    
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Table 1.2 WHO Classifications of acute leukaemia’s. Adopted from Vardiman et al 
(2009) and Dohner et al (2010) [22, 48]. 
Categories 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22)or t(16;16)(p13.1;q22); CBFB-MYH11 
AML with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23);MLLT3-MLL 
AML with t(6:9)(p23;q34); DEK-NUP214 
AML with inv(3) (q21q26.2) or t(3,3)(q21;q26.2);RPNI-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional etity: AML with mutated NPMI 
Provisional entity: AML with mutated CEBPA 
AML with myelodysplasia- related changes 
Therapy- related myeloid neoplasm 
AML, not otherwise specified  
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/ monocytic leukemia 
Acute erythroid leukaemia 
          Pure erythroid leukemia 
          Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis  
Myeloid sarcoma (syn; extramedullary myeloid tumor; granulocytic sarcoma; chloroma) 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute leukemia of ambiguous lineage 
Acute undifferentiated leukaemia 
Mixed phenotype acute leukaemia with t99;2209q34;q11.2);BCR-ABL1 
Mixed phenotype acute leukaemia with t(v;11q23);MLL rearranged 
Mixed phenotype acute leukaemia, B/myeloid, not otherwise specified 
Mixed phenotype acute leukaemia, T/myeloid, not otherwise specified 
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1.5 Cytoprotection 
Cellular cytoprotection and resistance towards chemotherapeutics is governed by a 
number of transcription factors; Bach1, NF-κB and Nrf2 and their genes; HO-1, NQO1, 
GCLM and GCLC of which, each will be discussed in detail during the course of this 
chapter.  
 
1.5.1 NF-κB 
The mammalian NF-κB family is composed of 5 members, class 1 proteins NF-κB1 
(p105 → p50), NF-κB2 (p100 → p52), class II proteins RelA (p65), RelB and c-Rel [49]. 
Its activation is governed by a number of stimuli including pro-inflammatory cytokines; 
tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and epidermal growth factor 
(EGF) [50, 51]. NF-κB signalling occurs via two main pathways the Classical and 
Alternative pathway [52, 53]. In non-stimulated cells, NF-κB remains inactivate within the 
cytoplasm, upon activation NF-κB subunits move into the nucleus. 
 
NF-κB represents a major anti-apoptotic pathway that must be overcome if cancer cell 
cytotoxicity is to be achieved.  Many cytotoxic agents have been shown to inhibit NF-κB 
pathways as part of their cell killing mechanisms.  The relationship between NF-κB and 
Nrf2 pathways was recently shown by our group to be pivotal to understanding better 
cytotoxic efficacy in cancerous versus non-cancerous cells [54-56].  
 
We have previously shown under NF-κB inhibition and TNF treatment, HO-1 regulation 
was increased in AML cell lines but not primary white blood cells. Increased HO-1 
regulation conferred protection towards cell death in AML cell lines whilst the primary 
white blood cells underwent cell death. Next, HO-1 expression was blocked using HO-1 
targeted siRNA, the cells were yet again exposed to both TNF treatment and NF-κB 
inhibition and increased cell death was seen. ROS generation within the AML cell lines 
was also shown to be up-regulated in response to TNF treatment and NF-κB inhibition. 
Which induced Nrf2 activation resulting in increased HO-1 regulation thus providing 
cellular resistance to TNF-induced cell death [57]. Moreover, HO-1 appears to be 
supressed by NF-κB activation, of which NF-κB subunits p50 and NF-κB1 an p65 
subunit appear to be responsible for HO-1 suppression in AML cell lines [49]. 
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Figure 1.4. The classical and Alternative NF-κB pathways utilised during 
cytoprotective responses within all cells.  Figure adapted from [58]. 
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1.5.2 Nuclear factor erythroid-derived 2 related factor 2  
The Cap ’N’ Collar transcription factor family member, Nuclear factor erythroid-derived 2 
related factor 2 (Nrf2) is localised in the cytoplasm and bound to Keap1 in its inactive 
state [59]. In response to either oxidative stress or electrophilic stress, Nrf2 is released 
from Keap1 and translocates into the nucleus where it heterodimerizes with a b-zip 
partner and then goes on to bind to the anti-oxidant response element (ARE) within its 
target genes promoters [60] [59]. Nrf2 is responsible for the expression of phase II 
detoxifying and oxidative stress enzymes for example HO-1, NQO1 and GCLM.  
 
1.5.3 Kelch-like ECH-Associated Protein 1 
Kelch-like ECH-Associated Protein 1 (Keap1) a member of the Kelch family, which 
possess Kelch repeats at the C terminus and an BTB/POZ domain near the N terminus 
[61]. Keap1 consists of two structural domains; the DGR moiety also known as the Kelch 
motif and the BTB protein interaction domain. It is localised within the cytoplasm. It binds 
to the amino-terminal domain on Nrf2 forming an interaction between ‘Neh-DGR’ which 
represses Nrf2 transcriptional activity [60]. Both the Neh2-DGR interaction and Keap1’s 
cellular location lead Itoh et al to suggest Keap1 is involved in bridging Nrf2 with the cells 
actin cytoskeleton [60].  There is inhibitory relationship between Keap1 and Nrf2 as well 
as Bach1 and Nrf2 (see Figure 1.5).  In the cytoplasm, Keap1 binds Nrf2 and keeps it 
inactive. Upon oxidative stress of the cell, Keap1 dissociates from Nrf2 where it 
translocates to the nucleus, where it can replace Bach1 at the anti-oxidant response 
elements (ARE) for cytoprotective genes.  Nrf2 is now free to act as the transcription 
factor at the ARE to elicit gene expression of many different cytoprotective proteins. 
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Figure 1.5. Keap1 and Nrf2s relationship. (A) Inactive Nrf2 is bound to Keap1 within 
the cytoplasm. In response to either oxidative or electrophilic stress, Nrf2 is activated 
and released by Keap1 where it translocates into the nucleus. (B) Nrf2 binds to the ARE 
complex resulting in phase II detoxifying and oxidative stress enzyme expression. 
Diagram adapted from [62]. 
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1.5.4 Haem Oxygenase -1 
Haem Oxygenase-1 (HO-1) is encoded by the HMOX1 gene, its expression is induced in 
response to oxidative stress [63]. To date, three isoforms of haem oxygenase (HO-1) 
have been identified, HO-1, HO-2 and HO-3 [64]. HO-2 is encoded for by HMOX2, its 
expression is constitutive [63]. Haem is a protoporphyrin IX ring which contains a Fe2+ 
atom. HO-1 provides protection against cellular stress, regulates cellular haem levels 
and converts intracellular haem into carbon monoxide, free iron and biliverdin [64]. 
Biliverdin is further reduced into the potent antioxidant bilirubin [65, 66] by biliverdin 
reductase [67]. Depletion of the cyto-protectant bilirubin by RNA interference towards 
biliverdin reductase, has been shown to increase ROS levels in tissues and thus causes 
cellular apoptosis. However, bilirubin is oxidised back into biliverdin, via a ‘redox cycle’ 
and can be reduced back into bilirubin via biliverdin reductase, thus explaining how 
bilirubin can act as an antioxidant [66]. However, decreased glutathione levels, results in 
a reduced increase in ROS and cellular apoptosis [66]. Florczyk et al (2011) explored 
the relationship between both HO-1 and biliverdin reductase in genetically modified NIH 
3T3 mouse fibroblasts. They demonstrated the over expression of biliverdin reductase 
resulted in increased HO-1 expression which conferred protection against 
chemotherapeutics; cisplatin and doxorubicin [68].  
 
HO-1 possesses the following cytoprotective properties anti-inflammatory, anti-oxidative 
and anti-apoptosis [69, 70]. HO-1 belongs to the heat shock protein family (Hsp-32), its 
expression is triggered by a variety of stress inducing stimuli including UV radiation, 
hyperthermia, inflammatory cytokines, bacterial endotoxins and heavy metals [71-75]. 
HO-1 regulation is under the control of signalling components [76, 77] and a number of 
transcription factors such as  nuclear factor-κB (NF-κB), NF-E2-related factor 2 (Nrf2) 
and activator protein-1 (AP-1) [78-80]. 
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Figure 1.6. Haem is converted into ferrous iron, CO and biliverdin. Heam is cleaved 
by HO-1 into three products; ferrous iron, CO and biliverdin. Biliverdin is further coverted 
into bilirubiin by biliverdin reductase, which can be oxidised back into biliverdin.  
 
 
1.5.5 NAD(P)H:quinine oxidoreductase-1 
NAD(P)H:quinine oxidoreductase-1 (NQO1) is an FAD-binding protein that is involved in 
the electron transfer chain, and is a cytoplasmic electron reductase enzyme.  NQO1 
mutations have been implicated in breast cancers, as well as in Alzheimer’s disease and 
in models of hepatotoxicity. 
 
1.5.6 Glutathione Synthesis 
The antioxidant, Glutathione (GSH) a non-protein thiol is involved in cellular protection 
against oxidative stress. Glutathione synthesis is governed by the availability of cysteine, 
the sulphur amino acid precursor and Glutamate Cysteine Ligase, the rate limiting 
enzyme. Glutamate Cysteine Ligase (GCL) is composed of two subunits; Glutamate 
Cysteine Ligase Catalytic (GCLC) and Glutamate Cysteine Ligase Modifier (GCLM) 
subunit [75].  
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1.6 MicroRNA 
During the last decade the involvement of microRNAs (miRNAs) within cancer diagnosis, 
progression and treatment has started to be extensively researched. They have been 
shown to regulate a number of transcription factors and in turn control cellular 
cytoprotective gene expression. Possibly indicating their potential as future therapeutic 
targets or biomarkers in AML treatment and diagnosis. Therefore we have decided to 
explore miRNAs expression in response to chemotherapeutics exposure in AML 
treatment.  
 
1.6.1 miRNA Biogenesis 
miRNAs are small pieces of non-coding conserved RNA usually between 18 and 25 
nucleotides in length thus act as expression regulators of genes involved in 
development, differentiation, proliferation, survival and cell death [81]. miRNA biogenesis 
occurs in the nucleus, where long primary miRNA (pri-miRNA) are transcribed from non-
coding/ non- messenger DNA by RNA polymerase II [82]. These transcripts are then 
cleaved by RNA polymerase III (drosha) producing the precursor miRNA (pre-miRNA) 
which is approximately 70 nucleotides long [83]. This is subsequently transported via 
Exportin 5 (Nuclear export factor) out of the nucleus and into the cytoplasm. Whilst in the 
cytoplasm another ribonuclease, Dicer complexed with a double stranded RNA binding 
protein (TRBP) [84] processes the pre- miRNA into a mature double stranded miRNA of 
approximately 22 nucleotides in length [85]. The duplex then separates into two separate 
strands, the passenger and the functional strand. The functional strand is incorporated 
into the RNA-induced silencing complex (RISC). Once incorporated into the RISC 
complex the functional strand is unwound and involved in target recognition (3’UTR) and 
incorporating specific target mRNAs into the RISC complex. Whilst the passenger 
strand, is degraded.  [84, 86, 87]. It is thought that miRNAs control gene expression by 
binding to the 3’-untranslated region (3’-UTR) of the targeted mRNA. RISC is guided 
towards the target mRNA via the functional strand. The mechanism of silencing the 
target mRNA expression employed is dependent on the degree of complementarily 
dictated by the functional strand for the target mRNA. The mRNA will be cleaved if full 
complementarily for the target mRNA is present if not then translation, expression or 
alterations to the target mRNA will take place.  
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Figure 1.7. miRNA Biogenesis. Initially occurs in the nucleus, RNA Polymerase 11 
transcribes miRNAs into pri-miRNA, long primary miRNA transcripts. RNA Polymerase 
111 also known as Drosha, cleaves Pri-miRNA into pre-miRNA which is transported into 
the cytoplasm via exportin 5. Pre-miRNA is further processed by Dicer, another RNase 
enzyme into a miRNA duplex, of 19-25 nucleotides in length. The miRNA duplex 
separates, the mature strand is incorporated in to RNA-induced silencing complex 
(RISC).  Diagram adapted from R. Garzon. 2010 [88] and R. Lima et al. 2011 [89].  
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1.6.2 miRNAs can target a number of genes and proteins 
It is thought that one miRNA can target and block a number of target mRNAs being 
transcribed. One mRNA can also be targeted by a number of miRNAs, for example 
PTEN which is mediated by both miR-21 and 222.  
 
1.6.3 miRNAs involvement in leukaemia progression  
A number of studies have shown that miRNAs are involved in cancer generation. Mi et al 
discovered that miRNA can be used to differentiate ALL from AML by looking at 27 
miRNAs which were either over or under expressed in the opposite condition. miRNAs 
can act as either oncogenes or tumour suppressor genes. The following miRNAs might 
possess oncogenic activity as they have been shown to be up-regulated in tumour cells. 
These are miR-21, miR-155, miR-221, miR-222 and mir-17-92 [90]. 
 
1.6.4 miRNAs, cell proliferation and chemotherapy- induced resistance 
More recently, attention has turned to the role that miRNAs play not only in the 
progression of AML disease, but also in the development of a chemotherapy-resistance 
phenotype. Cell lines studies have highlighted a potential role of some miRNAs involved 
in acquired resistance.  Some of these more recent examples are outlined below [8].  
 
1.6.4.1 miR-21 is highly expressed in DNR resistant CML cell line, K562 
miR-21 has a number of targets of which both phosphatase and tensin homologue 
(PTEN) [91] and programmed cell 4 death (PDCD4) [92] are activated in leukaemia. Bai 
et al have shown miR-21 is highly expressed in the DNR resistant leukaemia cell line, 
K562. miR-21 contributes towards DNR resistance by regulating PTEN expression in 
K562 cells. Thus the authors go on to suggest the up regulation of miR-21 and the 
sequential down regulation of PTEN could potentially be a novel DNR resistance 
mechanism in leukaemia cells [91]. When miR-21 was over expressed the P13K/Akt 
pathway was activated leading to a decrease in PTEN, indicating PTEN is a target for 
miR-21 [91]. An anti-miR-21 oligonucleotide was used to down regulate miR-21 
expression in HL60 cells which were subsequently treated with ara-C resulting in cellular 
apoptosis. Suggesting miR-21 is playing a part in the cells increased sensitivity towards 
ara-C. miR-21 directly targets PDCD4, which was up-regulated in response to miR-21 
down regulation. Therefore the authors suggest the down regulation of miR-21 results in 
ara-C induced apoptosis which could be partially due to the up regulation of PDCD4 [93]. 
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1.6.4.2 Cell proliferation is inhibited when miR-222 expression is suppressed 
Zhang and his colleagues have demonstrated both miR-221 and miR-222 target PTEN 
in SGC7901 cells, a gastric cancer cell line via a luciferase construct. When miR-221 
and miR-222 expression is suppressed, both cell proliferation and invasion is inhibited 
whilst cell apoptosis is induced. PTEN up regulation results in increased radio sensitivity 
within the cell line [94, 95]. 
 
1.6.4.3 miR-34a has been shown to inhibit cell proliferation in the CML cell line, 
K562. miR-34a a tumour suppressor gene, inhibits SIRT1 expression, however p53 
regulates miR-34a expression [96]. Yamakuchi et al have suggested p53 induces miR-
34a expression which in turn increases p53 activity via SIRT1 in a positive feedback loop 
[96]. miR-34a targets SIRT1, p53 targets miR-34a. miR-34 family 3 miRs which are 
coded for by two different genes.  
 
Ichimura et al explored miRNA regulation in K562 cells during megakaryocytic 
differentiation induced by Phorbol 12-myristate 13-acetate (PMA). PMA activates the 
extracellular signal-regulated protein kinase (ERK) which in turn induces miR-34a 
expression. Interestingly the group found over expression of miR-34a significantly 
reduced K562 proliferation [97]. 
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Figure 1.8. p53 and miR-34a relationship regarding apoptosis. p53 induces miR-34a 
expression which subsequently inhibits SIRT1 and Bcl-2 expression promoting 
apoptosis. However SIRT1 activates p53 transcription and in turn p53 targets e.g. PUMA 
[98]. Diagram adapted from H. Hermeking. 2009 [98]. 
 
1.6.4.4 miR-181a targets Bcl-2 and has been shown to be involved in acquired ara-
C resistance in the AML cell line HL60s 
The Nrf2 pathway is regulated and repressed by the presence and absence of Keap1.  
Bai et al concluded miR-181a directly targets Bcl-2, via both reporter gene assay and 
immunoblot analysis. They investigated miR-181a role within resistance in a cytarabine 
resistant AML cell line; HL60 (HL60-ara-C). miR-181a was found to be down regulated 
whilst Bcl-2 was up-regulated in these cells compared to their expression in the wild type 
HL60 cells. However when the authors overexpressed miR-181a in the HL60-ara-C cell, 
they became more sensitive to the presence of ara-C thus indicating miR-181a is 
involved in ara-C resistance [99].  Interestingly, Bcl2 expression could be significantly 
up-regulated in the THP1ara-C(1) suggesting miR-181a and Bcl2 are not involved in ara-
C resistance in THP1ara-C(1). 
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1.7 Project aims 
The present studies were undertaken to investigate the following points: 
 The role of HO-1 in regulating cellular cytoprotective responses in response to 
ara-C and DNR, the two front-line chemotherapeutic agents for the treatment of 
AML. 
 Explore acquired ara-C resistance in a ara-C resistant AML cell line, THP1ara-
C(1). 
 Investigate miRNA expression in both wt THP1 cells and ara-C resistant 
THP1ara-C(1) cells. 
 Explore miR-196a and Bach1s relationship in response to continual ara-C 
exposure and subsequent generated resistance in  wt THP1 cells. 
 
The current MacEwan laboratory focus revolves around AML cytoprotection and 
acquired cellular resistance. Previously, the laboratory has investigated the effects of 
TNF, NF-κB and bortezomib (Figure 1.9: 1.2.3.4.) on HO-1 expression in AML cells. So 
far, little work has been performed on investigating the effect of front-line 
chemotherapeutic agents or miRNA expression in relation to cytoprotection and cellular 
resistance. Therefore, the studies undertaken during the course of this thesis will aim to 
shed light on these important clinical points. 
 
Figure 1.9.  Diagramatic representation of the presently understood points of knowledge 
from within our laboratory. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
Unless otherwise stated all reagents were purchased from Sigma Aldrich inc.  
 
2.2 Cell Culture 
All cell lines, except 293FT, were cultured in RPMI 1640 Medium (Invitrogen Gibco) 
supplemented with 10% (v/v) heat inactivated FBS (Fetal Bovine Serum; Biosera) and 
1% (v/v) L-Glutamine (Invitrogen Gibco) in 75 cm2 flasks (Corning) and incubated at 37 
ºC and  5% CO2. 293FT were cultured in DMEM High Glucose (Invitrogen ;Gibco) 
supplemented with 10% heat inactivated FBS, 6 mM L-Glutamine, 0.1 mM MEM Non-
Essential Amino Acid solutions (Invitrogen Gibco) and 1 mM Sodium Pyruvate 
(Invitrogen Gibco). Cells were incubated in media until confluent. When splitting cells the 
dilution used was dependent on the cell line being passaged (Table 2:1).  
 
Table 2.1: Cell lines.  
Cell line Cell type Passage 
dilution 
Source 
U937 Human leukemic monocyte 
lymphoma cell line 
1:9 every three 
days. 
European 
Collection of cell 
cultures 
THP-1 Human acute monocytic 
leukaemia  
1:1 every four 
days. 
European 
Collection of cell 
cultures  
THP1ara-
C(1)  
Ara-C resistant human 
acute monocytic leukaemia 
1:1 every four 
days. 
European 
Collection of cell 
cultures  
THP1ara-
C(1) TW 
Ara-C resistant human 
acute monocytic leukaemia 
1:1 every four 
days. 
European 
Collection of cell 
cultures  
HL60 Human promyelocytic 
Leukaemia 
1:9 every three 
days. 
European 
Collection of cell 
cultures 
K562 Human 
erythromyeloblastoid 
leukaemia  
1:1 every four 
days. 
European 
Collection of cell 
cultures 
293 FT Primary embryonic human 
kidney transformed with 
sheared human adenovirus 
type 5 DNA. 
1:5 every four 
days 
Invitrogen 
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2.2.2 Developing ara-C resistant U937 and THP-1 cells.  
Parent THP-1 and U937 cells were treated with 0.5 µM of ara-C (Sigma Aldrich) weekly 
until the cells had developed resistance towards ara-C [44]. Resistance was confirmed 
by exposing the cells to various doses of ara-C and assessing cell death over 72 hours 
using the Promega Celltitre 96 AQueous One Solution Reagent MTS assay. 1 µM of ara-C 
is a clinically achievable concentration obtained in situations where a standard dose of 
ara-C therapy is administered to a patient [42]. Thus a reduced dose was selected to 
treat the resistant cells, which would simulate the clinical environment without killing the 
entire population. The resistant cells were cultured like the parent cells and thus split 
normally.   
 
 
2.2.3 Freezing and thawing Cells 
5 x106 cells were centrifuged at 1200 r.c.f. for 5 min before the supernatant was 
removed to leave the exposed pellet. This was subsequently re-suspended in 1.5 mL of 
freezing solution (90% (v/v%) RPMI 1640 supplemented medium and 10% DMSO 
[Sigma Aldrich] and transferred to a CryoTubeTM vial (Nunc). A 5100 Cryo 1°C Freezing 
Container (Nalogene) was used during the first 24 h to prevent potential damage to the 
cells caused by freezing. Samples were stored at -80 ˚C.  
 
To thaw cells CryoTubesTM were removed from -80˚C and placed into an incubator (37ºC 
and 5% CO2) for 2 min. The contents of the CryoTubes
TM was re-suspended in 10 mL of 
fresh RPMI 1640 supplemented medium and centrifuged for 5 min at 1200 r.c.f. The 
supernatant discarded; the exposed pellet was re-suspended in 10 mL of fresh RPMI 
1640 supplemented medium and transferred to a 25 cm3 flask (Nunc). 
 
2.2.4 AML sample preparation 
Donor blood or bone marrow aspirate was slowly pipette onto 10 mL of 
Histopaque®1077 (Sigma-Aldrich) to create two distinct layers. The mixture was 
centrifuged for 20 min at 1200 r.c.f, and 21˚C to create a density gradient (Figure 2.1). 
The autologous plasma layer was removed and filtered through a 0.2 μM pore Minisart® 
high flow syringe filter (Sartorius).  20 mL of serum free RPMI 1640 medium was added 
to the filtered plasma. The white blood cells (WBC) layer was removed and washed in 1x 
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Hanks Balanced Salts Solution (HBSS; Gibco). WBC were centrifuged for 10 min at 
1200 r.c.f. The supernatant was discarded to leave the exposed pellet that was then re-
suspended in the RPMI 1640 medium supplemented with the previously filtered 
autologous plasma.  
 
 
Figure 2.1: Density gradient separation of donor blood or bone marrow aspirate. 
 
2.2.5 Trypan Blue Exclusion assay of cell viability 
20 μL of cell suspension was diluted 1:1 with Trypan Blue Solution (Sigma Aldrich) . The 
sample was transferred to the haemocytometer and viewed under the microscope. The 
number of cells present were counted and recorded to establish the number of viable 
cells present within the population under investigation. Dead and dying cells present 
within the suspension take up the Trypan Blue through their damaged cell membranes 
thus appearing blue under the microscope whilst the live cells remain uncoloured 
because their membranes are still intact. 
 
2.3 Virus construction and infection 
Virus construct were performed by Dr. Lyubov Zaitseva (University of East Anglia). 
Briefly; microRNA (miRNA) sequence miRNA-HO-1-166 (5’-
TCCTCATGAACTCAGCATTCT-3’) targeting human HO-1 was selected with Block-iT 
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WBC 
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RBC 
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RNAi Designer software (Invitrogen) and pcDNATM6.2-GW/EmGFP-miR-neg plasmid 
(Invitrogen) (Paisley, UK) was used as the source for the negative control. miRNA-
encoding viruses were produced with Block-iT Lentiviral Pol II miRNAi Expression 
system purchased from Invitrogen (Paisley, UK) in 293FT cells. Lentiviral stocks were 
concentrated using the Lenti-XTM Concentrator and titres were obtained with the Lenti-
XTM qRT-PCR Titration kit (Clontech). For transduction, 2.5 x 105 U937 cells were 
infected with lentiviral stock at an MOI of 10 in presence of Polybrene (hexadimethrine 
bromide; Sigma Aldrich) and analysed by flow cytometry, qRT-PCR and Western Blot 48 
h after infection.  Stably transduced cells were selected using Blasticidin (8 μg/ml, 2 
weeks). 
 
2.4 Nucleofection and Lipofection 
Suspension cells: 2 x 106 cells were centrifuged at 1200 r.c.f. for 5 min before 
supernatant was discarded and samples were re-suspended in non-supplemented RPMI 
1640 medium and centrifuged for a further 5 min. Supernatant was discarded and cells 
were again re-suspended in non-supplemented 1640 medium before cells were 
transferred into AmaxaTM certified 100 µL Aluminium Electrode Curvettes (Lonza) with 
25 µM of transfection reagent (Table 2.2) and transfected using the Amaxa Biosystems 
Nucleofector® II (Lonza), programme T 001. Following transfection cells were re-
suspended in 2 mL of fresh supplemented RPMI 1640 medium. 
 
Adherent cells: DNA vectors/ transfection reagents (Table 2.2) and Lipofectamine 2000® 
(Life Technologies) were diluted in OPTI-MEM GlutaMaxTM (Invitrogen Gibco) separately 
and incubated at room temperature for 5 min before being combined. The mixture was 
incubated for a further 20 min at room temperature before being added to 3.5-4 x 105 
cells, drop wise. Cells were incubated for a further 48 h at 37˚C and 5% CO2. 
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Table 2.2: Transfection Reagents 
 Mature miRNA sequence Manufacture 
Silencer® 
negative control 
# 1 
 Ambion 
miR-21 5-‘UAGCUUAUCAGACUGAUGUUGA-3’ Qiagen 
miR-145 5-‘GUCCAGUUUUCCCAGGAAUCCCU-’3 Qiagen 
miR-196a 5’-UAGGUAGUUUCAUGUUGUUGGG-3’ Qiagen 
 
miR-196a 5’-UAGGUAGUUUCAUGUUGUUGGG-3’ Ambion 
miR-222 5’-AGCUACAUCUGGCUACUGGGU-3’ Qiagen 
 
2.5 Luciferase Assay 
Suspension cells: 2 x 105 cells were transfected via nucleofection with the desired 
transfection reagent (Table 2.2), 400 ng pMIR-REPORTTM-β-galactosidase control 
plasmid (pMIR-REPORTTM System, Applied Biosystems) and 400 ng of the desired DNA 
construct in a pMIR-REPORTTM plasmid as previously described in section 2:2.7.1 Cells 
were incubated at 37˚C, 5% CO2 for 48 h.  
 
Adherent cells: 3.5 - 4 x 104 cells were transfected via Lipofectamine2000TM, with the 
desired reagent (Table 2.2), 400 ng pMIR-REPORTTM-β-galactosidase control plasmid 
and 400 ng of the desired DNA construct in a pMIR-REPORTTM plasmid as previously 
described in section 2:2.7.1. Cells were incubated at 37˚C, 5% CO2 for 48 h. 
 
Both pMIR-REPORTTM plasmid and pMIR-REPORTTM-β-galactosidase control plasmid 
activities were assessed using the Dual-Light® Combined Reporter Gene Assay System 
for Detection of Luciferase and β-galactosidase (Applied Biosystems). Briefly, both 
suspension and adherent cells were washed twice with sterile PBS, cells were 
centrifuged at 400 r.c.f, 4˚C for 5 mins before supernatant was removed to leave the 
exposed pellet. Either 25 μL (suspension cell lines) or 75 μL (adherent cell lines) of Lysis 
Solution was added to each sample before being centrifuged at maximum speed for 2 
min to pellet debris. The supernatant was then transferred to a fresh tube and stored at -
70˚C until analysis. 
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10 μL of sample extract was added to a 96 well plate (Corning), Buffer A and Buffer B; 
Galacton-Plus (100:1) were added according to the manufactures instructions. After 1-2 
seconds delay the luciferase signal was read using the Envision 2103 Multilabel Reader 
and Wallac EnVision Software (PerkinElmer). Samples were left to incubate at room 
temperature for a further 60 min, before Accelerator-ll was added to each well. β-
galactosidase signal was analysed again on EnVision 2103 Multilabel Raeder. 
 
2.6 Flow Cytometry 
2.6.1 Annexin V-FITC Apoptosis Detection  
Approximately 1 x 105 cells were centrifuged at 4,000 r.c.f. for 1 min, before supernatant 
was discarded. The cell pellet was re-suspended in Annexin V binding buffer containing 
0.005% (w/v) Propidium Iodide (PI) and 0.02% (w/v) Annexin-FITC Annexin V-FITC 
Apoptosis Detection Kit; Abcam) and each sample was incubated for 5 min at room 
temperature. Cell death was then evaluated by flow cytometery using the BD AccuriTM 
C6 Flow Cytometer (BD bioscience).  2 x 104 events per sample were recorded at 
medium velocity.  
 
2.6.2 ROS quenching assay 
5 μM NAC (N-Acetyl Cysteine; Sigma Aldrich) was added to 1 x 106 cells and incubated 
for 20 min at 37ºC and 5% CO2. Cells were then treated with either ara-C (0.5 µM) or 
DNR (0.2 µM; Sigma-Aldrich), or a combination thereof, and incubated for a further 24 h 
at 37ºC and 5 % CO2. Cells were centrifuged at 4000 r.c.f. before supernatant was 
removed and discarded and the pellet was re-suspended in PBS. Cell death in the 
presence of the ROS-quenching NAC was analysed by flow cytometry as detailed in 
2:2.9.1. 
 
2.6.3 ROS generation H2DCFDA assay  
Following any treatment, 1 μM or 10 μM H2DCFDA (2’,7-dichlorodihydrofluorescein 
diacetate; Invitrogen) was added to 1 x 106 cells and incubated for 15 min at 37˚C and 
5% CO2. Cells were centrifuged at 4000 r.c.f. for 1 min before supernatant was 
discarded and the pellet re-suspended in PBS. Fluorescence intensity was examined 
using the BD AccuriTM C6 Flow Cytometer. The mean channel fluorescence of each 
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sample is expressed as a percentage of the untreated control. The relative fluorescence 
intensity of H2DCFDA detected represents the relative steady state of ROS generation. 
 
2.6.4 Cell cycle analysis 
1 x 106 cells were centrifuged at 4,00 r.c.f. for 1 min before supernatant was discarded 
and the pellet was re-suspended in PBS, Ethanol was added to a final concentration of 
70% (v/v) to fix cells, and the cells were incubated for 20 mins on ice. Fixed cells were 
centrifuged at 4,000 r.c.f for a further 5 min before supernatant was removed and the 
pellet was re-suspended in PBS containing 0.005% (w/v) PI, 0.1 mg/mL RNase A 
(Sigma-Aldrich) and 0.05% Triton-XTM 100 (Sigma-Aldrich) before being analysed on the 
BD AccuriTM C6 Flow Cytometer. 
 
2.7 Cell Viability assays 
2.7.1 Promega CellTiter 96 AQueous One Solution Reagent MTS cell viability assay 
CellTiter 96 AQueous One Solution Reagent (Promega) was added to 1 x 10
5 cells in a 1:9 
dilution and incubated at 37˚C, 5% CO2 for between 2 and 4 h depending on the cell line 
and cell type. CellTiter 96 AQueous One Solution Reagent contains a novel tetrazolium 
compound which is reduced to a formazan product. The concentration of the formazan 
product present within the well is directly proportional to the number of living cells 
present within the culture. The absorbance was read at 490 nM using the FLUOstar 
OMEGA micro plate reader (BMG Labtech). 
 
2.7.2 CellTitre-Glo® Luminescent Cell Viability Assay 
CellTitre-Glo® Luminescent Cell Viability Assay reagent (Promega) was added to 5 x 
104 cells in a 1:1 dilution and incubated at room temperature for 30 mins before 
luminescence was read using the FLUOstar OMEGA micro plate reader. 
 
2.8 qRT-PCR 
2.8.1 Total RNA extraction 
1 x 106 cells were lysed in Total RNA Lysis Solution (Applied Biosystems), diluted 1:1 in 
PBS, then vortexed. Cell lysates were stored at -20°C until use.  
 
Total RNA was extracted from cell lysates using the 6100 Nucleic Acid Prep Station 
(Applied Biosciences) and Total RNA Purification Tray (Applied Biosystems) according 
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to the manufacturer’s instructions. Briefly, after cultured cell lysates were disrupted and 
stabilised by Total RNA Lysis Solution (Applied Biosystems) and transferred to the 6100 
Nucleic Acid Prep Station (Applied Biosciences), samples were washed to remove cell 
debris and contaminates before the purified RNA was eluted. RNA was eluted into 100 
µL of Nucleic acid purification solution (Applied Biosystems). Samples were used 
immediately or stored at -20°C until use. Total RNA yield was assessed via the ND-100 
Spectrophotometer (Nanodrop Technologies) at 260 nm and 280 nm. 260/280 nm ratio ≥ 
1.8 indicated good quality uncontaminated RNA.   
 
2.8.2 Reverse Transcription 
Reverse transcription of mRNA was performed using the GeneAmp® RNA PCR Core Kit 
(Applied Biosystems) according to the manufacturer’s instructions. Roughly 350 ng of 
RNA was added to master mix 1 (1 µL Random Hexamers 0.1 µg/µL [Quiagen], 2.5 µL 
Mgcl2 solution 25 mM, 1 µL 10 x RT Buffer, 1 µL dNTP Mix [with dTTP] 10 mM [2.5 mM 
each], 0.3 µL  MultiScribe Reverse Transcriptase enzyme 50 Units/µL and 0.3 µL RNase 
Inhibitor 20 Units/µL). Samples were mixed and centrifuged at 400 r.c.f. for 1 min then 
transferred to the BioRad C1000 where they were incubated initially at 42ºC for 15 min, 
then 95ºC for 3 min and finally 4ºC until required. cDNA was ready for qRT-PCR or 
stored at -80ºC. Briefly collected purified mRNA was reverse transcribed into cDNA and 
then amplified before qRT-PCR.  
  
2.8.3 quantitative Real Time-PCR 
cDNA from the reverse transcription reaction was diluted 1:9 in RNase-free water before 
5 μL of the diluted cDNA was added to 15 μL of Master Mix 2. Master Mix 2 was 
composed of 10 μL 2 x SYBR, 1 μL Primer under investigation 10 nM (Invitrogen) and 4 
μL RNase free water (Sigma). SYBR green technology (Roche) was used to detect 
amplification of DNA for the primers under investigation. After pre-amplification at 95ºC 
for 2 min the PCRs were amplified for 45 cycles of 95ºC for 15 s and 60ºC for 10 s and 
72ºC for 10 s on the LightCycler® 480 Real-Time PCR System (Roche)). Relative mRNA 
expression of the gene of interest was standardised against GAPDH mRNA expression 
and experimental controls using the comparative CT (2
-ΔΔC
T) method and is expressed as 
fold change. Briefly, cDNA undergoes denaturing, annealing and finial elongation each 
cycle. SYBR green intercalates with the double stranded DNA and fluoresces. 
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Fluorescence intensity increases with increasing cycle number and PCR product 
accumulation.. 
 
2.8.4 Primers 
All primers were designed using InvitrogenTM Custom DNA Oligos software and 
purchased from Invitrogen except GAPDH (Qiagen).  
 
Table 2.3: Primers  
Gene Primer sequence: F (5’-3’) Primer sequence: R (5’-3’) 
Base 
pair 
position 
Amplicon 
size 
GAPDH ACCAGCCTCAAGATCATCAGC TGCTAAGCAGTTGGTGGTGC 624-672 48 bp 
Annexin1 CAGGTCACCTTGAGGAGGTTGT CAGCACGAAGTTCATCAGCATC 376-450 74 bp 
Bach-1 CCAGAAGAGGTGACAGTTAAAGG TTGCACACTTCATCCACATTC 370-467 97 bp 
Bcl-2 CACCTGTGGTCCACCTGAC AGCTGGCTGGACATCTCG 762-850 88 bp 
BIM AGCGATACAGGTCTCGTTCC TCTGTAATCGCGACGATAATCT 348-433 85 bp 
Fas L TGGGGATGTTTCAGCTCTTC GTGTGCATCTGGCTGGTAGA 453-525 72 bp 
GCLC GGCGATGAGGTGGAATACAT GTCCTTTCCCCCTTCTCTTG 626-739 113 bp 
GCLM GCGAGGAGCTTCATGATTGT CTGGAAACTCCCTGACCAAA 412-496 84 bp 
HO-1 ATGGCCTCCCTGTACCACATC TGTTGCGCTCAATCTCCTCCT 258-312 54 bp 
IKKa CTGTACCAGCATCGGGAACT ATGGCACCATCGTTCTCTGT 146-235 89 bp 
IRAK1 CTCCAGCCCCTTCTTCTACC CTGCAGGAGGGACACTGAG 597-654 57 bp 
NQO1 GCCGCAGACCTTGTGATATT TTTCAGAATGGCAGGGACTC 471-533 63 bp 
Nrf2 AACCACCCTGAAAGCACAGC TGAAATGCCGGAGTCAGAATC 1546-1596 50 bp 
P65 GGCGAGAGGAGCACAGATAC CCTGGTCCTGTGTAGCCATT 282-350 68 bp 
PgP 
(MDR1) 
GATGAAGCCACGTCAGCTCT CCTTCTCTGGCTTTGTCCAG 4091-4164 73 bp 
PUMA GACGACCTCAACGCACAGTA GAGATTGTACAGGACCCTCCA 717-803 86 bp 
TRAF 6 TGGCATTACGAGAAGCAGTG TGGACATTTGTGACCTGAAT 609-699 94 bp 
 
 
2.8.5 miRNA Reverse Transcriptase 
Naturally miRNAs are not polyadenylated compared to mRNA which are. Therefore 
during reverse transcription miRNA are polyadenylated by poly(A)polymerase and then 
converted into cDNA. miRNA was reverse transcribed from total RNA using the Qiagen 
miScript Reverse Transcription kit (Qiagen) as per the manufacturer’s instructions. 
Briefly 400 ng of template RNA was added to each tube containing the reverse-
transcription master mix (2 µL 5 x miScript RT Buffer [contains Mg2+, dNTPS and 
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primers], 0.5 µL miScript Reverse Transcriptase Mix [poly(A) polymerase and  reverse 
transcriptase] and  2.5 µL RNase-free water). Samples were incubated for 60 min at 
37˚C followed by a further incubation at 95˚C for 5 min. miRNAs are polyadenylated by 
poly(A) polymerase whilst the RNA is converted into cDNA by Reverse transcriptase.  
 
2.8.6 miRNA Real time PCR 
cDNA was diluted 1:9 with RNase free water, Master Mix 2 mix was prepared as outlined 
above (2:2.11.3) However the reverse primer was removed and replaced with 1 μL of  
Universal primer. PCRs were pre and amplified for 45 cycles as previously described in 
2:2.11.3. miRNA expression of the primer under investigation was standardised against 
U6 expression, using the comparative CT (2
-ΔΔC
T) method and expressed as fold change. 
 
Table 2.4: miRNA Primers  
miRNA Sequence (5’-3’) 
U6 CGCAAGGAUGACACGCAAAUUC 
SN25 ACTGAGCTCCGTGAGGATAAAT 
miR-196a TAGGTAGTTTCATGTTGTTGG 
miR-200a TAACACTGTCTGGTAACGATGT 
miR-21 TAGCTTATCAGACTGATGTTGA 
miR-222 AGCTACATCTGGCTACTGGGTCTC 
miR-145 GTCCAGTTTTCCCAGGAATCCCTT 
miR-15a TAGCAGCACATAATGGTTTGTG 
miR-92a TATTGCACTTGTCCCGGCCTG 
miR-101 TACAGTACTGTGATAACTGAAG 
miR142-3p TGTAGTGTTTCCTACTTTATGGA 
miR-146a TGAGAACTGAATTCCATGGGTT 
miR-149 TCTGGCTCCGTGTCTTCACTCC 
miR-183 TATGGCACTGGTAGAATTCACTG 
miR-186 CAAAGAATTCTCCTTTTGGGCTT 
miR-34a TGGCAGTGTCTTAGCTGGTTGT 
Universal Primer GAATCGAGCACCAGTTACGC 
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2.9 Western Blotting 
2.9.1 Total Protein extraction  
Approximately 1 x 106 cells were washed with PBS and lysed with Radio 
Immunoprecipitation Assay Buffer (RIPA; 10% [v/v] PBS, 1% [v/v] Novidet P-40 [NP-40] 
substitute [Fluka Biochemika], 0.5% Sodium Deoxycolate [Sigma], 0.1% [W/V] SDS 
[Melford], made up in dH2O plus one cOmplete Mini, EDTA free, Protease Inhibitor 
Cocktail Tablet [Roche]). Samples were either stored at -20 ˚C until use otherwise on ice 
ready to be used. Samples were further centrifuged at 161000 r.c.f for 15 min at 4 ˚C, 
supernatant was retained and returned to ice.  
 
Protein concentration was established by spectrophotometry using the Eppendorf 
BioPhotometer (Eppendorf). Protein concentration was by dilution with PBS. Protein was 
diluted 1:1 in 2 x Sample Buffer (20% [v/v] Glycerol, 10% [v/v] β-mercaptoethanol, 5% 
[w/v] SDS, 20% [v/v] 1.0 M Tris HCL pH 6.7 and 2 mg Bromophenol blue made up with 
dH2O) and heated at 100°C for 5 min to denature proteins before being returned to ice. 
 
2.9.2 Cytosolic and nuclear protein extraction 
5 x 106 cells were harvested and centrifuged at 3000 r.c.f. for 5 min. Supernatant was 
discarded and the pellet was re-suspended in 1 mL of ice cold PBS and centrifuged at 
3000 r.c.f. for a further 5 min. Supernatant was discarded and the pellet was re-
suspended in 50 µL of buffer A (1% [w/v] 1M HEPES pH 7.9, 1% [w/v] 1M KCL, 30% 
[w/v] 1M Sucrose, 0.12% [w/v] 1M MgCl2, 0.05% [v/w] 1M DTT, 0.1% [v/v] NP-40, 1 x 
cOmplete Mini, EDTA free, Protease Inhibitor Cocktail Tablet made up with dH2O), which 
lysesd the cell membranes therefore releasing the cytosolic proteins. Samples were 
returned to ice for a further 5 min before beginning pulse centrifuged for 5 s at 134000 
r.c.f. The supernatant was transferred to a fresh tube (cytosolic fraction), whilst the pellet 
(nuclear fraction) was re-suspended in 50 µL of Buffer B (2% [w/v] 1M HEPES pH 7.9, 
10% [w/v] 1M KCL, 2% [w/v] 5M NaCl, 0.05% [v/w] 1M DTT, 20% [w/v] Glycerol, 1 x 
cOmplete Mini, EDTA free, Protease Inhibitor Cocktail Tablet made up in dH2O) and 
vortexed. Protein samples were diluted 1:1 with 2 x Sample Buffer and stored as 
previously described in 2:2.13.1. 
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2.9.3 SDS-PAGE and Transfer                           
Approximately 50 µg of protein sample and 10 µL of BioRad Precision Plus Protein 
Ladder Dual Colour (BioRad) were loaded into a 5% Poly acrylamide Stacker gel (16.9% 
Acryl amide 30% [Bis solution, 37.5:1,2.6%] mix [BioRad], 12.64% 1.0  M TRIS Base pH 
8.8 [Fisher Scientific],10% SDS [Melford],10% APS [Sigma], 0.10% TEMMED [BioRad] 
in d2H2O)  and resolved on a 12% Poly acrylamide Resolving Gel (40% Acryl amide 30% 
[Bis solution, 37.5:1,2.6%] mix [BioRad], 25% 1.5  M TRIS Base pH 8.8 [Fisher 
Scientific],   1% SDS [Melford]   1% APS  [Sigma], 0.004%TEMMED [BioRad] in d2H2O) 
(selected due to the molecular weight of the proteins under investigation). For 40 min at 
200 v in 1 x Running Buffer (Glycine 1.5% [w/v], TRIS 0.3% [w/v], SDS 2.4% [w/v] in 
dH2O). 
 
Immun-Blot PVDF Membranes (BioRad) were activated with methanol (Sigma) for 10 s 
and then washed with 1 x Transfer buffer (Glycine 1.5% [w/v], TRIS 0.3% [w/v] in dH2O) 
for 5 min. Protein from the resolving gel was transferred onto the PVDF membrane for 
60 min at 100 V and 4°C. After protein transfer the PDVF membranes were blocked with 
5% (w/v) non-fat milk powder (Marvel) in PBS for 60 min. The Primary antibody was 
diluted in 5% (w/v) non-fat milk powder in PBST (1% [v/v] PBS with 0.1% [v/v] Tween 
*20 [Fisher Scientific]) and incubated with the membrane either over night at 4°C or for 1 
h at room temperature. Membranes were washed with PBST before incubation with 
secondary antibody (in 5% [w/v] non-fat milk powder in PBST) for 60 min at room 
temperature. The membranes were washed with PBST 5 x 10 min before storage in 
PBS at 4°C until required. 
 
Table 2.1: Primary Antibodies 
Antibodies Manufacturer Molecular 
weight (kDa) 
Dilution 
used 
Species 
HO-1 AbCam 32 1:500 mouse 
HO-1 R & D Systems 32 1:2000 goat 
Nrf2 AbCam 68 1:1000 rabbit 
Nrf2 Santa Cruz Biotechnology 57 1:200 rabbit 
β-Actin Sigma-Aldrich 40 1:100,000 mouse 
Bach-1 Santa Cruz Biotechnology 92 1:200 goat 
NQO1 Santa Cruz Biotechnology 31 1:200 mouse 
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Table 2.2: Secondary Antibody 
Antibodies Manufacturer Dilution 
Anti -mouse HRP Abcam 1:1000 
Anti -goat HRP Abcam 1:1000 
Anti -rabbit HRP Abcam 1:1000 
 
 
2.9.4 Protein Detection 
Membranes were incubated in ECL solution, composed of 50`µL Reagent A (68 mM p-
couraric acid [Fluka] in DMSO), 5 mL of Reagent B (1.25 mM luminal [Sigma] in 0.1 M 
Tris, pH 8.5) and 1.5 µL of hydrogen peroxide (Sigma) for approximately 1 min. 
Exposure time required is dependent on the primary antibody being detected. 
 
2.9.5 Stripping Membranes 
Membranes were stripped with 10 x Re Blot Plus Strong Solution (Millipore) diluted 1:10 
with dH2O. Membranes were then washed with PBST 3 x for 10 min before being re 
blocked with 5% [w/v] non-fat milk and PBST for a further h at room temperature.  
 
2.10 Immunohistochemistry Protocol 
Approximately 1 x 105 cells were collected and cytospined at 35 r.c.f. for 5 min before 
being fixed with 4 % paraformaldehyde (Sigma) dissolved in PBS, pH 7.4 for 15 min. 
Samples were washed with PBS and blocked for a further 15 min in 30 % Goat Quench 
(30 % goat serum: 70 % gelatine quench). Cells were then permeabilised with 0.05 % 
Triton x-100 (Acros Organics) in 30 % goat quench for 20 min. Primary antibody diluted 
according to manufacturers instruction (Table 2.: Primary antibody dilutions) in 30 % 
goat quench and incubated for either 1 h at room temperature or 4°C over night. 
Samples were washed 3 x with PBS every 5 min. The secondary antibody was diluted in 
30 % goat quench according to the manufactures instructions and incubated for a further 
60 min at room temperature. The samples were washed again 3 x with PBS every 5 min. 
Samples were stained and incubated with DAPI  (Sigma) diluted with PBS (1:2000) for a 
further  20 min before being mounted with 1.5 µL of Fluoromount G (Southern Biotech) 
and stored at 4°C until examination. 
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Table 13: Immunohistochemistry Antibodies 
Primary 
antibody 
Manufacture Molecular 
weight/ kDa 
Dilution Species 
Keap1 Santa cruz biotechnology 69 1:50 goat 
Nrf-2 Santa cruz biotechnology 57 1:50 rabbit 
NQO1 Santa cruz biotechnology 31 1:50 mouse 
HO-1 R and D Biosystems 32 1:50 goat 
 
2.11 Colony forming cell assay  
Approximately 2 x104 cells were re-suspended in RPMI supplemented media and mixed 
slowly into 500 μL of methylcellulose media (HSC003, R & D Systems). Samples were 
left to incubate for 20 min allowing any air bubbles a chance to escape. Samples were 
then transferred to a 24 well plate (Nunc) and slowly decanted into their designated well. 
The gaps between the wells were filled with sterile water to ensure the required humidity 
was maintained throughout the experiment for colony development. Optimal cell plating 
concentrations varies and is dependent on the cell line being studied. The plates were 
incubated for 14 days at 37ºC and 5 %CO2.  Colony Scoring was performed at the end 
of the experiment.  
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Chapter 3: Does Haem Oxygenase-1 protect Acute 
Myeloid Leukaemia cells from front-line 
chemotherapeutic agents? 
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3.1 Introduction  
The standard induction treatment for either young or fitter AML patients consists of the 
antimetabolite, ara-C and the anthracycline antibiotic DNR [5, 19].  Depending on the 
clinicopathological characteristics, patients who go into remission would commonly 
receive consolidation therapy with either high dose ara-C or allogeneic stem cell 
transplant [22]. Even with these intensive treatment strategies a significant number of 
patients relapse and only 50% of younger fitter patients can be cured. Treatment 
outcomes are dependent on a number of clinical and biological factors including 
cytogenetics, age and drug-resistance [19, 21]. 
 
To date three isoforms of haem oxygenase have been identified, HO-1, HO-2 and HO-3 
[64]. HO-1, which is the most intriguing in terms of providing cell protection against 
cellular stresses, regulates the intracellular haem levels, and converts intracellular haem 
into carbon monoxide, free iron and biliverdin [64].  Biliverdin is further reduced into the 
potent antioxidant bilirubin [65, 66] by biliverdin reductase [67]. This metabolite 
possesses cytoprotective properties including anti-inflammatory, anti-oxidative and anti-
apoptosis [69, 70]. HO-2 is constitutively expressed and HO-3 is not catalytically active 
and thought to be involved in oxygen-sensing.  HO-1 belongs to the heat shock protein 
family (Hsp-32), thus its expression is triggered by a variety of stress inducing stimuli 
including, ultraviolet irradiation, hyperthermia, inflammatory cytokines, bacterial 
endotoxins and heavy metals [71-74, 100]. The regulation of HO-1 is under the control of 
many transcription factors including NF-κB, Nrf2 and activator protein-1 (AP-1) [78, 79]. 
 
Increased regulation of the cytoprotective gene HO-1 has been shown in response to a 
number of chemotherapeutic agents in various cancer cell lines and patient samples. We 
have previously shown, HO-1 expression is increased in response to bortezomib 
exposure in both the multiple myeloma (MM) cell line RPMI8226 and patient samples 
over an 8 h time course. An increase in basal HO-1 expression was also seen in 
response to Bortezomib acquired resistance, potentially indicating HO-1s involvement in 
acquired resistance [46]. Bortezomib is usually used in MM treatment [5] however it has 
been shown to induce the expression of the following cytoprotective genes; HO-1, 
ferritin, GSR, GCLM and NQO1 in both AML cell lines (HL60 and wt THP1 cells) and 
primary AML samples [47].  
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We have also investigated NF-κB expression in relation to HO-1 activation. In AML cells 
high NF-κB basal expression is seen. However when NF-κB expression is inhibited, 
induced HO-1 expression is reported which enables HO-1 to act as a silent anti-
apoptotic factor therefore preventing apoptosis. The reverse was seen in control non-
malignant cells. Furthermore, when both NF-κB and HO-1 expression was inhibited in 
AML cells, induced cell death was seen, however the same response was not seen in 
the control non-malignant cells. This inhibitory mechanism involving both HO-1 and NF-
κB expression could potentially be utilised in the treatment of resistant AML  [49]. 
 
3.2 Aims   
HO-1 regulation in response to both ara-C and DNR has not been explored in the 
following AML cell lines; U937 and wt THP1 cells. Therefore we wanted to examine the 
role of this cytoprotective gene and determine its involvement in the regulation of 
cytoprotection in response to the chemotherapeutics agents; ara-C and DNR, which are 
both widely used in treating patients presenting with AML.   
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Table 3:1 Differential HO-1 regulation in response to induced cell death or 
chemotherapeutic exposure.  
 
Leukaemia Cell line/ 
patient cells 
Comments Reference 
AML 
 
wt THP1 and U937 
primary AML cells 
Induced HO-1 expression in 
response to ara-C and DNR 
exposure, however cell viability 
decreased when HO-1 expression 
was silenced. 
[101] 
AML wt THP1 primary AML 
cells 
NF-κB activation supresses HO-1 
expression in AML cells, however 
upon NF-κB inhibition, HO-1 
expression is induced providing 
secondary protection to 
chemotherapeutics. 
[49] 
AML HL60, wt THP1 and 
U937 
primary AML cells 
NF-κB inhibition leads to Nrf2 
activation by TNF leading to HO-1 
induction thus inhibiting TNF 
induced cell death. 
[57] 
AML HL60, wt THP1 and 
primary AML cells 
Induced HO-1, ferritin, GSR, 
GCLM and NQO1 in response to 
bortezomib exposure. 
[47] 
CML K562 cells either  
expressing wt  
BCR/ABL or imatinib-
resistant mutants of 
BCR/ABL. 
When Hsp32/HO-1 is targeted, 
growth is inhibited in both imatinib 
sensitive and resistant CML cells. 
Thus drugs targeting Hsp32/HO-1 
inhibit growth and induce apoptosis 
in these cells. 
[102] 
MM RPMI8226 Induced HO-1 in response to 
bortezomib exposure. Increased 
basal HO-1 expression in response 
to bortezomib acquired resistance. 
[46] 
 
.   
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Table 3.2: Characteristics of study patient samples. AML disease characteristics 
including world health organisation (WHO) diagnosis and cytogenetics. Percent blast 
denotes percentage of AML blasts after purification using density gradient centrifugation 
(* denotes % of blasts and promyelocytes). Previous treatments are as outlined [101] . 
 
 
 
Age Gender WHO  
diagnosis 
Cytogenetics % 
Blasts 
Previous 
treatment 
AML 8 40 male Acute promyelocytic 
leukaemia with 
t(15;17)(q22:q12) 
PML-RARA 
t(15;17) 95 * 1999 DAT, 
DAT, MACE, 
MiDAC 
AML 9 49 male AML with maturation normal 80 not known 
AML 10 84 male Acute monoblastic 
and monocytic 
leukaemia 
not available n/a not known 
AML 11 46 female AML with maturation +4,+8, t(9;22) 70 not known 
AML 12 78 male AML with 
myelodysplasia 
related changes 
not available 85 not known 
AML 13 27 male AML with 
t(8;21)(q22;q22) 
RUNX1-RUNX1T1 
t(8;21) n/a not known 
AML 14 28 female Acute 
myelomonocytic 
leukaemia 
normal n/a not known 
AML 15 51 female AML with maturation normal 75 not known 
AML 16 66 female Therpay related 
myeloid neoplasm 
complex 85 1999 DAT, 
DAT, MACE, 
MiDAC 
AML 17 82 female AML with 
myelodysplasia 
deletion 13 85 not known 
AML 18 77 male AML with 
myelodysplasia 
related changes 
complex 95 not known 
AML 19 31 female AML with minimsl 
differtiation 
normal n/a not known 
AML 20 40 male AML monoblastic and 
monocytic leukaemia 
constitutional 
XYY only 
90 not known 
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3.3 Results 
3.3.1 AML resistance to ara-C and DNR. To better understand the mechanisms 
underlying chemo resistance in AML, levels of cell-death in AML cell lines and primary 
AML patient samples were examined in response to both ara-C and DNR at 
physiologically relevant concentrations. Concentrations were selected and based on 
previous studies [103, 104]. For example; 1 μM of ara-C is a clinically achievable plasma 
concentration, which can be obtained when a standard dose of ara-C is administered to 
a patient [105]. 
 
Figure 3.1 A shows a dose-dependent significant decrease in percentage viable cells in 
response to ara-C (0.5, 1 μM) and DNR (0.2, 0.5 μM) 24 h post treatment in all AML 
cells lines and 6 AML samples analysed. However cell viability in both AML-9 and AML-
20 was significantly increased when they were treated with ara-C (0.5 μM). Cell viability 
was also significantly increased when AML-8 was treated with DNR (0.2 μM). Potentially 
due to experimental variation. To further investigate the effect of ara-C and DNR on AML 
cells we utilised the AML cell lines wt THP1 and U937. Figure 3.1 B shows cell-death 
induced by ara-C (0.5 μM), DNR (0.2 μM) or a combination thereof in these cells lines 
using annexin-V, PI staining and flow cytometry. Interestingly when the 
chemotherapeutic agents are used alone DNR elicits a greater response than ara-C. 
However, when ara-C and DNR are combined, the percentage of cells undergoing both 
early and late apoptosis is actually less (U937 58.4%, wt THP1 22.9%) than when the 
AML cells are treated individually with DNR (U937 82.2%, wt THP1 33.3%).  
 
3.3.2. Primary AML cell response to classic AML chemotherapeutics.  To further 
explore the response of primary AML cells to classic chemotherapies, one AML patient 
sample was chosen (AML-11) for further investigation. Figure 3.2 shows primary AML 
cell response to varying concentrations of key chemotherapeutics used in the clinic; 
amsacrine, bortezomib, DNR, etoposide and mitoxantrone, over a 48 h time course. 
With all five agents the percentage of viable cells present within the population 
decreased with increasing dose and duration of drug exposure. With all 
chemotherapeutic agents except etoposide there was significant decrease in viability 
with the four highest concentrations. Figure 3.3 A shows cell-death induced by 
bortezomib, DNR and mitoxantrone in AML-17 using annexin-V, PI staining and flow 
cytometry. The percentage of cells undergoing both early and late apoptosis is increased 
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with increasing chemotherapeutic concentration. AML-17 was diagnosed with AML with 
myelodysplasia using the WHO diagnosis, previous treatments used prior to sample 
collection was not supplied. 
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Figure 3.1: AML cell resistance to ara-C and DNR. (A) AML cell lines and patient 
samples were treated with ara-C (0.5 μM or 1 μM, top panel) or DNR (0.2 μM or 0.5 μM, 
bottom panel) for 24 h before cells were stained with annexin-V and PI and percentage 
of viable cells was established using flow cytometry. Bars represent mean ± SEM from 
three independent experiments (n = 3). (B) U937 and wt THP1 cells were treated with 
ara-C (0.5 μM) or DNR (0.2 μM) or combination thereof for 24 h. Samples were prepared 
for flow cytometry as described above (n = 1). Statistical significance was calculated by 
Student’s t-test; *p≤ 0.05.   
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Figure 3.2: Primary AML cell response to varying concentrations of classic 
chemotherapeutics. Patient sample  AML-11 was treated with varying concentrations 
of (A) amsacrine (0, 0.1, 0.5, 1, 5, 10 μM), (B) bortezomib (0, 0.1, 0.5, 1, 5, 10 nM), (C) 
DNR (0, 0.02, 0.05, 0.1, 0.2, 0.5 μM), (D) etoposide (0, 0.1, 0.5, 1, 5, 10 μM), or (E) 
mitoxantrone (0, 0.1, 0.5, 1, 5, 10 μM). Cell viability 24 and 48 h post treatment was 
examined by MTS assay. (Biological replicates = 1: technical replicates = 3).   
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Figure 3.3: Patient sample AML-17 resistance to various chemotherapeutics.  (A) 
Patient sample AML-17 was treated with bortezomib (0, 2.5, 5, 10, 25 nM), DNR (0, 0.2, 
0.5, 1, 1.5 μM) and mitoxantrone (0, 0.02, 0.05, 0.1, 0.2 μM).  Cells were stained with 
annexin-V and P1, number of viable cells was established using flow cytometry, (n = 1).  
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3.3.3 Ara-C and DNR induce HO-1 expression in AML cells. Previous work from our 
laboratory has shown that HO-1 protects AML cells from apoptotic stimuli, such as 
exposure to cytotoxic chemotherapeutics [57]. We wanted to determine whether ara-C or 
DNR are also able to induce HO-1 expression in AML cells. Figure 3.4 A shows a 
significant increase in HO-1 mRNA expression in both AML cell lines and ten out of 
eleven patient samples in response to either ara-C or DNR treatment for 24 h. In 
general, HO-1 expression is induced in a dose-dependent manner. To explore this 
induction of HO-1 mRNA expression, AML cell lines were treated for 24 h with either ara-
C, DNR or a combination thereof. HO-1 mRNA expression in response to these drugs is 
significantly increased when compared to the control, when both AML cell lines are 
treated with a combination of both chemotherapeutic agents. However previously, we 
didn’t see an addictive effect regarding cell viability when both agents where used in 
combination. HO-1 mRNA fold increase is greater in U937s treated with ara-C compared 
to wt THP1 cells. However the percentage of viable cells present within the same 
population of U937 cells was less than that of the equally treated wt THP1 cells (Figure 
3.1 B). Possibly, suggesting HO-1 mRNA expression is involved in a cellular protection 
mechanism. Figure 3.5 A shows a Western blot indicating total HO-1 protein expression 
in both U937 and wt THP1 cells treated with either ara-C or DNR for 24 h. HO-1 protein 
expression is increased in both cell lines after ara-C or DNR exposure, however wt 
THP1 cells show higher levels of HO-1 in response to DNR compared with U937 cells.  
 
HO-1 induction in response to ara-C, DNR or a combination of both agents was further 
investigated in patient sample AML-15. Cells were treated with ara-C, DNR or a 
combination thereof for 24 h, before HO-1 mRNA expression was examined using qRT-
PCR. Figure 3.6 A shows a significant increase in HO-1 mRNA expression in response 
to ara-C, DNR or a combination thereof, therefore reiterating the above findings in Figure 
3.4.  
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Figure 3.4: HO-1 mRNA expression is up-regulated in primary AML cells and AML 
cell lines in response to ara-C and DNR.  (A) AML cell lines (U937, wt THP1 and 
K562) and AML patient samples were treated with either ara-C (0.5μM or 1μM) or DNR 
(0.2 μM or 0.5 μM) for 24 h before HO-1 mRNA expression was measured via qRT-
PCR. (Cell lines n = 3, primary patient AML samples n = 1) (B) AML cell lines (U937 and 
wt THP-1) were treated with ara-C (0.5 μM), DNR (0.2 μM) or in combination, for 24 h 
and HO-1 mRNA expression was analysed using qRT-PCR. Bars represents the mean ± 
SEM (n = 3). Statistical significance was calculated by Student’s t-test; *p≤ 0.05.   
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Figure 3.5: Total HO-1 protein expression is up-regulated in AML cell lines in 
response to ara-C and DNR. (A) Both U937 and wt THP1 cells were treated with either 
ara-C (0.5 μM or 1 μM) or DNR (0.2 μM or 0.5 μM) for 24 h before whole cell protein 
extracts were collected and separated using SDS-PAGE and then investigated using 
Western immunoblotting analysis of HO-1 expression. Equal sample loading across the 
membrane was assessed by probing for β-actin. Blots are representative of three 
separate experiments.    
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Figure 3.6: HO-1 mRNA expression is up-regulated in patient sample AML-15 in 
response to ara-C and DNR. AML-15 was treated with ara-C (0.5 μM), DNR (0.2 μM) or 
a combination thereof for 24 h before HO-1 mRNA was analysed using qRT-PCR. (n = 
2).   
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3.3.4 Silencing HO-1 expression increases apoptosis to ara-C and DNR in wt THP1 
and U937 cells. A lentiviral-based miRNA delivery systems based on a GFP backbone 
was developed by the group to target HO-1 mRNA. Therefore reducing  HO-1 
expression in targeted cells. Figure 3.7 A shows a 97% transfection efficiency achieved 
using this system and measured via flow cytometry. To confirm knock-down both HO-1 
mRNA and protein expression were investigated in wt THP1 and U937 cells transfected 
with either HO-1 targeting miRNA (HO-1 miRNA) or non-targeting negative miRNA 
(negative miRNA). Figure 3.7 B indicates HO-1 expression in both wt THP-1 and U937 
HO-1 silenced cells is less than 5% of the negative miRNA control.  Figure 3.7 C shows 
a Western blot indicating reduced HO-1 protein expression in U937 cells transfected with 
HO-1 miRNA compared to un-transfected and negative miRNA control samples.  
 
To investigate whether HO-1 expression confers protection from cell death on AML cells 
we utilised the lentiviral-based miRNA system characterised above. Untreated control, 
negative miRNA, and miRNA HO-1 transfected wt THP1 and U937 cells were treated 
with either ara-C or DNR for 24 h.  Figure 3.8 A shows the apoptotic response in these 
cells after treatment measured by annexin V /PI staining and flow cytometry. The HO-1 
miRNA transfected wt THP1 and U937 cells were more susceptible to apoptosis 
compared to their relevant controls thus suggesting HO-1 may be involved in protection 
against apoptosis and AML cell resistance to these chemotherapeutic agents.  
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Figure 3.7: Lentiviral- based HO-1 targeting miRNA in wt THP1 and U937 cells. (A) 
Flow cytometry was used to assess the transfection efficiency of the lentiviral based 
miRNA HO-1/GFP knockdown construct. (n = 1). Both HO-1 mRNA and protein 
expression were assessed in HO-1 silenced and control wt THP1 and U937 cells. (B) 
HO-1 mRNA expression was assessed using qRT-PCR. Bars represent the mean ± 
SEM (n = 3). Statistical significance was calculated by Student’s t-test; *p≤ 0.05. (C) 
Whole protein extracts were collected and separated using SDS-PAGE, and then 
investigated using western immunoblotting analysis of HO-1 expression. Equal sample 
loading across the membrane was assessed using β-actin. Blots are representative of 
three separate experiments. 
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Figure 3.8: Apoptotic response to ara-C and DNR exposure was increased in HO-1 
silenced cells. (A) HO-1 silenced and miRNA negative wt THP1 and U937 cells were 
treated with either ara-C (0.5 µM) or DNR (0.2 µM) for 24 h. Cells were stained with 
annexin-V and PI and number of viable cells was established using flow cytometry. wt 
THP1 (n = 1), U937 (n = 1). Abbreviations: neg = negative.  
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3.3.5 ROS modulate the apoptotic potential of ara-C and DNR in AML cells.  In 
healthy cells the cytoprotective effect of HO-1 is activated via ROS. As HO-1 expression 
appears to confer some protection to AML cells, we wanted to determine whether the 
enhanced HO-1 expression in response to ara-C or DNR was being medicated through 
a ROS-dependent response. wt THP1 and U937 cells were treated with either ara-C or 
DNR for up to 6 h, before incubation with the ROS indicator fluorescent probe H2DCFDA 
(1 μM). Flow cytometry was then used to examine ROS generation over time. Figure 3.9 
A shows significantly enhanced H2DCFDA oxidation in wt THP1 cells over time in 
response to both ara-C and DNR exposure, indicating increased ROS levels. Figure 3.9 
B indicates a ‘bi-phasic’ response to ara-C in U937 cells, a significant decrease in ROS 
generation can be seen in the first 30 min of ara-C exposure, before a return to basal 
levels. A significant increase can be seen in response to DNR in U937 cells with levels 
remaining raised throughout the time course. Potentially suggesting ROS levels are 
affected by ara-C and DNR in AML cells and therefore may be implicated in the HO-1 
protective response.   
 
3.3.6 NAC inhibits apoptosis induced by ara-C and DNR exposure. To confirm the 
role of ROS in the HO-1 protective response we utilised the antioxidant NAC, which 
quenches ROS activity present within the cellular environment. We wanted to determine 
whether NAC could block ara-C or DNR induced apoptosis by inhibiting ROS dependent 
HO-1 induction. We treated both wt THP1 and U937 cells with ara-C or DNR with or 
without NAC. Figure 3.10 A shows that NAC inhibits apoptosis and (B) represses HO-1 
induction in both ara-C and DNR treated wt THP1 and U937 cells suggesting that ROS 
is partly responsible for ara-C and DNR induced cell death in AML cells.  
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Figure 3.9: Generation of ROS in AML cells in response to ara-C and DNR. (A) wt 
THP1 and (B) U937 cells were treated with ara-C (0.5 µM, left panels) and DNR (0.2 µM, 
right panels) for up to 6 h, then washed with PBS and incubated for a further 15 min with 
the fluorescent probe H2DCFDA (10 μM). Cleavage of H2DCFDA/ ROS production in 
response to chemotherapeutic drug exposure was examined using flow cytometry. 
Circles represent mean ± SEM (n = 3). Statistical significance was calculated by 
Students t-test; * p≤0.05.  
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Figure 3.10: N-acetylcysteine (NAC) inhibits apoptosis induced by ara-C and DNR 
exposure and prevents induction of HO-1.  (A) U937 and wt THP1 cells were treated 
with ara-C (0.5 µM) or DNR (0.2 µM) and incubated for 24 h, with or without 30 min NAC 
pre-treatment (10 µM for DNR treated cells and 5 µM for ara-C treated cells). Cells were 
washed and stained with annexin-V/ PI, before flow cytometry.  (n = 1). (B) U937 and wt 
THP1 cells were treated as above before RNA was extracted and HO-1 mRNA 
expression was measured using qRT-PCR. Bars represent mean ± SEM. (n = 1). 
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3.4 Discussion 
In this chapter we have explored the role of HO-1 within cytoprotection and cell survival 
in response to either ara-C or DNR treatment in both AML patient samples and AML cell 
lines.  We have shown increased HO-1 expression in response to both ara-C and DNR 
in a time and dose-dependent manner. This reflects our previous work, which shows that 
enhanced basal levels of HO-1 protects AML cells from apoptosis in response to both 
NF-κB inhibition with BAY11-7082 and the proteasome inhibitor, bortezomib, another 
chemotherapeutic agent used in the treatment of MM. [47, 49].  
 
Cell viability is decreased in both AML cell lines and patient samples in response to 
increasing chemotherapeutic agent (ara-C and DNR) concentration and exposure time 
(Figure 3.1 and 3.2) which would be expected. We also investigated the effect of varying 
concentrations of etoposide, amsacrine, bortezomib, DNR and mitoxantrone on cell 
viability over a 48 h time course. Yet again both increasing drug concentration and 
exposure time was shown to significantly reduce cell viability within the population. 
   
HO-1 expression is consistently induced over 24 h in response to ara-C and DNR in a 
broad range of morphologic and cytogenetic subtypes of primary human AML cells and 
human AML cell lines [101]. Even though HO-1 expression is increased in response to 
either ara-C or DNR treatment interestingly, HO-1 mRNA expression is increased further 
when AML cells are treated with a combination of both agents (Figure 3.4 B). This could 
potentially be due to each chemotherapeutic agent utilising a different mode of action to 
induce apoptosis. However, the percentage of viable cells present within the combined 
treatment population is actually between that of with separate ara-C or DNR exposure 
(Figure 3.1 B). 
 
When HO-1 expression is silenced in both wt THP1 and U937 cells in combination with 
either ara-C or DNR treatment a greater apoptotic response is induced. This in 
combination with the enhanced ROS generation observed reinforces the chemo-
protective role of HO-1 in AML cells. By quenching the ROS levels induced by these 
drugs we were able to prevent HO-1 up-regulation. This suggests that protection from 
apoptosis conferred to the AML cell is mediated through the generation of ROS. 
Interestingly, another report has shown enhanced ROS generation in response to ara-C 
in U937 cells [103].  
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Kim et al (2006) confirmed HO-1 involvement in cytoprotection against cisplatin 
exposure in the auditory cell line, H4I-OC1. Protection was provided by carbon 
monoxide and bilirubin which inhibited the generation of ROS [106].  
 
Furthermore, a study from Nuhn et al (2008), has shown that HO-1 expression is usually 
increased in human pancreatic cancer cells and is increased further by the addition of 
cytotoxic agents [107]. Both ROS and HO-1 expression have also been shown to be up 
regulated in response to cisplatin treatment in A549 cells, a lung cancer cell line. 
Interestingly, when a HO-1 inhibitor, ZnPP was added, ROS expression was elevated 
even further [108].  Our study, however, is the first to show that chemotherapy-induced 
ROS levels may be linked to the expression of HO-1 in AML [101]. 
 
Silencing of HO-1 expression in both wt THP1 and U937 cells showed a strong decrease 
in the percentage of viable cells after ara-C or DNR treatment. Therefore we suggest 
inhibiting HO-1 could potentially enhance AML cell response to ara-C and DNR 
treatment in vivo.  Kim et al (2008) also transfected A549 cells with HO-1 siRNA, a 
decrease in cell viability in response to cisplatin exposure was noted [108]. Whilst Fang 
et al (2004) have shown the presence of a HO-1 inhibitor in vivo can enhance tumour 
responsiveness to chemotherapeutic agents [109].  
 
There are a number of different proposed mechanisms for the cytoprotective effect of 
ROS-induced HO-1 in AML cells.  The first is by decreasing the levels of the pro-oxidant, 
haem [109, 110] the second by increasing the concentration of bilirubin, an antioxidant 
[109];  and the final mechanism is by increasing the levels of carbon monoxide, an anti-
apoptotic molecule [66, 111, 112]. Together, these mechanisms may act either alone or 
in combination to protect cancer cells from apoptosis.  Interestingly AML cells seem to 
have the ability to manipulate this pathway in order to provide themselves with a growth 
advantage over normal non-cancerous cells.  
 
We have recently reported that basal levels of HO-1 are low compared to normal non-
cancerous cells and that NF-κB regulation reduces basal HO-1 expression [49]. 
Moreover, Nrf2 activation is able to override this regulation [49]. In fact, a number of 
transcription factors can regulate HO-1 expression such as Nrf2, AP-1 and NF-κB [78-
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80].  During this chapter we have concentrated on the role of HO-1 expression in 
regulating chemotherapy induced apoptosis but we are not in a position to exclude the 
involvement of other transcriptional elements. 
 
 
 
 
Figure 3.10: Overview of cell viability in relation to HO-1 expression. Diagrammatic 
representation of HO-1s expression in relation to cell viability. (A) ara-C and DNR or a 
combination thereof induce HO-1 mRNA and protein expression resulting increased cell 
viability and reduced cell apoptosis. (B) When HO-1 expression is silenced, cell viability 
is reduced thus increase cell apoptosis was seen [99]. 
 
 
To conclude, we report silencing HO-1 expression increases the in-vitro sensitivity of 
AML cells to ara-C and DNR, the two front-line chemotherapy agents currently widely 
used to treat the disease. Previously we have shown that HO-1 plays an important role 
in protecting AML cells from apoptotic stimuli and here we propose that this is likely to be 
clinically relevant. Therefore HO-1 warrants further investigation as a potential target for 
future therapeutic strategies.  
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Chapter 4: Exploring cytarabine resistance in AML 
cells 
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4:1 Introduction 
Currently within the clinic setting ara-C and DNR are both used to treat AML in younger 
and fitter patients. After extensive literature review regarding AML ara-C resistance and 
the follow on from our groups focus we decided to investigate ara-C resistance in more 
detail. Over the last 10 years a number of research groups have developed various 
leukaemia resistant cells lines to front-line chemotherapeutic agents.  
 
For example Oerlemans et al (2008) produced a THP1 bortezomib resistant cell line 
which over-expressed the proteasome subunit β5 (PSMB5) [113].  Bortezomib is 
licenced for use in MM treatment [5] however a number of groups have recently been 
investigating its use within AML treatment [114]. Whilst Funato et al (2000) developed an 
ara-C resistant K562 (K562/AC) cell line by increasing ara-C concentration and 
exposure over a 3 month period.  KF-19, an human Myeloid Leukaemia cell line was 
established by Fukuda et al (1996), they also went on to develop three resistant sub 
lines which were resistant to ara-C, adriamycin and vincristine; KF-19AraC, KF-19ADR 
and KF-19VCR [115]. 
 
Funato et al (2000) then went onto explore K562/AC sensitivity towards other 
chemotherapeutics agents; vincristine, adriamycin and etoposide. The K562/AC cells still 
maintained a similar degree of sensitivity towards each of above agents compared to 
that of their parental K562 cells. However a decrease in Deoxycytidine Kinase (dCK) 
expression was noted. Thus the authors proposed a link between decreased dCK 
expression and ara-C resistance in leukaemia cells. During ara-C metabolism, ara-C is 
phosphorylated by dCK, before being incorporated into the cell’s DNA. Therefore 
reduced dCK could result in cellular resistance to ara-C because ara-C initial 
phosphorylation is inhibited [44].  
 
A number of ara-C resistance mechanisms within AML primary and cell lines have been 
proposed recently, briefly explained in Table 4.1. 
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Table 4.1: Resistance Theories 
Cell line Resistance mechanism Reference 
THP1 bortezomib resistant 
cell line 
PSMB5  over-expression [113] 
K562/AC dCK down regulation 
thus initial ara-C 
phosphorylation inhibited 
[44] 
K562/AC  IGF-1 up-regulation in 
response to ara-C 
[43] 
Ara-C resistant cell lines DFS linked to hENTI 
expression. Absence of 
hENTI results in shorter 
DFS 
[42] 
 
Abe et al (2006) utilised Funatos’ (2000) ara-C resistant K562/AC cells to explore 
insulin-like growth factor 1 (IGF-1) expression and its involvement in ara-C resistance. 
IGF-1 was subsequently up-regulated in the ara-C resistant cells, K562/AC. When ara-C 
sensitive K562 cells were incubated with both ara-C and the IGF-1 ligand, protection 
against ara-C induced apoptosis was seen. However the addition of IGF-1 receptor 
neutralizing antibody, significantly inhibited cell growth and increased apoptosis. 
Potentially indicating that IGF-1 is involved in cellular acquired ara-C resistance. The 
group goes on to further explore IGF-1 expression in 27 patient AML samples and found 
IGF-1 expression to be higher in patients in the refractory stage after therapy containing 
ara-C than those at diagnosis. Therefore, suggesting inhibiting IGF-1 could prove be a 
potential therapeutic approach to overcoming ara-C resistance [43]. 
 
Another proposed ara-C resistance mechanism involves Human equilibrative nucleoside 
transporter 1 (hENT1). Galmarini et al (2002) found that 93% of AML patients showed 
expression for hENT1 at diagnosis. The small minority of patients who did not express 
the transporter, had shorter Disease Free Survival (DFS) than those who did, therefore 
suggesting the absence of the transporter, hENTI could be involved in ara-C resistance 
[42].  hENT1 is one of the main transporters of ara-C in AML blast cells [116].  
 
Ara-C resistant cell lines have also been shown to have increased Cytoplasmic 5’-
nucleotidase (5NT) expression and enzyme activity compared to their sensitive controls. 
Galmarini et al (2002) have gone on to connect high 5NT expression in AML patients 
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with ara-C resistance [42]. However, the group have previously reported high 5NT 
expression is related to AML patient outcome [41]. But, they later went on to report CR 
(complete remission) is related to ara-C dose in patients expressing low levels of 5NT at 
diagnosis [42]. 
 
However we appear to be the first group to investigate the cytoprotective gene, HO-1s 
involvement and regulation in ara-C acquired resistance in AML cell lines.  
 
4.2 Aims 
In this chapter we aim to create an ara-C resistant THP1 cell line (THP1ara-C(1)) to 
explore the cytoprotective pathways involved within apoptosis. We want to investigate 
functional changes which have occurred due to ara-C acquired resistance and establish 
whether the acquired ara-C resistance is a transient or stable response. 
 
4.3 Methods  
Cell culture containing wt THP1 cells was refreshed with ara-C (1 µΜ) weekly. Ara-C 
resistance was achieved by stepwise (an increase of 0.2 μM per week) weekly media 
refreshments (Figure 4.1) these cells were referred to as THP1ara-C(1) [113] [44].  The 
dose used to refresh the cells was selected on the therapeutic concentration (1 μM) 
found in AML patients treated with ara-C [105]. Resistance to ara-C was assessed via 
apoptotic assay using both CellTitre-Glo® Luminescent Cell Viability Assay and Trypan 
Blue Exclusion Assay. To explore whether ara-C resistance was a transient or stable 
response, ara-C media refreshment was withdrawn for 4 weeks and ara-C resistance 
was explored again as previously described, these cells are referred to as THP1ara-C(1) 
TW.     
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Figure 4.1: ara-C resistance development in THP1ara-C(1) over a 9 week period. wt 
THP1 cells were exposed to increasing doses of ara-C.   
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4.4 Results  
4.4.1 Confirming resistance to ara-C. To confirm that THP1ara-C(1) cells had acquired 
a resistance to ara-C, both THP1ara-C(1) and wt THP1 cells were treated with 
increasing doses of ara-C (0.2- 200 μM) over 48 h. Figure 4.2 A shows increased cell 
death within the wt THP1 population compared to that of the THP1ara-C(1) cells in a 
dose dependant manner. Similarly  Figure 4.2 B illustrates increased cell death within 
the wt THP1 population in response to 10 μM ara-C in a time-dependent manner and 
confirms that wt THP1 are significantly more susceptible to ara-C induced cell death 
than the THP1ara-C(1) population. 
 
Next we wanted to explore whether the THP1ara-C(1) cells showed any resistance 
towards other chemotherapeutic agents also used in the treatment of AML. Figure 4.3 A-
C demonstrates cell death in response to varying concentrations of bortezomib, 
etoposide and DNR after 24 h of drug exposure. Both wt THP1 and THP1ara-C(1) cells 
appear to be equally sensitive to etoposide (IC50 values for wt THP1 35 µM and 
THP1ara-C(1) 70µM) and DNR (IC50 values for wt THP1 0.5 µM and THP1ara-C(1) 0.55 
µM) and show a significant decrease in cell viability with increasing chemotherapeutic 
concentration. Interestingly however, the THP1ara-C(1) cells show a small but significant 
reduction in sensitivity towards bortezomib (IC50 values for wt THP1 9 nM and THP1ara-
C(1) 60 nM) compared to the wt THP1 cells (Figure 4.3 A).  
 
Table 4.1 states wt THP1 and THP1ara-C(1) IC50 values for ara-C, bortezomib, DNR 
and etoposide. 48 h post treatment with ara-C, wt THP1 IC50 value is 6 μM whilst 
THP1ara-C(1) IC50 is increased to 100 μM. IC50 values for bortezomib, DNR and 
etoposide are after 24 h exposure. 
Table 4.1: IC50 for chemotherapeutics used in AML treatment.  
  
chemotherapeutic agent 
IC50 
wt THP1 THP1ara-C(1) 
  ara-C    6 μM   100 μM 
  Bortezomib    9 nM    60 nM  
  DNR    0.5 μM   0.55 μM 
  etoposide    35 μM   70 μM 
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Figure 4.2: THP1ara-C(1) show decreased sensitivity towards ara-C compared to 
wt THP1. (A) Both wt THP1 and THP1ara-C(1) cells were incubated with varying doses 
of ara-C (0.2, 2, 10, 20, 200 μM) for 48 h before cell viability was analysed by CellTitre-
Glo® Luminescent Cell Viability Assay (n = 3).  (B) wt THP1 and THP1ara-C(1) cells 
treated with ara-C (10 μM) for 24, 48 and 72 h before cell viability was analysed by 
CellTitre-Glo® Luminescent Cell Viability Assay (n = 3). Cell number is expressed as a 
percentage of the control. Circles represent the mean ±SEM. Statistical significance was 
calculated by Student’s t-test; *p≤0.05.  
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Figure 4.3: THP1ara-C(1) cell maintain their sensitivity towards other 
chemotherapeutics used to treat AML. (A) wt THP1 and THP1ara-C(1) cell were 
treated with varying dose of bortezomib (0, 0.1, 1, 5, 10, 100 nM) (B) etoposide (0, 0.1, 
1, 5, 10, 100 μM) or (C) DNR (0, 0.05, 0.2, 0.5, 1, 5 μM) for 24 h before cell viability was 
analysed by CellTitre-Glo® Luminescent Cell Viability Assay. Cell number is expressed 
as percentage of control. Circles represent the mean ±SEM (n = 3). Statistical 
significance was calculated by Student’s t-test; *p≤0.05.  
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4.4.2 Ara-C resistance alters cell doubling rate. To investigate any potential 
difference in cell proliferation rate between both wt THP1 and THP1ara-C(1) cells we 
used both Trypan Blue exclusion assay and a clonogenic methylcellulose assay (Figure 
4.4). Figure 4.4 A shows the cell proliferation of both wt THP1 and THP1ara-C(1) cells 
as analysed by Trypan Blue exclusion assay. The cell doubling rate of THP1ara-C(1) is 
significantly increased compared to wt THP1 control cells. The doubling times for wt 
THP1 and THP1ara-C(1) are 2.2 days (SEM ± 0.10) and 2.7 days (SEM ± 0.07), 
respectively. Figure 4.4 B illustrates the number of THP1ara-C(1) colonies produced 
over 14 days is significantly reduced compared to that of the wt type THP1 cells. Figure 
4.4 C examines the granularity of both cell types as assayed by flow cytometry. Both 
forward and side scatter have increased for THP1ara-C(1) indicating the cells have 
increased in volume and granularity. 
  
Next we wanted to examine how continual ara-C exposure affected the cells ability to 
cycle. We investigated cell cycling in wt THP1, THP1ara-C(1) and THP1ara-C(1) 
Treatment Withdrawn (THP1ara-C(1) TW) cells (Figure 4.5). THP1ara-C(1) TW cells are 
ara-C resistant THP1ara-C(1) cells where weekly ara-C refreshment has been 
withdrawn. In the ara-C resistant THP1ara-C(1), a decrease in the number of cells 
undergoing G1 and G2 phase and an increase in the number of cells in S phase was 
reported in response to continual ara-C exposure compared to the control wt THP1 cells. 
Upon ara-C withdrawal (THP1ara-C(1) TW), both G1 and S phase appear to return to 
that of the control wt THP1 cells. Potentially suggesting the removal of continual ara-C 
exposure is rescuing the cells from S phase and allowing them to progress into G2 
phase.  Therefore ara-C is affecting the cells ability to progress from S phase to G2 
phase.    
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Figure 4.4: THP1ara-C(1) Cell proliferation is reduced compared to that of the wild 
type THP1 AML cells.  (A) 25x104 wt THP1 and THP1ara-C(1) were cultured for 7 days 
and the number of viable cells was determined daily by Trypan Blue exclusion assay. 
Each circle represents the mean ±SEM (n = 3).  (B) 2x104 wt THP1 or THP1ara-C(1) 
were plated in  methylcellulose medium and incubated for 14 days. Number of colonies 
present was imaged on days 1, 4, 7, 10, 13, and 14 (right panel) and visualised counted 
on day 14. Each bar represents the mean ±SEM (n = 3). (C) Granularity (forward and 
side scatter) of wt THP1 and THP1ara-C(1) cells was measured using flow cytometry. 
Statistical significance was calculated by Student’s t-test; *p≤ 0.05.   
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Figure 4.5: S phase is increased in THP1ara-C(1) cells. 2 x 106 wt THP1, THP1ara-
C(1) and THP1ara-C(1) TW cells were harvested and fixed using 100% ethanol. Cells 
were stained with PI before analysis using flow cytometry. (A) Visual diagrammatic 
representation of cell cycling within each cell line. (B) Bar chart indicating percentage of 
cells in each phase of the cell cycle. Each bar represents the mean ±SEM (n = 3). 
Statistical significance was calculated by Student’s t-test; *p≤ 0.05.   
  
75 
 
4.4.3 Exploring the effect of combination chemotherapy on ara-C resistant and 
non-resistant cells. During AML treatment, a number of chemotherapeutics agents can 
be used in combination; for example, ara-C and DNR are often combined in a ‘7+3’ 
treatment regime [19, 20] Bortezomib is licenced for use in Multiple Myeloma treatment 
however we have previously explored bortezomib effect on AML cells and found them to 
be less sensitive towards bortezomib than their control non-cancerous cells [47]. Thus 
we decided to explore the effect of different combinations of these drugs on cell death in 
both the wt THP1 and THP1ara-C(1) cells.  
 
wt THP1 and THP1ara-C(1) cells were treated with either ara-C (10 µM), DNR (0.2 µM), 
bortezomib (10 nM), or combinations thereof, for either 24 or 48 h (Figure 4.6 A-B). A 
significant increase in cell death was seen in both wt THP1 and THP1ara-C(1) cells in 
response to DNR, bortezomib and all drug combination treatments at 24 h. Again, 
THP1ara-C(1) showed reduced sensitivity towards bortezomib whilst they maintained 
sensitivity towards DNR.  However, by 48 h post bortezomib treatment the number of 
viable THP1ara-C(1) cells is greatly reduced compared to that at 24 h, thus suggesting 
the THP1ara-C(1) cells experience a delayed response to bortezomib. As expected wt 
THP1 cells show a significant increase in cell death in response to ara-C alone 48 h post 
treatment, whilst both wt THP1 and THP1ara-C(1) show a significant increase in cell 
death in response to DNR, bortezomib and  all combinations thereof.    
 
4.4.4. Ara-C resistance alters basal expression of cytoprotective genes. We wanted 
to explore the basal expression of genes involved in cytoprotection thus we used qRT-
PCR. As we have previously shown in chapter 3, upon ara-C and DNR treatment, HO-1 
expression is increased in wt THP-1, HL60, U937 cell lines and AML patient samples. 
Thus we predicted HO-1 expression would also be increased in the ara-C resistant 
THP1 cells and thus wanted to examine other cytoprotective gene expression in 
response to prolonged ara-C exposure. Figure 4.7 A illustrates the expression of HO-1, 
NQO1 and Nrf2 mRNA, all of which are significantly down-regulated in THP1ara-C(1) 
cells. Figure 4.7 B examines protein expression of these cytoprotective genes and 
reiterates the results observed at mRNA level. Due to the nature of maintaining ara-C 
resistance in THP1ara-C(1) cells we wanted to further investigate the natural variation in 
cytoprotective gene expression over a 7 day time course. qRT- PCR was again utilised 
to investigate HO-1, NQO1, Nrf2 and GCLM mRNA expression (Figure 4.8 A).  NQO1 
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and Nrf2 mRNA expression is down-regulated, relative to the control wt THP1 cells, 
throughout the 7 day time course. However, HO-1 is up regulated on Day 6 in the ara-C 
resistant THP1ara-C(1) cells. The increase in HO-1 regulation could be explained by the 
following scenario, the cells are usually refreshed with media and ara-C on Day 6, 
therefore prior to feeding we would expect elevated HO-1 levels due to increased 
cellular and oxidative stress induced by lack of media nutrients and the presence of ara-
C. Nrf2 expression also appears slightly elevated on Day 6 therefore mirroring HO-1s, 
which is unsurprisingly as Nrf2 is known to induce the expression of HO-1.   
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Figure 4.6: THP1ara-C(1) show delayed response to bortezomib but remain 
sensitive towards DNR and combinations of chemotherapeutic agents. (A) wt 
THP1 and THP1ara-C(1) cells were treated with ara-C (10 μM), bortezomib (10 nM), 
DNR (0.2 μM), or combinations thereof, for 24 h  or (B) 48 h before cell viability was 
analysed using CellTitre-Glo® Luminescent Cell Viability Assay. Cell number is 
expressed as percentage of control. Bars represent the mean ±SEM (n = 3). Statistical 
significance was calculated by Student’s t-test; *p≤0.05. Abbreviations Btz = Bortezomib. 
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Figure 4.7:  Basal expression of key cytoprotective genes is down-regulated in 
THP1ara-C(1) AML cells. (A) RNA was extracted from wt THP1 and THP1ara-C(1) for 
qRT-PCR analysis of basal  HO-1, NQO1 and Nrf2 mRNA expression. Bars represent 
the mean ±SEM (n = 3). (B) Whole cell protein extracts were collected from wt THP1 and 
THP1ara-C(1) for Western immunoblotting analysis of basal HO-1, NQO1 and Nrf2 
protein expression. Membranes were probed with β-actin to ensure equal protein loading 
across all samples (top panel). Quantity One 1-D Analysis software (BioRad) was 
utilised to quantify protein fold changes between cell types normalised to β-actin (bottom 
panel). Blots representative of three separate experiments. Bars represents mean ±SEM 
(n = 3). Statistical significance was calculated by Students t-test; * p≤0.05.  
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Figure 4.8: Examining natural variation of key cytoprotective genes over a 7 day 
time-course in THP1ara-C(1) cells. (A) RNA was extracted from wt THP1 and 
THP1ara-C(1) for qRT-PCR analysis of basal  HO-1, NQO1, Nrf2 and GCLM mRNA 
expression over a 7 day time course. Data for each time-point is normalised to wt THP1 
expression, represented by a dashed line. (Technical replicates = 2).  
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4.4.5 ROS production is elevated in ara-C resistant cells. Due to the altered 
expression of cytoprotective anti-oxidant genes in THP1ara-C(1) cells we further 
explored levels of ROS in these cells. Figure 4.9 A shows a significant increase in basal 
ROS production in THP1ara-C(1) cells. Next, we wanted to investigate ROS generation 
over a 7 day time course. Figure 4.9 B shows that ROS production cycles over the 7 day 
culture period and is dependent on levels of ara-C remaining in the culture medium. We 
decided to investigate how the enhanced ROS generation in the THP1ara-C(1) cells 
affected basal glutathione production. Figure 4.9 C shows a significant increase in 
glutathione production in the THP1ara-C(1) cells compared to control wt THP1s.  
 
 
4.4.6 Ara-C resistant cells show increased ROS generation in response to further 
ara-C exposure. We wanted to explore the potential for ROS generation in THP1ara-
C(1) and wt THP1 cells in response to either ara-C, DNR, bortezomib, or combinations 
thereof, after 24 h (Figure 4.10 A). ROS production is increased however not 
significantly, when either wt THP1 or THP1ara-C(1) cells are exposed to ara-C, DNR or 
a combination of both agents for 24 h. ROS generation is decreased, however not 
significantly, when either wt THP1 or THP1ara-C cells are exposed to bortezomib on its 
own or in combination with another chemotherapeutic agent. 
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Figure 4.9: Basal ROS levels are up-regulated in THP1ara-C(1). (A) wt THP1 and 
THP1ara-C(1) cells were incubated with the fluorescent probe H2DCFDA (1 µM) for 30 
min before ROS production was measured using flow cytometry and is expressed as a 
percentage of wt THP1 levels (n = 7). (B) This was repeated daily over a 7 day time 
course with wt THP1 levels represented by a black line (n = 3). (C) Glutathione 
production was investigated in wt THP1 and THP1ara-C(1) cells using Promega GSH-
Glo™ Glutathione assay. Bars represents mean ± SEM (n = 7). Statistical significance 
was calculated by Students t-test; * p≤0.05.  
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Figure 4.10: ROS production in wt THP1 and THP1ara-C(1) in response to 
chemotherapeutic agents. (A) Both wt THP1 and THP1ara-C(1) cells were treated with 
ara-C (5 µM), DNR (0.2 µM), bortezomib (10 nM) or combinations thereof for 24 h. Cells 
were collected and incubated with the fluorescent probe H2DCFDA (1 µM) for 30 min 
before ROS production was measured using flow cytometry. Bars represents mean 
±SEM (n = 3). Abbreviation Btz = bortezomib. 
 
  
83 
 
4.4.7 The effect of withdrawing ara-C from ara-C resistant THP1 cells. In order to 
find out whether ara-C resistance achieved in the THP1ara-C(1) cell line was a stable or 
transient response, weekly ara-C refreshment was withdrawn for 4 weeks prior to 
experimentation to produce a THP1ara-C(1) treatment withdrawn (THP1ara-C(1) TW) 
cell line. Cell doubling time was investigated and found to return to that of the wt THP1 
AML cells over a period of 7 days (Figure 4.11 A). Next, we wanted to examine whether 
THP1ara-C(1) TW resistance towards ara-C was maintained. Wt THP1 and THP1ara-
C(1) TW were treated with increasing doses of ara-C over a 72 h time course. 
Interestingly, resistance towards ara-C was maintained for at least 8 weeks after 
treatment withdrawal, suggesting a permanent changed has occurred to THP1ara-C(1) 
TW cells signalling pathways resulting in a transient resistance towards ara-C has been 
developed (Figure 4.11 B-C).  
 
 4.4.8 THP1ara-C(1) TW maintain reduced sensitivity towards combination 
chemotherapeutic treatment. (Figure 4.12 A-B) As we have previously shown that ara-
C resistance confers a level of resistance to bortezomib we wanted to explore the 
resistance of THP1ara-C(1) TW to different combinations of ara-C (10 μM), bortezomib 
(10 nM), DNR (0.5 μM),  for either 24 h or 48 h. At both 24 h and 48 h THP1ara-C(1) TW 
behaved in much the same way as THP1ara-C(1) (Figure 4.6 A-B).  
  
4.4.9 ROS production is reduced in THP1ara-C(1) TW. ROS production and 
Glutathione expression was explored in wt THP1, THP1ara-C(1) and THP1ara-C(1)TW 
cells to examine the effect of withdrawing ara-C treatment. A significant reduction in 
ROS production and glutathione expression was seen in THP1ara-C(1) TW  compared 
to both  wt THP1 and THP1ara-C(1) cells (Figure 4.13 A-B). ROS generation was 
examined further, after 24 h treatment with various combinations of ara-C (5 μM), DNR 
(0.2 μM) or bortezomib (10 nM). (B) ROS production was increased in wt THP1 and 
THP1ara-C(1) TW when treated with either ara-C, DNR or a combination thereof. 
However when treated with Bortezomib or combinations containing Bortezomib, ROS 
generation was decreased in both wt THP1 and THP1ara-C(1) TW cells. 
 
4.4.10 Nrf2 expression is increased after ara-C refreshment is withdrawn. Figure 
4.14 A shows Nrf2 mRNA expression is significantly increased after weekly ara-C 
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refreshment has been withdrawn. Whilst both HO-1 and Nrf2 mRNA expression remains 
similar to that of the control wt THP1 cells.  
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Figure 4.11: THP1ara-C(1) TW proliferation rate is returned to that of wt THP1s.  (A) 
25 x 104 wt THP1 and THP1ara-C(1) TW were cultured for 7 days and the number of 
viable cells was determined daily by Trypan Blue exclusion assay (n = 3).  (B) Both wt 
THP1 and THP1ara-C(1) TW cells were incubated with varying doses of ara-C (0.2, 2, 
10, 20, 200 μM) for 48 h before cell viability was analysed using CellTitre-Glo® 
Luminescent Cell Viability Assay  (n = 3).  (C) wt THP1 and THP1ara-C(1) TW cells 
treated with ara-C (10 μM) for 24, 48 and 72 h before cell viability was analysed using 
CellTitre-Glo® Luminescent Cell Viability Assay  (n = 3). Cell number is expressed as a 
percentage of the control. Circles represent the mean ±SEM. Statistical significance was 
calculated by Student’s t-test; *p≤0.05.   
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Figure 4.12: THP1ara-C(1) TW maintain delayed sensitivity towards combination 
chemotherapeutics therapy.  (A) wt THP1 and THP1ara-C(1) TW cells were treated 
with ara-C (10 μM), bortezomib (10 nM), DNR (0.2 μM), or combinations thereof, for 24 h  
or (B) 48 h before cell viability was analysed using CellTitre-Glo® Luminescent Cell 
Viability Assay. Cell number is expressed as percentage of control. Bars represent the 
mean ±SEM (n = 3). Statistical significance was calculated by Student’s t-test; *p≤0.05. 
Abbreviations Btz = Bortezomib. 
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Figure 4.13: THP1ara-C(1) TW  ROS production is reduced compared to both wt 
THP1 and THP1ara-C(1) cells. (A) Basal ROS production was investigated in wt THP1, 
THP1ara-C(1) and THP1 ara-C(1) TW cells following incubation H2DCFDA (1 μM) for 30 
min, using flow cytometry (n = 6). (B) Glutathione production was examined using 
Promega GSH-Glo™ Glutathione assay (n = 3). (C) wt THP1 and THP1ara-C(1) TW 
were treated with ara-C (10 μM), or bortezomib (10 nM)  DNR (0.2μM) for 24 h before 
samples were collected and ROS production was measured as described above (n = 3).  
Bars represents mean ±SEM. Statistical significance was calculated by (A, B) ANOVO 
(C) Students t-test; * p≤0.05.  
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Figure 4.14: Regulation of Nrf2 is elevated in THP1ara-C(1) TW. (A) RNA was 
extracted from wt THP1 and THP1ara-C(1) TW for qRT-PCR analysis of basal  HO-1, 
NQO1 and Nrf2 mRNA expression. (n = 3). Bars represent the mean ±SEM. Statistical 
significance was calculated by Students t-test; * p≤0.05. 
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4.5 Discussion  
During this chapter we have explored ara-C resistance in wt THP1 an AML derived cell 
line. Ara-C resistance was developed within these cells, over a period of 3 months, by 
stepwise increments in ara-C exposure (Figure 4.1) producing THP1ara-C(1) cells. Over 
the last decade a number of groups within the field have used similar methods to 
develop AML cell lines resistant to ara-C, DNR and bortezomib [44, 91, 113, 115]. 
Initially we investigated the extent of the acquired ara-C resistance in our THP1ara-C(1) 
cells compared to their wt THP1 control. During the 3 month course of ara-C exposure 
the THP1ara-C(1) cells developed a gradual decreased sensitivity towards moderate 
ara-C concentrations. However, they have still maintained sensitivity towards greatly 
increased ara-C concentrations, for example, 10 to 20 times greater than their usual 
weekly refreshment concentration (1 μM).   
 
Previously we have developed a lenalidomide and bortezomib resistant MM cell lines; 
RPM18226 and MM1S. They were produced by increasing the concentration and 
exposure of the desired chemotherapeutic agent over a 3 month period, thus producing 
RPMI8226 (Bz20 and Bz50) and lenalidomide (Len10 and Len20). Interestingly, basal 
HO-1 mRNA expression was increased in both lenalidomide and Bortezomib resistant 
RPMI8226 and MMIS cells [46]. However this does not appear to be the case in the ara-
C resistant THP1 ara-C(1) cells. 
 
Despite their resistance to ara-C we have shown that THP1ara-C(1) cells maintained a 
similar level of sensitivity towards other chemotherapeutic agents; DNR, etoposide and 
to a lesser extent bortezomib, compared to their control,  wt THP1. This is, perhaps, 
unsurprising as both the anthracycline antibiotic, DNR and etoposide utilise different 
mechanisms of action to initiate apoptosis [5]. Previous work by Funato et al (2000) has 
shown similar results in the ara-C resistant K562-derived cell line (K562/AC). Funato et 
al (2000) exposed K562/AC cells to other chemotherapeutics; vincristine, adriamycin, 
and etoposide used in the treatment of AML and found that the cells still maintained 
sensitivity towards these chemotherapeutic agents similar to that of the parental K562 
cells [44]. The K562 cells lacked Multidrug Resistant (MDR-1) and Multidrug Resistant 
Protein expression (MRP) which are both well known to be involved in drug resistance. 
Whilst dCK expression was reduced in the K562/AC cells which is consistent with other 
groups work involving ara-C resistance in leukaemia cell lines [44]. Fukuda et al (1996) 
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developed a new human myeloid leukaemia cell line, KF-19 and subsequent ara-C 
resistant; KF-19AraC. KF-19AraC showed decreased dCK expression along with cross 
resistance towards vincristine [115]. Suggesting decreased dCK expression and ara-C 
resistance are related. Funato et al went on to explore dCK effect within parental K562 
cells, dCK expression was inhibited via antisense oligonucleotides before ara-C 
treatment which resulted in decreased sensitivity towards ara-C [44]. dCK 
phosphorylates ara-C into its active metabolite which is incorporated into the cells DNA. 
[33] A reduction in dCK would therefore result in reduced ara-CTP generation and DNA 
incorporation therefore leading to potential ara-C resistance [44]. In the future we would 
like to explore the connection between ara-C resistant in THP1ara-C(1) cells and dCK, 
MDR-1 and MRP expression and whether cross resistance to the vinca alkaloid; 
vincristine exists.   
 
Oerlemans et al (2008) developed a bortezomib resistant THP1 cell line and noted an 
over expression of a mutant Proteasome subunit β5 (PSMB5) within the resistant cell 
line, thus linking bortezomib resistance to mutant PSMB5 over expression. The authors 
also confirmed resistance was not associated with increased expression of the MDR 
efflux pump [113].  
 
Using a variety of detection techniques we observed decreased proliferation rate in 
THP1ara-C(1) resistant cells (doubling time = 2.7 days; SEM ± 0.07) compared to that of 
the wt THP1 cells (doubling time = 2.2 days; SEM ± 0.10). This suggests that, despite 
their resistance to ara-C in terms of cell death, continual ara-C exposure is affecting the 
THP1ara-C(1)cells, cell cycle and cell doubling time. However upon weekly ara-C 
removal, the cells doubling time is restored to that of the wt THP1 cells, potentially 
suggesting the presence of continual ara-C exposure is suppressing THP1ara-C(1) 
ability to grow. Interestingly Funato et al (2000) found there wasn’t a difference in 
population doubling time between their ara-C resistant K562 and parental K562 cells 
[44]. 
 
We have previously shown increased HO-1 mRNA and protein expression in response 
to ara-C, DNR or a combination of both agents in AML patient samples and cell lines 
[101]. However this is not the case in the THP1ara-C(1) cells. There appears to be a 
significant decrease in both HO-1 mRNA and protein expression in response to 
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prolonged ara-C exposure along with NQO1, another cytoprotective gene. Interestingly 
Nrf-2 expression is also down regulated within these cells, thus potentially explaining 
HO-1’s and NQO1’s regulation. In chapter 6 we go on to explore Bach1’s regulation in 
greater detail. Bach1 is known to regulation a number of cytoprotective genes through 
the ARE complex.  
 
Kim et al (2008) reported a significant increase in HO-1 expression in A549 cells; a lung 
cancer cell line treated with cisplatin (10 μM). However, HO-1 basal expression is 
already significantly up regulated in A549 cells compared to other lung cancer cell lines. 
The authors go on to suggest A549 cells are more resistant to cisplatin than other lung 
cancer cell lines after investigating cell viability in response to a varying cisplatin 
concentrations, where A549 cells showed greater cell viability at each concentration than 
the other cell lines. Potentially suggesting the A549s’ increased cisplatin resistance 
could be due to increased HO-1 expression. Therefore, when A549 cells were treated 
with both a; HO-1 inhibitor, ZnPP and cisplatin, a significant decrease in cell viability, 
was seen. Suggesting HO-1 is involved in cisplatin resistance.  The authors then go onto 
the explore ROS generation in response to cisplatin or ZnPP or a combination thereof.  
ROS generation is increased in response to either of the above combinations and more 
so when both agents are used in combination. [108].This is similar to what we see in 
both wt THP1 and THP1ara-C(1) cells which are treated with either ara-C, DNR or in 
combination.   
 
Both ara-C and DNR exposure have been shown to increase ROS generation in AML 
cell lines [101]. Overall ROS generation is also significantly increased in THP1ara-C(1) 
cells. However on further daily examination, ROS generation remains increased up until 
the day before ara-C weekly refreshment and thereafter. The decrease in ROS 
generation in comparison to the wt THP1 control could be due to ara-C half-life resulting 
in reduced ara-C present in the media or increased stress in the wt THP1 control cells 
due to their increased cell doubling time. In response to increased ROS generation, 
glutathione generation was also up regulated in the THP1ara-C(1) cells.  
 
ROS generation in response to 24 h exposure to either ara-C or DNR or combinations 
thereof, was increased. However, when either wt THP1or THP1ara-C(1) cells were 
exposed to bortezomib or in combination with either ara-C or DNR, ROS production was 
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decreased, even though at least 80% of the THP1ara-C(1) population were viable and 
less so for wt THP1 cells. Potentially suggesting the pathways which bortezomib utilises 
to induce apoptosis are not reliant on ROS generation. 
 
Increased ROS generation in response to chemotherapeutics within AML cells has been 
shown by a number of groups [101]. The antineoplastic, Niclosamide used to treat 
tapeworm infections [5] results in increased ROS generation in the AML cell line HL60, 2 
h post exposure [117].  
 
 
 
Figure 4.15: Characteristics differences between wild type THP1 cells and 
THP1ara-C(1) cells. 
  
To conclude (Figure 4.16) the following cytoprotective genes; HO-1, NQO1, GCLM are 
significantly down regulated in THP1ara-C(1) cells along with the transcription factor 
Nrf2. However the regulation of Bach1 is significantly increased (explored in greater 
detail in Chapter 6). ROS generation is increased in response to ara-C exposure 
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however upon ara-C withdrawal ROS generation is reduced to below that of the control. 
Possibly suggesting the AML cells are utilising ROS generation to their advantage when 
exposed to continual ara-C.   
 
 
Figure 4.16: Proposed mechanism of action regarding cytoprotection and ROS 
generation. 
 
Even though, there does appear to be a number of functional changes which have 
occurred due to acquired ara-C resistance. Some of these changes appear to be 
reversed upon withdrawal of continuous ara-C refreshment for examples cell doubling 
time and ROS generation. 
 
Figure 4.17: Upon ara-C withdrawal ROS generation is decreased. 
 
However, upon ara-C withdrawal, THP1ara-C(1) TW still maintain a level of resistance 
towards ara-C and their sensitivity towards bortezomib and DNR which is comparable to 
the control wt THP1 cells. Thus potentially indicating the acquired ara-C resistance is a 
stable response and irreversible. It would be interesting to explore this response in vitro 
or with actual AML patient samples as opposed to cells lines and find out whether 
acquired ara-C resistance through continuous ara-C and DNR treatment cycles could be 
reversed upon chemotherapeutics  withdrawal once the patients is in remission.   
 
 THP1 
ara-C(1) 
TW 
   ROS 
  THP1 
ara-C(1) 
   ROS 
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Chapter 5: Ara-C resistance in relation to 
differential microRNA expression  
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5.1 Introduction  
We wanted to examine the regulatory role of miRNAs in the ara-C resistant AML cell 
line; THP1ara-C(1). Initially the SBI Cancer and Stem Cell miRNA Array was performed 
to identify any key miRNAs which were either up or down regulated in response to ara-c 
resistance. A number of miRNAs were highlighted and taken forward for further 
examination.  
 
miRNAs are short non-coding evolutionary conserved RNAs, between 18 and 25 
nucleotides in length. Their involvement in cell survival, proliferation and apoptosis has 
been implicated [8, 81, 88]. Recently a number of groups have investigated miRNA 
regulation within AML pathogenesis. 
 
Cimmino et al (2005) have shown both miR-15a and miR-16-1 target and negatively 
regulate the protein B Cell Lymphoma (Bcl-2) in Chronic Lymphocytic Leukaemia (CLL). 
Bcl-2 repression results in induced apoptosis [118].  
 
miR-21 has been shown to target both Phosphatase and Tensin Homolog Protein 
(PTEN) [91] and Programmed Cell Death Protein 4 (PDCD4) [93]. Li et al (2010) have 
suggested miR-21 is involved in ara-C sensitivity in the HL60 cell line, they found 
apoptosis was enhanced and ara-C sensitivity increased in response to anti-miR-21 
oligonucleotide and ara-C treatment. 
      
The quantification of miR-92a expression between plasma and leukaemia cells could 
potentially be used as a leukaemia monitoring parameter in ALL and AML patients [119]. 
miR-146a, miR-25, miR-26a, miR-25b and miR-196a have been found to be significantly 
associated with overall AML patient survival. Of which, miR-25 has been significantly 
associated with a good prognosis, whilst the other four miRNAs have linked to an 
negative outcome. In both AML and ALL patients which have a higher expression of 
miR-146a, a significantly shorter survival has been reported compared to that of patients 
with a lower miR-146a expression. After further analysis of additional patient samples 
the authors concluded miR-146a expression was significantly inversely associated with 
overall survival in AML patients thus it could be potentially be used as a prognostic 
marker [120]. 
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5.2 Aims 
During this chapter we aim to explore miRNA differential regulation in response to ara-C 
resistance in THP1ara-C(1) cells and explore miRNAs known to be involved in either 
proliferation or resistance and establish whether they are involved in THP1ara-C(1) 
reduced cell growth or acquired resistance.  
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5.3 Results 
5.3.1. Key miRNA involved in Cancer or Stem Cells were highlighted by SBIs’ 
QuantiMir Cancer or Stem Cell Arrays. MiRNA expression of miRNAs involved in 
either cancer or stem cell biology were investigated using the SBI’s QuantiMir Arrays 
(Figure 5.1 A). MiRNAs highlighted by either the SBIs’ QuantiMir Cancer or Stem Cell 
Array which fulfilled the following inclusion citeria were taken forward for further 
investigation (Figure 5.2); expression was either above 2 fold or below 0.5 fold of the 
control wt THP1 cells expression. miRNA was lsyed from synchronised control wt THP1 
cells and ara-C resistant THP1ara-C(1) cells following the protocol stated in 2.8.5. then,  
differentail miRNA expression was analysed. Finially, miRNA expression profiling 
identified 15 potential miRNAs which fulfilled the inclusion criteria. Figure 5.2 A 
investigates the differential expression of highlighted miRNAs from the arrays previously 
mentioned.  
 
miR-15a, miR-21, miR-92a, miR-149, miR-186, miR-200a and miR-222 miRNA 
expression was increased, whilst miR-101, miR-142-3p, miR-146a, miR1-83 and miR-
196a miRNA expression was decreased in the ara-C resistant cells. Table 5.1 briefly 
highlights key miRNAs and their target genes which are examined in greater detail 
throughout his chapter. 
Table 5.1: miRNA and their target gene.  
miRNA Targets Reference 
miR-15a Bcl-2 [118] 
miR-21 PTEN 
PDCD4 
[91] 
[93] 
miR-145 BIM [121] 
miR-146a TRAF6 
IRAK1 
[122]  
[123] 
miR-196a Bach1 
Annexin A1 
ERG 
[124] 
[125] 
[126] 
miR-200a Keap1 [127] 
miR-222 PTEN 
PUMA 
[128] 
[95] 
98 
 
 
Figure 5.1: SBI QuanitiMir Cancer and SBI QuanitiMir Stem cell Array. (A) miRNA 
was extracted from both wt THP1 and THP1ara-C(1) cells before SBI’s Cancer and 
Stem Cell Array was performed using qRT-PCR (n = 1). Table (right panel) states CT 
values for each miRNA included in the scatter plot.  
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THP1araC (1) CT value
CT values
THP1 araC(1) THP1
miR-92a 26.23 27.28
miR-93 29.89 29.80
miR-9 28.62 29.52
miR-101 36.99 34.90
miR-103 29.90 29.89
miR-106a 30.97 30.90
miR-106b 33.06 32.92
miR-107 33.96 33.82
miR-125a-5p 29.74 29.49
miR-125b 32.81 33.50
miR-126 33.34 33.67
miR-132 34.78 35.18
miR-134 35.77 35.41
miR-140 36.63 35.72
miR-142-3p 30.31 31.23
miR-145 37.56 36.40
miR-146a 35.03 36.67
miR-149 32.58 33.78
miR-155 28.98 29.33
miR-15a 30.88 31.93
miR-15b 26.89 27.66
miR-16 26.65 26.91
miR-17* 32.31 32.96
miR-17 29.96 30.48
miR-181a 34.42 35.04
miR-181b 32.67 32.70
miR-181c 29.39 29.49
miR-183 35.23 33.70
miR-185 32.77 32.97
miR-186 34.96 36.35
miR-18a 31.44 31.10
miR-191 25.77 25.91
miR-195 26.78 27.22
miR-196a 33.85 32.20
miR-30b 26.51 26.52
miR-19a+b 29.02 29.30
miR-200a 30.25 31.19
miR-206 34.82 34.96
miR-21 28.87 30.38
miR-210 30.95 30.37
miR-372 35.24 36.46
miR-221 28.89 27.96
miR-222 28.63 27.30
miR-223 24.16 24.85
miR-23a 25.36 26.27
miR-24 29.78 29.73
miR-25 27.65 28.52
miR-26a 29.50 29.87
miR-27a+b 32.91 33.02
miR-30c 24.34 24.70
miR-29a+b+c 33.84 34.49
miR-30a* 29.50 30.37
miR-30a 27.97 28.54
miR-296 35.97 35.42
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Figure 5.2:  miRNAs highlighted by the previous SBI QuantiMir Arrays taken 
forward for further investigation. (A) miRNA was extracted from wt THP1 and 
THP1ara-C(1) for qRT-PCR analaysis. THP1ara-C(1) fold change was standarised 
against control wt THP1 (represented by black line) expression which was  normalised to 
one. Bars represents mean ±SEM (n = 3). Statistical significance was calculated by 
Students t-test; * p≤0.05. 
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5.3.2 miR-15a expression is up regulated in the ara-C resistant, THP1ara-C(1) cells. 
miR-15a targets the pro-survival protein Bcl-2 in CLL [118]. Even though miR-15a 
expression is significantly up-regulated (Figure 5.3 A) in THP1ara-C(1) cells. Its target 
gene, Bcl-2 (Figure 5.3 B) expression is indifferent between both wt THP1 and THP1ara-
C(1) cells. These results appear inconclusive of whether miR-15a does target Bcl-2 in 
the ara-C resistant THP1ara-C(1) cells. We also need to consider both miR-15a and Bcl-
2 could potentially have other targets which affect their expression [129]. 
 
5.3.3 miR-21 is unaffected by ara-C treatment. miR-21 has been shown to target 
PTEN in K562 cells [91]. Figure 5.4 A shows miR-21 is significantly up regulated in 
THP1ara-C(1) cells, (B) whilst its target gene PTEN is significantly down regulated. 
Potentially confirming there is a miRNA and mRNA target relationship between miR-21 
and PTEN in THP1ara-C(1) cells. Both wt THP1 and THP1ara-C(1) cells were treated 
with additional ara-C for 24 h before miR-21 and PTEN mRNA expression in response to 
ara-C treatment was investigated using qRT-PCR. (C) miR-21 miRNA expression is 
significantly reduced further in wt THP1 cells in the presence of ara-C treatment, 
however its expression is indifferent between the control THP1ara-C(1) cells and 
additional ara-C treated THP1ara-C(1) cells. (D) In response to decreased miR-21 
miRNA expression in wt THP1, there is a slight increase in PTEN mRNA expression. 
However their does not appear to be a difference in PTEN mRNA between THP1ara-
C(1) treated and non-treated populations. These results appear inconclusive of whether 
miR-21 is affected by the presence of ara-C treatment.  
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Figure 5.3:  miR15a expression is up regulated in the ara-C resistant THP1ara-C(1) 
cells. miRNA and mRNA was collected from wt THP1 and THP1ara-C(1) cells, (A) miR-
15a miRNA basal expression and (B) Bcl-2 mRNA basal expression was analysed using 
qRT-PCR. Bars represent mean ± SEM (n = 3). Statistical significance was calculated by 
Students t-test; * p≤0.05. 
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Figure 5.4: miR-21 targets PTEN. miRNA and mRNA was collected from wt THP1 and 
THP1ara-C(1) cells before (A) miR-21 miRNA (B) PTEN mRNA expression were 
examined using qRT-PCR. wt THP1 and THP1ara-C(1) cells were treated with ara-C (10 
μM) for 24 h before miRNA and mRNA was collected for qRT-PCR investigation, (C) 
miR-21 miRNA and (D) PTEN mRNA expression. Bars represent mean ± SEM (n = 3). 
Statistical significance was calculated by Students t-test; * p≤0.05. 
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5.3.4 miR-34a expression is up regulated in THP1ara-C(1) cells whist their cell 
proliferation rate is repressed. miR-34a has been shown to target SIRT1 [96] whilst 
p53 has been shown to target miR-34a [130]. miR-34a is significantly up regulated by 14 
fold in the ara-C resistant THP1ara-C(1) cells compared to their control wt THP1s cells 
(Figure 5.5 A). In response, its target gene SIRT1 mRNA is significantly down-regulated 
confirming the miRNA and its target gene relationship in the ara-C resistant THP1ara-
C(1) cells. p53 mRNA expression is also down-regulated in the THP1ara-C(1) cells. 
 
We have previously shown during chapter 4 that the time taken for THP1ara-C(1) cells 
to double is significantly longer than that of wt THP1 control cells (Figure 4.3 A). We 
have also shown that upon withdrawal of ara-C refreshment, cell doubling rate returns 
back to that of the wt THP1 control cells (Figure 4.11 A). Thus suggesting miRNAs 
affected by continual ara-C exposure could be involved in cell doubling. We therefore 
wanted to explore miR-34a expression in THP1ara-C(1) TW cells. Ara-C refreshment 
was withdrawn for at least 4 weeks (Figure 5.5 C) prior to the experiment, miR-34a 
expression is significantly reduced in THP1ara-C(1) TW cells possibly suggesting its 
involvement  in cell doubling rate. 
 
5.3.5 miR-145 rescues AML cells from apoptosis. miR-145 expression is significantly 
down regulated in THP1ara-C(1) compared  to control wt THP1 cells (Figure 5.6 A). 
miR-145 indirectly targets the pro apoptotic gene Bim [121, 131], its mRNA  expression 
is unchanged by the presence of reduced miR-145 expression (Figure 5.6 B) in the 
THP1ara-C(1) cells. Bim, a member of the Bcl-2 family, is in involved in mitochondrial 
apoptosis [132]. The anti-apoptotic proteins Bcl-2 and Bcl-xl and pro apoptotic protein 
Bax mRNA expression are also unchanged between both wt THP1 and THP1ara-C(1) 
cells (Figure 5.6 C). 
 
Next we were intrested in establishing the functional repsonse of miR-145 in relation to 
ara-C treatment. miR-145 was overexpressed using a mimic which was transfected via 
nulecofection into both wt THP1 and THP1ara-C(1) cells. Cells were treated 8 h post 
transfection with ara-C (10 μM) before cell viabailty was examined 48 h post ara-C 
treatment. No difference between cell viabilty was observed after ara-C treatment with 
increased miR-145 expression in wt THP1 cells (Figure 5.7 A). However (Figure 5.7 B) 
when miR-145 expression was over expressed in THP1ara-C(1) cells,  a signiifcant 
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increase in cell viabilty post ara-C treatment was seen. Thus potentially suggesting 
increased miR-145 expression is involved in cell survival and chemoresistance 
responses.   
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Figure 5.5: A correlative relationship is shown between induced miR-34a 
expression and repressed cell doubling. miRNA and mRNA was collected from wt 
THP1 and THP1ara-C(1) cells (A)  miR-34a basal expression and (B) p53 and SIRT1 
mRNA expression was analysed using qRT-PCR. (C)  miRNA was collected from wt 
THP1 and THP1ara-C(1) TW cells, basal miR-34a expression was analysed using qRT-
PCR. (D) Diagrammatic representation of how cell doubling time is potentially regulated 
by miR-34a. Bars represent mean ± SEM. (n = 3) Statistical significance was calculated 
by Students t-test; * p≤0.05. 
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Figure 5.6: miR-145 targets BIM, a pro-apoptotic gene. miRNA and mRNA was 
collected from wt THP1 and THP1ara-C(1) cells before qRT-PCR analysis (A) miR-145 
miRNA expression, (B) Bim mRNA expression and (C) Bax, Bcl-xl and Bcl-2 mRNA 
expression. Bars represent mean ± SEM (n = 3). Statistical significance was calculated 
by Students t-test; * p≤0.05. 
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Figure 5.7: miR-145 rescues AML cells from apoptosis. 2 x 106 wt THP1 and 
THP1ara-C(1) cells were transfected via nucleofection (Amaxa) with either miR-145 
mimic (25 μM) or unscrambled miR-RNA (25 μM) control before (A) wt THP1 and (B) 
THP1ara-C(1) cells were treated with ara-C (10 μM) 8 h post transfection. 48 h post ara-
C treatment cell viability was analysed using CellTitre-Glo® Luminescent Cell Viability 
Assay. Bars represent mean ± SEM (n = 3). Statistical significance was calculated by 
Students t-test; * p≤0.05. Aberrations, miR = miR-196a mimic, C = ara-C (10 μM). 
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5.3.6 IRAK1 and TRAF6 are all down regulated in THP1ara-C(1) cells. miR-146a has 
been show to target both IRAK1 and TRAF6 [122] [123], however they are all down 
regulated in the THP1ara-C(1) cells of which IRAK1 is significant (Figure 5.8 A-B). 
Potentially suggesting the relationship between miR-146a and its target genes is specific 
to certain disease models.  
 
miR-222 is known to target both PTEN and PUMA expression [128] [95]. There is a 
slight increase in miR-222 expression (Figure 5.8 C) in the ara-C resistant THP1ara-C(1) 
cells, in response, both (D)  PTEN and PUMA mRNA is down regulated. However these 
experiments do not prove a miRNA- mRNA targeting relationship instead a trend.  
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Figure 5.8: miR-146a targets IRAK1 and Traf6 whilst miR-222 targets both PTEN 
and PUMA. miRNA and mRNA was collected from wt THP1 and THP1ara-C(1) cells,(A)  
miR-146a miRNA expression, (B) IRAK1 and Traf6 mRNA expression, (C) miR-222 
miRNA expression and (D) PTEN and PUMA expression was analysed using qRT-PCR, 
Bars represent mean ± SEM (n = 3). Statistical significance was calculated by Students 
t-test; * p≤0.05. 
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5.4 Discussion 
A number of miRNAs involved in both cancer and stem cell biology were highlighted by 
SBIs’ QuantiMir Cancer and Stem cell Array and thus taken forward for further 
examination. The selection of miRNA taken forward was based on the inclusion criteria 
previously mentioned in 5.3.1. Highlighted miRNAs were differentially expressed 
between the ara-C resistant and non-resistant THP1 cells. The aim of this chapter was 
to explore miRNA regulation in response to acquired ara-C resistance.  
 
The following highlighted miRNAs miR-15a, miR-21, miR-92a, miR-149, miR-186, miR-
200a and miR-222 were all up-regulated in the ara-C resistant; THP1ara-C(1) cells 
whilst miR-101, miR-142-3p, miR-145, miR-146a, miR-183 and miR-196a were all down 
regulated. miR-196a regulation in regards to ara-C resistance will be further discussed in 
Chapter 6. 
 
Dai et al (2011) noted an increase in miR-101 expression in docetaxol resistant head 
and neck squamous cell carcinoma cell lines; UMSCC-1 and SQ20B. Interestingly, a 
decrease in miR-101 expression was seen in the THP1ara-C(1) cells. Potentially 
suggesting miR-101 is involved in chemotherapeutic acquired resistance [133]. 
 
We have previously shown the THP1ara-C(1) have developed a reduced rate of 
proliferation compared to their  wt THP1 control cells (Chapter 4; Figure 4.3 A-C). Over-
expressed miR-15a and miR-16-1 in both K562 and HL60 cells has been shown to 
significantly inhibit cell proliferation. Gao et al (2011) observed miR-15a and miR-16-1 
indirectly targets the oncogene, Wilms’ tumour gene (wt1). They suggest miR-15a and 
miR-16-1 act as tumour suppressors by down regulating wt1 and therefore regulating 
cell proliferation [129]. wt1 is also known to regulate Bcl-2 expression [134]. We have 
shown an increase in miR-15a expression in the THP1ara-C(1) cells compared to their 
wt THP1 control cells. Thus, increased miR-15a expression could potentially be 
responsible for inhibited cell proliferation rate. We would like to explore the effect of a 
miR-15a mimic on cell proliferation within the THP1ara-C(1) cells. 
 
miR-15a also targets the anti-apoptotic gene Bcl-2 in CLL. When Bcl-2 is repressed by 
miR-15a, apoptosis is induced in the human megakaryoblastic leukaemia cell line, MEG-
01 [118]. However, miR-15a is significantly up regulated in the ara-C resistant, THP1ara-
111 
 
C(1) cells, whilst Bcl-2 expression remains indifferent between both ara-C resistant and 
non-resistant cells. In light of the above findings, I would expect the anti-apoptotic gene 
Bcl-2, expression to be increased in response to continuous ara-C exposure in 
THP1ara-C(1) cells. However this does not appear to be the case. Possibly suggesting 
miR-15a does not target Bcl-2 in AML cells, Bcl-2 has a different function or other 
miRNAs are also acting on Bcl-2 expression within THP1ara-C(1) cells for example miR-
125b or miR-155 [135]. We would like to explore miR-16-1 role and expression profile 
within ara-C resistance. 
 
The relationship between miR-21 and ara-C resistance has been explored by a number 
of research groups in different cell lines. miR-21 is known to target PTEN [91] and 
PDCD4 [92, 93]. Li, et al (2010) observed in HL60 cells, the presence of an antimiR-21 
oligonucleotide significantly sensitised the cells to ara-C treatment by inducing 
apoptosis, increased PDCD4 regulation was also seen, potentially explaining the cells 
response [93]. A similar response was reiterated in K562 cells by Hu et al (2010). miR-
21 was yet again inhibited by an antisense oligonucleotide, cell apoptosis was enhanced 
whilst PDCD4 regulation was increased [92]. miR-21 up regulation was also seen in 
K562 DNR resistant cells, however when PTEN expression was silenced, cell survival 
was significantly increased. The same response was seen when miR-21 was over 
expressed [91].  
 
We have also seen a significant increase in miR-21 expression and a subsequent 
decrease in its target gene, PTEN mRNA expression in the ara-C resistant THP1ara-
C(1) cells. Potentially reinforcing miR-21 involvement in ara-C acquired resistance. 
When wt THP1 and THP1ara-C(1) cells were treated with ara-C, 24 h post ara-C 
treatment a significant decrease in miR-21 expression and increased PTEN mRNA 
expression was seen in the wt THP1 cells, however miR-21 expression remained 
indifferent between the control and ara-C treated THP1ara-C(1) cells. We have 
previously shown in Chapter 4; Figure 1 A decreased cell viability in response to ara-C 
(10 µM) in wt THP1 control cells whilst cell viability remained the same in the THP1ara-
C(1) cells. Therefore, we have shown miR-21 expression is decreased in response to 
ara-C treatment in non-resistant AML cells. Further investigation is required regarding 
miR-21 and PTENs relationship in response to ara-C exposure and induced apoptosis in 
both ara-C resistant and non-resistant THP1 cells. We would also like to explore PDCD4 
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regulation and find out its involvement in ara-C induced apoptosis within the THP1ara-
C(1) cells.  
 
 
 
Figure 5.9: Exploring miR-21 and PTEN relationship in response to ara-C 
treatment. 
 
A number of studies have examined the role of miR-34a in cancer over the last four 
years. miR-34a expression has been shown to be reduced in both cancer cell lines and 
patient samples compared to control non-cancerous cells by a number of authors. For 
example  Li. Y et al (2009) reported miR-34a expression is reduced in human 
glioblastoma tissue [136] whilst Li. L et al (2012) have shown reduced expression in 5 
breast cancer cell lines and 14 out of 17 patient samples [137]. When both breast cancer 
cells and glioblastoma cells were transfected with miR-34a cell growth was inhibited 
[136, 137]. miR-34a was significantly up regulated in the ara-C resistant THP1ara-C(1) 
cells compared to their wt THP1 control whilst cell growth rate was significantly reduced.  
However when weekly ara-C refreshment was withdrawn from the THP1ara-C(1) cells 
for a minimum of 4 weeks, miR-34a expression returned to below that of control wt 
THP1 cells, whilst their cellular growth rate was returned to that of the wt THP1 control 
cells. Suggesting the presence of continuous ara-C exposure could be involved in both 
miR-34a regulation and cell proliferation rate. A similar response was seen by Ichimura 
et al (2010) when they stimulated K562 cells with PMA [97]. miR-34a’s target gene, 
SIRT1 [96] was down regulated in response to miR-34a increased expression. miR-34a 
could potentially regulate cell proliferation via SIRT1 and Bcl-2 regulation, due to down 
regulated SIRT1 and Bcl-2 in response to over expressed miR-34a via transient 
transfection [137]. However Bcl-2 was not down regulated in our THP1ara-C(1) cells, 
thus this theory is probably not likely for this particular disease model.  
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Havelange et al (2011) have shown both miR-145 and miR-196a are positively 
correlated with pro-apoptotic genes such as BIM and PTEN based on their miRNA-
mRNA profiling integration analysis [121]. When miR-145 is over expressed using an 
oligonucleotide, apoptosis was enhanced in K562 cells, an increase in BIM protein 
expression was also seen [121]. Due to the lack of predicted miRNA and mRNA 
interaction sites, BIM is regulated indirectly by miR-145 [121, 131]. In the ara-C resistant 
THP1ara-C(1) cells, miR-145 expression is down regulated basally when compared to 
the control wt THP1 cells whilst BIM expression is only marginally up-regulated, which 
could potentially be explained by the indirect relationship.  
 
However, over-expressed miR-145 in the ara-C resistant THP1 cells; THP1ara-C(1) 
rescues them from additional ara-C exposure and induced cell death. Diagram 5.2 briefly 
demonstrates this response.  
 
 
Figure 5.10: Increased miR-145 expression protects ara-C resistant AML cells from 
ara-C induced cell death. 
 
miR-146a has been shown to target TRAF6 in SNK6 a NK/T Cell Lymphoma (NKTL) 
cells [122] and IRKA1 [123]. However miR-146a, TRAF6 and IRKA1 are all down 
regulated in the ara-C resistant TH1ara-C(1) cells. 
 
We have shown a slight increase in miR-222 expression in the ara-C resistant THP1ara-
C(1) cells. miR-222 has been shown to target both PTEN [128] and PUMA [95]. A 
decrease in both PTEN and PUMA mRNA expression was seen in the THP1ara-C(1) 
cells therefore re-iterating the miRNA and mRNA targeted relationship in AML cell lines.  
 
To conclude we have explored the regulation of a number of miRNAs which were initially 
highlighted by SBIs Cancer and Stem Cell Arrays throughout this chapter. We have 
114 
 
shown over expressed miR-145 rescues ara-C resistant; THP1ara-C cells from high 
concentration of ara-C induced death. We have also explored the expression of miR-15a 
and miR-34a known to be involved in the regulation of cell proliferation.   
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Chapter 6: miR-196a and Bach-1 relationship in 
wild type THP1 and THP1ara-C(1) cells 
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6.1 Introduction  
Previously we have highlighted and discussed both Cancer and Stem cell specific 
miRNAs which were differential expressed in ara-C resistant and non-resistant THP1 
cells. miRNAs are short (between 18 and 25 nucleotides) evolutionary conserved RNAs 
[8, 88]. miR-196a was highlighted by the array and down regulated in the ara-C resistant 
THP1ara-C(1) cells compared to their wt THP1 control cells. miR-196a has been shown 
to target Annexin A1 [125], ETS transcription factor (ERG) [126], HOXA5 [138], HOX-C8 
[139] and Bach1 [124]. We have previously shown the transcription factor Bach1 is up 
regulated in the ara-C resistant, THP1ara-C(1) cell line. Thus we feel the relationship 
between miR-196a and its target gene Bach1 in ara-C resistance warrants further 
investigation.   
 
Recently a number of groups have explored miR-196a and its regulatory effect on its 
target genes. Luthra et al (2008) reported an inverse relationship between the 
expression of miR-196a and one of its targets, annexin A1 in twelve oesophageal, breast 
and endometrial cancer cell lines. The relationship was also observed in a further ten 
esophageal adenocarcinomas. The authors went on to investigate miR196a and annexin 
A1 expression in paired normal and tumour tissues from ten patients, they observed an 
increase in miR-196a expression and a subsequent decrease in annexin A1 expression 
in the tumour samples analysed. Over expression of miR-196a resulted in decreased 
annexin A1 expression in oesophageal, breast and endometrial cancer cell lines thus 
confirming miR-196a targets annexin A1 [125]. miR-196a has also shown to inhibit 
proliferation and enhance differentiation of mesenchymal stem cells which are derived 
from human adipose tissue, by binding to HOXC8 3-‘UTR [140]. Both miR-196a and 
miR-196b have been identified as regulators of ERG, Coskun et al (2011) explored the 
expression of both miRNAs during hematopoietic differentiation. A significant increase in 
miR-196a and miR-196b expression was seen in AML patient samples compared to 
control healthy samples  [126].  
 
Bach1 has been shown to regulate HO-1 expression in AML cells. Miyazaki et al (2001) 
observed reduced Bach1 mRNA expression and subsequent increased HO-1 mRNA 
expression which resulted in enhanced cell survival [70]. Hou et al (2010) concluded 
miR-196a represses Bach1, by directly acting on its 3’-UTR therefore transnationally 
repressing its expression and furthermore leading to the up regulation of HO-1 
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expression in human hepatoma cells. miR-196a has also been shown to inhibit hepatitis 
C virus expression (HCV) in human hepatocytes  [124]. 
 
miRNAs can target the regulation of both transcription factors and genes involved in 
cellular cytoprotection. Alongside miR-196a, miR-155 is also known to target and 
repress Bach1 expression in endothelial cells therefore allowing the induction of HO-1, 
its expression is induced via the NF-ƘBpathway by TNFα [141]. miR-101 and miR-132 
are both predicted to target Nrf2 expression by microRNA.org [142]. miR-217 and miR-
377 combined target HO-1 protein expression which leads to reduced HO-1 enzyme 
activity. When both miR-217 and miR-377 are knocked down HO-1 reduction is reversed 
in HEK 293 cells [143]. miR-128, miR-220b and miR-200c are all predicted to target HO-
1 expression using mircoRNA.org [142]. miR-122 has been shown to target HO-1 in 
Hepatocellular carcinoma cell line, Huh-7-cells [144]. 
 
We have previously shown the expression of HO-1 (Chapter 3) is increased in response 
to chemotherapeutics treatment. However we next wanted to explore the regulation of 
other cytoprotective genes in response to ara-C acquired resistance. This was examined 
with the aid of a ara-C resistant cell line developed in house; THP1ara-C(1). Interestingly 
a number of cytoprotective genes; HO-1, NQO1 and GLCM and their transcription factor 
Nrf2, were all down regulated in response to acquired ara-C resistance. Hence why we 
wanted to explore Bach1 regulation in THP1ara-C(1) cells. miR-196a has been shown to 
regulated Bach1, thus its and Bach1 relationship will be further explored during the 
content of this chapter. 
 
6.2 Aims 
The aim of this chapter is to explore both miR-196a and Bach1s relationship and 
expression in relation to ara-C acquired resistance in THP1ara-C(1) cells. We also want 
to confirm whether the regulation of miR-196a affects ROS generation and establish 
whether this is involved in ara-C resistance. Finally explore whether differential 
expression in miR-196a reverses ara-C acquired resistance. 
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6.3 Results  
6.3.1 Exploring the regulation of miRNAs involved in cellular cytoprotection. (A) 
SBI QuantiMir Cancer and Stem Cell Arrays combined results. miR-196a known to 
target Bach1, is down regulated in the ara-C resistant THP1ara-C(1) cell and is 
highlighted by a red dot. We were interested in investigating the expression of miRNAs 
which regulate BACH1, HO-1 or Nrf2 expression therefore we identified potential 
miRNAs using both microRNA.org [142] and relevant literature. (B) The expression of 
the identified miRNAs is displayed and represented as fold change. miR-377, miR-217, 
miR-155, miR-200b and miR-128 were all up-regulated in ara-C resistant THP1ara-C(1) 
cells whilst miR-132, miR-101, miR-122 and miR-196a were down regulated. Whilst 
miR-200c regulation was indifferent between the ara-C resistant and non-resistant THP1 
cells.  
 
Both miR-155 and miR-196a target Bach1 expression however their expression is 
subsequently different. Whilst HO-1 is targeted by miR-128, miR-200b, miR-217 and 
miR-377, their regulation is up, compared to the non-resistant control wt THP1 cells 
however miR-122 is down regulated compared to the other miRNAs and miR-200c 
regulation is indifferent between the ara-C resistant, THP1ara-C(1) and non-resistant wt 
THP1 cells. Nrf2 is targeted by both miR-101 and miR132 of which both are down 
regulated in the ara-C resistant, THP1ara-C(1) cells. A diagrammatic representation of 
the miRNA and their target genes mentioned above is present in 
 Figure 6.1 C. 
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Table 6.1: miRNAs and their target genes.  
 
miRNA Target Reference Source 
miR-155 
miR-196a* 
Bach1 [141] 
[124] 
miR-122 
miR-128 
miR-200b 
miR-200c 
miR-217 
miR-377 
HO-1 [144] 
microRNA.org [142] 
microRNA.org [142] 
microRNA.org [142] 
[143] 
[143] 
miR-101 
miR-132 
Nrf2 microRNA.org [142] 
microRNA.org [142] 
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Figure 6.1: miRNA which target cytoprotective genes HO-1 and Nrf2 in ara-C 
resistant, THP1ara-C(1) cells. (A) SBI QuantiMir Cancer and SBI QuantiMir Stem cell 
Array was performed on both wt THP1 and THP1ara-C(1) cells, samples were analysed 
using qRT-PCR. Results from both arrays were combined and presented (n = 1). (B) 
miRNAs involved in cellular cytoprotection, table represents miRNA fold change (n = 3). 
(C) Diagrammatic representation of miRNAs and corresponding cytoprotective target 
genes. Circles represent mean ± SEM, Statistical significance was calculated by 
Students t-test; * p≤0.05. 
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6.3.2 Bach1 basal expression is up regulated in THP1ara-C(1) cells in response to 
mi-196a down regulation. miR-196a has been shown to target the transcription factor, 
Bach1 [124]. The SBI QuantiMir Cancer Array indicated miR-196a expression was down 
regulated in the THP1ara-C(1) cells compared to their control, wt THP1 cells. Thus we 
wanted to explore the regulation of Bach1 in response to down regulated miR-196a. 
Figure 6.2 shows (A) miR-196a miRNA expression and (B) Bach1 mRNA expression 
which was investigated using qRT-PCR. miR-196a expression is significantly down 
regulated in THP1ara-C(1)  cells  whilst the regulation of Bach1, its target gene is 
significantly up regulated in THP1ara-C(1) cells compared to that of the wt THP1 control. 
Bach1 protein expression was analysed using Western immunoblotting. Figure 6.3 A 
reiterates the above point, increased Bach1 protein expression was seen in THP1ara-
C(1) cells (top panel). Difference in Bach1 expression from three independent Western 
blots was explored in greater detail using Quantity One 1-D Analysis Software which 
showed Bach1 expression was greater in THP1ara-C(1) cells.  
 
6.3.3 miR-196a mediates Bach1 expression. Next we wanted to confirm the direct 
targeting relationship between the miRNA, miR-196a and its target gene, Bach1. 
Genomic DNA extraction, primer PCR design and subcloning of the pMIR-REPORT 
reporter construct, were performed by Dr Lyubov Zaitseva as described previously [52]. 
This was examined using the Dual Glo Luciferase Assay System Kit (Figure 6.4 B). 
Previously mentioned, Bach1 is significantly up regulated in the ara-C resistant 
THP1ara-C(1) cells (Figure 6.2 B). miR-196a mimic was transfected into HEK 293 cells 
which significantly reduced pMIR-REPORT 3’UTR-Bach1 luciferase activity. Figure 6.4 
C explores different miR-196a mimic concentrations and its effect on pMIR-REPORT 
3’UTR-Bach1 luciferase activity. A significant decrease in pMIR-REPORT 3’UTR-Bach1 
luciferase activity was seen in response to varying miR-196a mimic concentration. To 
further explore and confirm the relationship between miR-196a and Bach1, (Figure 6.4 
D) miR-196 mimic was transfected into THP1ara-C(1) cells via nucleofection, before 
Bach1 mRNA expression was examined using qRT-PCR. A significant decrease in 
Bach1 mRNA expression was seen in the THP1ara-C(1) cells further confirming miR-
196a and Bach1s relationship. 
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Figure 6.2: miR-196a expression is down regulated in THP1ara-C(1) cells.  (A) 
miRNA and mRNA was collected from wt THP1 and THP1ara-C(1) cells before miR-
196a basal expression and (B) Bach1 basal expression was analysed  using qRT-PCR. 
(C) Diagrammatic representation of miR-196a expression in both wt THP1 and 
THP1ara-C(1) cells. Bars represent mean ± SEM (n = 3). Statistical significance was 
calculated by Students t-test; * p≤0.05.  
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Figure 6.3: Bach1 expression is up regulated in ara-C resistant, THP1ara-C(1) 
cells. (A) Whole cell protein extracts were collected from wt THP1 and THP1ara-C(1) for 
Western immunoblotting analysis of basal Bach1 protein expression (top panel) 
Membranes were probed with β-actin to ensure equal protein lysate loading across 
samples. Quantity One 1-D Analysis software (BioRad) was utilised to quantify protein 
expression changes between cell types (bottom panel). Blot is representative of three 
separate experiments, however Quantity One 1-D Analysis is representative of all three 
experiments. (B) Diagrammatic representation of predicted signalling pathway involving 
miR-196a and Bach1. Bars represent mean ± SEM (n = 3). Statistical significance was 
calculated by Students t-test; * p≤0.05. 
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Figure 6.4: miR-196a mediates Bach1 regulation. (A) Bach1 and miR-196a 3’UTR 
diagrammatic representation.  (B) HEK 293 cells were plated onto 6-well plates at 3.5-4 
x105/well and transfected using LipofectamineTM 2000  with total 500 ng DNA (250 ng 
pMIR-REPORTTM-Luciferase or pMIR-REPORT -3’UTR-Bach1 and 250 ng pMIR-
REPORTTM-β-gal Control Plasmid) with optional 25 µM miR-196a mimic and incubated 
before luciferase and β-galactosidase activities were measured 48 h after transfection 
using Dual-Glo Luciferase Assay System Kit (Applied Biosciences) on a 
WALLAC_Envision, 2103 Multi Label Reader (n = 3). (C) HEK 293 cells were transfected 
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as before with optional 25 µM, 37.5 µM or 50 µM miR-196a mimic before luciferase and 
β-galactosidase activities were measured as before (n = 1). (D) 2 x106 THP1ara-C(1) 
cells were transfected with either scrambled control siRNA (25 μM) or miR-196a siRNA 
(25 μM) via nucleofection technology and incubated for 24 h before Bach1 mRNA 
expression was analysed using qRT-PCR. Bars or Circles represent mean ± SEM (n = 
3). Statistical significance was calculated by Students t-test; * p≤0.05. 
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6.3.4 ROS generation is reduced in ara-C resistant THP1ara-C cells in response to 
reduced Bach1 expression. Previously shown in Chapter 4 Figure 4.10 A and again 
here, in Figure 6.5 A basal ROS generation is significantly increased in THP1ara-C(1) 
cells compared to that of their control wt THP1. Therefore, we next wanted to investigate 
whether miR-196a was involved in ROS generation in ara-C resistant; THP1ara-C(1) 
cells. (B) miR-196a mimic was transfected into THP1ara-C(1) cells using nucleofection 
before incubation with H2DCFDA, cells were harvested and ROS generation analysed 
using flow cytometry. However, when miR-196a is over-expressed a decrease in ROS 
generation was observed, potentially indicating miR-196a is involved in ROS regulation. 
We next wanted to investigate cell viability using CellTitre-Glo® Luminescence Viability 
Assay in response to increased miR-196a expression and reduced ROS generation. 
(Figure 6.6 A) Cell viability was reduced over a 48 h time course in the presence of 
increased miR-196a expression. (B) Finally, we wanted to explore what effect increased 
miR-196a expression would have on the cells ability to cycle. Both wt THP1 and 
THP1ara-C(1) cells were transfected with either the miR-196a mimic or unscrambled 
control via nucleofection. A decrease in S phase was seen in both wt THP1 + M and 
THP1ara-C(1) + M cells in response to increased miR-196a expression compared to 
their relevant controls. However a slight increase in G1 and a decrease in G2 phase was 
seen in the THP1ara-C(1) + M compared to their control; THP1ara-C(1) cells.  
 
6.3.5 In response to over-expressed miR-196a, Bach1 expression was down 
regulated whilst the cytoprotective gene, HO-1 expression was enhanced in the 
ara-C resistant THP1ara-C(1) cells. Both wt THP1 and THP1ara-C(1) cells were 
transfected with either miR-196a mimic or unscrambled control before Bach1 and HO-1 
mRNA expression was analysed using qRT-PCR. Figure 6.7 A shows a decrease in 
Bach1 mRNA and an increase in HO-1 mRNA expression in response to the miR-196a 
mimic in both ara-C resistant THP1ara-C(1) cells and control wt THP1 cells. Increased 
Bach1 mRNA expression and decreased HO-1 mRNA expression was also seen 
between the wt THP1 control cells and the ara-C resistant THP1ara-C(1) control cells.  
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Figure 6.5: ROS regulation is reduced in response to increased miR-196a 
expression.  (A) wt THP1 and THP1ara-C(1) AML cells were incubated with H2DCFDA 
(1 µM) for 30 min. Cells were harvested and re-suspended in PBS. ROS production was 
measured using flow cytometry (n = 7). (B) 2 x106 THP1ara-C(1) cells were transfected 
with either unscrambled control siRNA (25 μM) or miR-196a siRNA (25 μM) via 
nucleofection technology and incubated for 24 h before being incubated with H2DCFDA 
(1 µM) for 30 min. Cells were treated as previously outlined in A. Bars represent the 
mean ±SEM (n = 3). Statistical significance was calculated by Students t-test; * p≤0.05.  
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Figure 6.6: Increased miR-196a expression results in decreased cell viability. (A) 
cell viability was assessed 24 and 48 h post transfection with CellTitre-Glo® 
Luminescence Viability Assay (n = 3). (B) 2 x106 wt THP1 and THP1ara-C(1) cells were 
transfected with either unscrambled control siRNA (25 μM) or miR-196a siRNA (25 μM) 
via nucleofection technology and incubated for 48 h before cells were fixed and stained 
with PI before Cell cycling was determine using flow cytometry. Bars represent the mean 
±SEM (n = 3). Statistical significance was calculated by Students t-test; * p≤0.05. 
(Abbreviations M = miR-196a mimic).  
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Figure 6.7: HO-1 expression is increased in the presence of increased miR-196a 
expression. (A) 2 x 106 wt THP1 and THP1ara-C(1) cells were transfected with either 
unscrambled control siRNA (25 μM) or miR-196a siRNA (25 μM) via nucleofection 
technology and incubated for 48 h before mRNA was collected from wt THP1, wt THP1 
+ M, THP1ara-C(1) and THP1ara-C(1) + M cells before Bach1 and HO-1 mRNA 
expression was analysed  using qRT-PCR.  Abbreviations M = miR-196a mimic. 
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6.3.6 ROS generation is increased further after additional ara-C exposure in 
THP1ara-C(1) cells. THP1ara-C(1) cells were treated with ara-C (10 μM) for 24 h and 
then incubated with H2DCFDA for a further 30 min before ROS generation was 
determined using flow cytometry. Figure 6.8 A shows a significant increase in ROS 
generation in response to additional ara-C exposure. (B) THP1ara-C(1) cells were 
transfected with either unscrambled siRNA or miR-196a mimic 24 h before ara-C (10 
μM) treatment. Cell viability was determined 24 and 48 h post ara-C treatment using 
CellTitre-Glo® Luminescence Viability Assay. Cell viability remained unchanged with the 
addition of ara-C at both 24 and 48 h which we have previously shown (Chapter 4: 4.2 
A) However, a decrease in the percentage of viable cells was seen in the presence of 
increased miR-196a expression at both 24 and 48 h, of which 24 h was significant. 
Finally, we wanted to explore cell viability in response to both increased miR-196a 
expression and additional ara-C treatment. A significant decrease in cell viability was 
seen at both 24 and 48 h potentially suggesting increased miR-196a expression is 
reversing THP1ara-C(1) cells ara-C acquired resistance. 
 
6.3.7 Even when weekly ara-C refreshment is withdrawn, Bach1 mRNA expression 
remains elevated in THP1ara-C(1) TW cells. We wanted to explore whether both miR-
196a miRNA and Bach1 mRNA expression were altered upon withdrawal of ara-C 
weekly refreshment. Therefore we withdraw weekly ara-C refreshment for at least 4 
weeks before examining miRNA and mRNA expression using qRT-PCR. Figure 6.9 A 
indicates miR-196a is down regulated, whilst its target gene, (B) Bach1 mRNA 
expression is significantly increased in THP1ara-C(1) TW cells. Suggesting up regulated 
Bach1 expression is involved in ara-C acquired resistance as opposed to just the 
presence of continual ara-C exposure.  
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Figure 6.8: ROS generation is increased further when ara-C resistant cells; 
THP1ara-C(1) are treated with additional ara-C. (A) 1 x 106 THP1ara-C(1) cells 
treated with ara-C (10 μM) for 24 h before cells were collected and incubated with the 
fluorescent probe H2DCFDA (1 µM) for 30 min before ROS production was measured 
using flow cytometry. (B) 2 x 106 THP1ara-C(1) cells were transfected with either 
unscrambled control siRNA (25 μM) or miR-196a siRNA (25 μM) via nucleofection 
technology and incubated for 24 h before ara-C treatment (10 μM). Cell viability was 
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assessed 24 and 48 h post ara-C treatment with CellTitre-Glo® Luminescence Viability 
Assay (n = 3).  Bars represents mean ±SEM (n = 3). Statistical significance was 
calculated by (A) Students t-test; * p≤0.05 and (B) ANOVA; * p≤0.05.  
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Figure 6.9: Bach1 mRNA expression in THP1ara-C(1) TW remains elevated.  (A) 
miRNA and mRNA was collected from wt THP1 and THP1ara-C(1) TW cells miR-196a 
basal expression and (B) Bach1 basal expression was analysed using qRT-PCR. Bars 
represent the mean ±SEM (n = 3). Statistical significance was calculated by Students t-
test; * p≤0.05.  
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6.4 Discussion  
We have previously explored the expression profile of key cytoprotective genes involved 
in cellular cytoprotection. Therefore we wanted to examine the expression profile of 
miRNAs either known or predicted to target genes involved in cellular cytoprotection. We 
have previously shown in Chapter 4 Nrf2, HO-1 and NQO1 are all down regulated in the 
ara-C resistant THP1ara-C(1) cell line. Figure 6.10 highlights miRNAs known to target 
both transcription factors and genes whos expression is differential regulated in the 
THP1ara-C(1) cells compared to their control wt THP1 counterparts.  
 
 
 
Figure 6.10: Overview of miRNA targets. A diagrammatic representation of which 
miRNAS have been proven or predicted to target Bach1, HO-1, Keap1 and Nrf2s 
expression. 
 
HO-1 is down regulated in the ara-C resistant THP1ara-C(1) cells, however all of the 
miRNAs either known or predicted to target HO-1 expression, which we examined were 
up regulated apart from miR-122.  
 
Both miR-101 and miR-132 are predicted to target Nrf2 by microRNA.org [142], 
however, their expression is down regulated alongside Nrf2s in the THP1ara-C(1) cells.  
Either suggesting both of these miRNAs do not target Nrf2 in AML cell lines or their 
effect on Nrf2 expression is over thrown by other miRNAs/ transcription factors. Further 
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investigation to confirm the miRNA and mRNA targeting relationship would be required 
to comment on the involvement of these two miRNAs.   
 
Both miR-155 and miR-196a have previously been shown to regulate Bach1 expression. 
miR-155 miRNA and Bach mRNA were both up regulated in the ara-C resistant cells, 
THP1ara-C(1) cells whilst miR-196a expression was down regulated. miR-155 have 
been shown to target Bach1 in endothelial cells [141]. However there appears to be a 
difference in miR-196a and miR-155 miRNA expression in the THP1ara-C(1) cells. The 
difference in miRNA expression could be due to miR-155 posing a different function 
within AML cells and potentially therefore is not targeting Bach1. Or miR-196a and 
Bach1s targeting relationship is greater, therefore miR-155 effect on Bach1s regulation 
is being over ridden. However both miR-196a and miR-155 are known to repress Bach1 
expression [124, 141]. We also need to consider miR-155 and miR-196a regulate a 
number of other genes as well as Bach1 and their expression is also directly or indirectly 
regulated by other transcription factors and genes.   
 
Here we have shown miR-196a is down regulated in the ara-C resistant THP1ara-C(1) 
cell line compared to its wt THP1 control. Xia et al (2008) have also reported decreased 
miR-196a expression in SGC7901/VCR cells, a multi-drug resistant gastric cancer cell 
line [145]. Potentially linking miR-196a to cell acquired drug resistance. Hou et al (2010) 
have previously reported miR-196a targets Bach1 in human hepatoma cells [124]. We 
have also confirmed miR-196a and Bach1s relationship in HEK 293 cells using the Dual 
Glo Detection Luciferase Assay Kit. Bach1 expression is up regulated in the ara-C 
resistant THP1ara-C(1) cells, whilst the cytoprotective transcription factor and genes; 
Nrf2, HO-1 and NQO1 are all down regulated as previously shown. When miR-196a was 
over expressed in THP1ara-C(1) cells a significant decrease in Bach1 expression was 
seen, thus reiterating that Bach1 is one of miR-196a targets. In response to over 
expressed miR-196a miRNA, the cytoprotective gene HO-1 expression is increased in 
both wt THP1 and THP1ara-C(1) cells.   
 
We experienced a number of technical problems during the optimisation of the Dual Glo 
Detection Luciferase Assay which are outlined in Diagram 6.13. Briefly, wt THP1 cells 
are notoriously known to be difficult to transfect, thus we eventually decided to use HEK 
293 cells as a tool to confirm the miRNA and mRNA relationship instead, even though 
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they are a different type of cell line, after extensive literature review we established the 
norm in miRNA research is to present the relationship between the miRNA under 
investigation and its target mRNA in HEK 293 cells.    
 
We have previously shown in Chapter 4 Figure 4.9 A, ROS expression is elevated in the 
ara-C resistant THP1ara-C(1) cells. However when miR-196a is over expressed ROS 
generation is in turn reduced. Potentially suggesting miR-196a is implicated in ROS 
generation and cellular cytoprotection. However, ROS generation is increased further in 
response to ara-C (10 µM) exposure in additional to their weekly ara-C refreshment in 
THP1ara-C(1) cells. Furthermore, when THP1ara-C(1) cells are treated with additional 
ara-C (10 µM) and miR-196a is over expressed via the addition of a miR-196a mimic 
and nucleofection, decreased cell viability was seen. Potentially suggesting reduced 
Bach1 expression and reduced ROS generation is reversing THP1ara-C(1), ara-C 
acquired resistance. 
 
When miR-196a was over expressed in the ara-C resistant THP1ara-C(1) cells, the 
percentage of cells undergoing each phase of the cell cycling was altered. A reduction in 
S phase and an increase in G1 phase was seen in the THP1ara-C(1) cells.  
 
However when continual ara-C treatment is withdrawn; decreased basal miR-196a 
expression and increased Bach1 mRNA expression is still seen in the THP1ara-C(1) TW 
cells. 
 
 
Figure 6.11: Reduced Bach1 expression leads to increased ara-C induced cell 
death. 
 
To conclude reducing Bach1 expression in ara-C resistant THP1ara-C(1) cells reverses 
ara-C acquired resistant whilst reducing ROS generation. Therefore targeting and 
inducing miR-196a expression in acquired ara-C resistant AML cells could potentially 
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prove to be a viable method of treatment. However further investigating surrounding 
miR-196a and Bach1 relationship needs to be explored in vitro with ara-C resistant AML 
patients samples.  
 
 
 
Figure 6.12: Overview of reversing ara-C acquired resistance in THP1ara-C(1) 
cells.  
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Figure 6.13: Luciferase time line. Diagrammatic represenation of the problems 
encounterd during luciferase assay optimisation. 
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Chapter 7: Discussion 
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7.1 Overview of results. We have shown an increase in both HO-1 expression and 
ROS generation in AML primary cells and AML derived cell lines in response to ara-C 
and DNR exposure. However when HO-1 was silenced, cell viability in response to 
chemotherapeutic exposure was increased indicating HO-1s involvement in acquired 
cellular resistance. Next we explored ara-C acquired resistance by developing a ara-C 
resistant form of an AML derived cell line THP1 (THP1ara-C(1), by continual exposure to 
ara-C. Differential regulation of the cytoprotective gene HO-1 was seen in response to 
ara-C acquired resistance whilst ROS generation was enhanced. However upon 
withdrawal of continual ara-C exposure, ROS generation is once again reduced but the 
cells still maintain resistance towards ara-C. Finally miRNAs which target cytoprotective 
gene expression were explored in both the wt THP1 and THP1ara-C(1) cells. miR-196a 
known to target Bach1 is down regulated in response to ara-C acquired resistance whist 
its target is up-regulated. 
 
7.2 Does HO-1 rescue AML cells from induced cell death? We have previously 
shown in AML derived cell lines, NF-κB inhibition results in acquired cellular resistance 
towards TNF induced cell death. Furthermore an increase in HO-1 mRNA expression 
was seen in response to TNF stimulation when NF-κB was inhibited TNF stimulation 
induced ROS generation, which in turn induced Nrf2 mRNA expression followed by HO-
1 mRNA induced expression and thus protection from cell death [57]. Increased basal 
NF-κB expression has been reported in AML cells compared to their non-cancerous 
counterparts [46]. We have also previously shown HO-1 acts as a silent anti-apoptotic 
factor. Its expression is revealed and induced only when NF-κB is inhibited. Whilst HO-
1s basal expression is suppressed in AML cells compared to control CD34+ non-
malignant cells. In AML cells HO-1 mRNA suppression is regulated by NF-κB subunits 
p50 and p65. When both NF-κB and HO-1 mRNA expression was inhibited in AML cells 
a significant decrease in cell viability was reported compared to the non-cancerous 
control cells. This potentially suggests, inhibiting both HO-1 and NF-κB expression could 
be a viable therapeutic target for targeted AML treatment [49]. FLIP has been shown to 
indirectly induce HO-1 mRNA regulation in AML cells in response to TNF stimulation, 
however this response does not occur in non-cancerous control cells. When FLIPLs 
expression is knocked down, an increase in HO-1 mRNA expression within a small 
population of these cells is reported displaying cytoprotection and increased resistance 
towards TNF induced cell death [76]. Finally we have reported induced Nrf2 mRNA 
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expression in response to bortezomib exposure which subsequently leads to induced 
HO-1 mRNA expression and cytoprotection in AML derived cell lines [47]. A similar 
induction in HO-1 expression was also seen in both primary AML cells and cell lines in 
response to ara-C, DNR or a combination thereof exposure [101].  
 
The regulation of HO-1 in response to TNF stimulation differs between both AML and 
non-cancerous human monocytes. Suggesting the regulation of both transcription 
factors and genes involved in the cells cytoprotective responses are differential 
regulated during cancer progression. We have shown TNF regulation is responsible for 
the expression of the transcription factor Nrf2, via the generation of ROS in human 
monocytes. Nrf2 then subsequently induces the expression of both cytoprotective and 
detoxifying genes. However, the expression of HO-1 mRNA is reduced in response to 
TNF stimulation within these cells, consistent with other reported results [146]. This is 
the reverse of what was reported in AML derived cell lines stimulated by TNF.  
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Figure 7.1 The regulation of HO-1 in response to chemotherapeutic exposure, TNF 
stimulation and NF-κB inhibition within AML cells. Diagrammatic representation of 
results reported by Professor MacEwan’s laboratory regarding HO-1 induction in 
response to various stimuli in primary AML cells and AML derived cell lines. (1) TNF 
stimulation induces Nrf2 expression which induces HO-1 expression [57]. (2) NF-κB 
subunits p50 and p65 inhibit HO-1 expression however inhibition of NF-κB results in 
induced HO-1 expression [49]. (3) Bortezomib exposure up-regulates Nrf2 expression 
which in turn induces HO-1 expression [47]. (4) Ara-C and DNR exposure induces HO-1 
expression [101]. (5) FLIP indirectly induces HO-1 expression in response to TNF 
stimulus [76] .  
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Figure 7.2: The transcription factor, Nrf2 induces cytoprotective and detoxification 
gene expression in response to TNF activation in human monocytes. ROS 
generation regulates the transcription factor, Nrf2 activation in response to TNF 
stimulation. Nrf2 subsequently induces NQO1, GSTA1 and GCLM  mRNA expression. 
However HO-1 mRNA remains un-regulated. Diagram based on results reported by 
Rushworth et al (2011) [146] . 
  
The concept behind HO-1 potentially rescuing AML cells from undergoing induced 
apoptosis either by TNF stimulation or exposure to chemotherapeutic agents has been 
extensively researched within the group. The AML cells ability to induce HO-1 
expression and potentially lead to resistance upon chemotherapeutic exposure lead to 
the development of the ara-C resistant THP1 cell line (THP1ara-C(1)). Where we 
explored cytoprotective gene expression and proliferation rate, in response to continual 
ara-C exposure and acquired ara-C resistance during the course of this research project. 
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However basal Nrf2, HO-1 and NQO1 mRNA and protein expression was reduced in 
response to continual ara-C exposure. Finally, we explored miRNAs and their target 
genes expression involvement in cytoprotection within AML cells and ara-C resistance 
development. 
 
7.3. Ara-C and DNR both induce HO-1 expression. Initially in chapter 3 we reported 
for the first time, HO-1 mRNA and protein expression is induced in response to exposure 
to ara-C, DNR or a combination thereof in both AML derived cell lines and AML patient 
samples. Furthermore, when the chemotherapeutics agents were used in combination, a 
further increase in HO-1 mRNA and protein induction was seen. This could be due to 
both ara-C and DNR utilising different modes of action. A number of groups have 
reported induced HO-1 expression in response to chemotherapeutic exposure within 
leukaemia cells. For example Barrera et al (2012) observed an increases in HO-1 mRNA 
expression in response to bortezomib exposure in the MM cell line RPMI8226 [46].  
 
ROS generation in both wt THP1 and U937 cells was also increased in response to ara-
C or DNR exposure. Interestingly ROS generation was enhanced with increasing 
chemotherapeutic exposure time. A number of other agents for example, the 
antieoplastic, niclosamide has been shown to also induce ROS generation [117]. 
Niclosamide has been observed inhibiting the NF-ƘBpathway whilst inducing ROS 
generation resulting in induced cellular apoptosis. Jin et al (2010) went on to explore the 
connection between both processes involved in apoptosis and revealed they were 
independent of each other. Interestingly when niclosamide was used in combination with 
other agents; ara-C, DNR or etoposide its affect was synergetic. These results show 
promise and enhance niclosamide potential as an chemotherapeutic agent suitable for 
trial consideration in AML treatment [117].  
 
Interestingly when HO-1 expression was silenced in both wt THP1 and U937 cells, cell 
viability was reduced upon chemotherapeutic exposure. Potentially indicating HO-1 is 
involved in cellular cytoprotection and acquired resistance. In hindsight we should have 
explored the effect of HO-1 silencing on ROS generation to establish whether ROS is 
involved in acquired chemotherapeutic resistance. 
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Figure 7.3: HO-1 expression is induced in response to ara-C exposure in AML 
cells. Diagrammatic prediction of cytoprotective gene regulation in response to ara-C 
stimulation. Control; In the cytoplasm, Nrf2 is bound to Keap1, whilst Bach1 is bound to 
MARE within the nucleus. Upon ara-C stimulation, Nrf2 is released from Keap1, its 
transported from the cytoplasm into the nucleus and binds to MARE. Subsequently up 
regulating the expression of the cytoprotective genes.  
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7.3.1 Development of ara-C acquired resistance and its impact on induced cell 
apoptosis. To be able to explore ara-C acquired resistance further we developed a ara-
C resistance THP1 cell line (THP1ara-C(1)) by increasing ara-C exposure gradually over 
a 9 week period. THP1ara-C(1) cells were refreshed weekly with ara-C (1 µM). The 
developed cell line was used as a model to explore the relationship between ara-C 
acquired resistance and cytoprotective gene regulation in response to chemotherapeutic 
exposure within AML cells. 
 
The THP1ara-C(1) cells showed decreased sensitivity towards therapeutic 
concentrations of ara-C compared to their wt THP1 control cells. However the ara-C 
resistant THP1ara-C(1) cells have maintained sensitivity towards other 
chemotherapeutic agents used in AML treatment; DNR and etoposide and to a lesser 
extent bortezomib. Similar findings were reported by Abe et al [42] when exploring the 
K562ara-C cell lines sensitivity towards etoposide [42-43], indicating ara-C utilises a 
different method of action compared to the other agents investigated. Decreased dCK 
mRNA expression was reported within the ara-C resistant K562ara-C cell line. dCK 
phosphorylates ara-C into ara-CTP which is subsequently incorporated into cellular 
DNA. Thus dCK action is imperative to ara-C therapeutic function. The decrease in dCK 
expression potentially explains K562ara-C acquired ara-C resistance [44]. 
 
As previously mentioned, HO-1 mRNA and protein expression was induced in response 
to ara-C, DNR or a combination thereof exposure in both AML derived cell lines and 
AML primary cell. However in the ara-C resistant THP1ara-C(1) cells; Nrf2, HO-1 and 
NQO1 expression was down regulated even though they were continual exposed to ara-
C. Interestingly ROS generation remained elevated in response to ara-C exposure in 
both wt THP1 and THP1ara-C(1). Cell proliferation rate was affected and reduced in 
response to continual ara-C exposure and acquired resistance. 
 
7.3.2 Continual ara-C exposure withdrawn affects both proliferation rate and miR-
34a expression. Next we explored the effect of removing continual ara-C refreshment 
producing the ara-C resistant THP1ara-C(1) Treatment Withdrawn (THP1ara-C(1) TW) 
sub line. THP1ara-C(1) TW maintained sensitivity towards ara-C similar to that of the 
resistant THP1ara-C(1) cells. However both ROS and gluthatione generation was below 
that of the control wt THP1 cells. Interestingly Nrf2 mRNA expression was up regulated 
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in response to ara-C withdrawal but HO-1 and NQO1 mRNA was unchanged between 
them and their control wt THP1 counterparts. Furthermore, an increase in proliferation 
rate was seen and returned to that of the control wt THP1 cells.  
 
Ichimura et al reported repressed proliferation in response to over expressed miR-34a in 
K562 cells [97]. A similar response was seen in our ara-C resistant THP1ara-C(1) cells,  
were miR-34a was over expressed whilst cell proliferation rate was reduced compared to 
the wt THP1 control cells. However, when weekly ara-C refreshment was withdrawn 
from the media both cell proliferation rate and miR-34a miRNA expression were returned 
to that of the wt THP1 control cells. Potentially indicating cell proliferation rate and miR-
34a expression are responsive towards ara-C refreshment and thus reversible.  
 
Abe et al (2006) assumed all cellular characteristics between both ara-C resistant and 
sensitive K562 cells remained identical unless differential expression was implicated in 
ara-C resistance [43]. Even though differential expression in cytoprotective genes was 
seen between our wt THP1 and both ara-C resistant THP1ara-C(1) and THP1ara-c(1) 
TW cells, miR-34a expression differed between the THP1ara-C(1) and THP1ara-C(1) 
TW cells. However, when continual ara-C refreshment was withdrawn, miR-34a 
expression was down regulated whilst cellular proliferation rate was also increased.   
 
7.3.3 Differential miRNA expression between ara-C resistant and non-resistant 
THP1 cells. miR-222 has been shown to target PTEN and PUMA. We have observed no 
difference in miR-222 between the THP1ara-C(1)  and wt THP1 cells. Interestingly Bai et 
al (2011) reported a decrease in miR-222 expression in their DNR resistant K562 
leukaemia cells which is the reverse to what we have reported in ara-C resistant THP-1 
cells [91]. Suggesting miR-222 is involved in DNR acquired resistance and not ara-C 
acquired resistance. However a decrease in both PTEN and PUMA mRNA expression 
was seen.  
 
Bai et al (2012) observed down regulated miR-181a expression in the ara-C resistant 
HL60 cell line (HL60/Ara-C) which showed reduced sensitivity towards both ara-C at 1 
and 10 μM [96]. Similar to what was seen in the ara-C resistant THP1ara-C(1) cells. 
miR-181a has been reported and confirmed to target Bcl-2 in HL60 cells. The authors 
noted increased basal Bcl-2 protein expression in the ara-C resistant HL60/Ara-C cells. 
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However when miR-181a was over expressed in the ara-C resistant HL60/Ara-C cells, 
sensitivity towards ara-C treatment was developed alongside decreased Bcl-2 
expression. Moreover, when Bcl-2 expression was knocked down using siRNA a similar 
survival response was seen therefore confirming miR-181a role within ara-C acquired 
resistance. The authors go on to suggest the expression of miR-181a during ara-C 
treatment could potentially be targeted as a possible AML treatment [99].  
 
However Bcl-2, Bcl-xl and Bax expression is indifferent between both the ara-C 
resistant, THP1ara-C(1) and control wt THP1 cells. Thus potentially indicating Bcl-2 is 
not involved in ara-C acquired resistance in THP1 cells. Interestingly miR-15a has also 
been shown to target Bcl-2 in MEG-01 cells [118], yet again this does not appear to be 
the case in the ara-C resistant THP1ara-C(1) cells.  
 
Yang et al (2011) miR-28 has been shown to target Nrf2 in breast epithelial cells. Over 
expression of miR-28 results in a reduction in endogenous Nrf2 mRNA and Nrf2 protein 
expression which is independent of Keap1 involvement with Nrf2 and its Keap1 protein 
expression. The authors go on to suggest miR-28 could control breast cancer 
progression by utilising the Nrf2 pathway [147]. 
 
7.4 Exploring miR-196a and its target, Bach1s relationship. We have reported 
reduced miR-196a and increased Bach mRNA expression in the ara-C resistant THP1 
ara-C(1) cell line compared to their wt THP1 control. As previously mentioned Bach1 
inhibits the expression of cytoprotective genes such as HO-1 and NQO1. Thus 
potentially explaining why these cytoprotective genes and their transcription factor Nrf2 
regulation is reduced in response to ara-C acquired resistance. However ROS 
generation still remains elevated in the presence of continual ara-C exposure.  
Furthermore, when miR-196a expression was increased via the addition of a miR-196a 
mimic, both Bach1 and ROS generation were reduced. Upon stimulation with additional 
ara-C a decrease in cell viability was seen therefore suggesting miR-196a is potentially 
involved in reversing the acquired ara-C resistance developed by these cells (THP1ara-
C(1). 
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7.5 General conclusions 
To conclude HO-1 is involved in cellular cytoprotective responses against the front-line 
chemotherapeutic agents; ara-C and DNR, in both primary AML samples and AML 
derived cell lines.  We show here for the very first time a crucial role for HO-1 and its 
transcription factor Nrf2, involvement in drug-resistance mechanisms developed by AML 
cells. We have shown acquired ara-C resistance is a stable response and irreversible 
upon withdrawal of ara-C from the cellular environment. We have also highlighted miR-
196a and its target Bach1 have a fundamental role in this drug-resistance AML model.  
The interrelationship between Bach1, HO-1 and Nrf2 were uncovered. Moreover, the 
potential for pharmacological intervention with miR-mimics or anti-miRs that target HO-1, 
Nrf2 or Bach1 have been proven. 
 
7.6 Future work 
A number of areas of investigation have been highlighted during the course of this 
extended research project.  The studies that I believe would shed most light on the drug 
resistance mechanisms that we were investigating include experiments to explore 
whether: 
 THP1 cells also respond in a similar manner.  One would develop a DNR-
resistant THP1 cell line and repeat the key experiments, to uncover whether 
there are any similarities between DNR-resistant cells and the THP1ara-C(1) 
cells.  
 Explore etoposide resistance.  Etoposide is only used as an add on therapy in 
the clinic to treat AML, so these studies would be of less relevance.  
 Branch out to other leukaemia cell lines regarding ara-C resistance for example 
U937, K562 and HL60. 
 Find out what the role of miR-196a is in multiple myeloma cells.  These studies 
are ongoing within the group currently. 
 Further explore the role of Annexin A1 and miR-196a in regards to cell 
proliferation and apoptotic balance within AML cells. 
 Explore the influence of bortezomib in more depth, and discover whether the 
miRNA changes that we observed here, are also true of brotezomib-resistance.  
 Explore ara-C and DNR effects on the NF-κB pathways in both ara-C resistant 
and control non-resistant AML cells.  
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 Explore miR-181a involvement in ara-C resistance in the THP1ara-C(1) cell line. 
Additionally, find out why Bcl-2 regulation is indifferent between the wt THP1 and 
THP1ara-C(1) cell types.  
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SBI QuantiMir Cancer Array 
Well MicroRNA MicroRNA Sequence(s) Well MicroRNA MicroRNA Sequence(s)
A1 let-7-family ugagguaguagguuguauaguu, 
ugagguaguagguuguaugguu, 
agagguaguagguugcauagu, 
ugagguaguagauuguauaguu 
E1 miR-18a uaaggugcaucuagugcagaua
A2 miR-7 uggaagacuagugauuuuguug E2 miR-190 ugauauguuugauauauuaggu
A3 miR-92a uauugcacuugucccggccug E3 miR-191 caacggaaucccaaaagcagcu
A4 miR-93 aaagugcuguucgugcagguag E4 miR-192 cugaccuaugaauugacagcc
A5 miR-9 ucuuugguuaucuagcuguauga E5 miR-194 uguaacagcaacuccaugugga
A6 miR-101 uacaguacugugauaacugaag E6 miR-195 uagcagcacagaaauauuggc
A7 miR-103 agcagcauuguacagggcuauga E7 miR-196a uagguaguuucauguuguugg
A8 miR-106a aaaagugcuuacagugcagguagc E8 miR-197 uucaccaccuucuccacccagc
A9 miR-106b uaaagugcugacagugcagau E9 miR-198 gguccagaggggagauagg
A10 miR-107 agcagcauuguacagggcuauca E10 miR-199a+b cccaguguucagacuaccuguuc, 
cccaguguuuagacuaucuguuc
A11 miR-10b uacccuguagaaccgaauuugu E11 miR-30b uguaaacauccuacacucagcu
A12 miR-1 uggaauguaaagaaguaugua E12 miR-19a+b ugugcaaaucuaugcaaaacuga, 
ugugcaaauccaugcaaaacuga
B1 miR-122 uggagugugacaaugguguuugu F1 miR-95 uucaacggguauuuauugagca
B2 miR-125a-5p ucccugagacccuuuaaccugug F2 miR-20a uaaagugcuuauagugcagguag
B3 miR-125b ucccugagacccuaacuuguga F3 miR-200a uaacacugucugguaacgaugu
B4 miR-126 cauuauuacuuuugguacgcg F4 miR-200b uaauacugccugguaaugaugac
B5 miR-128 ucacagugaaccggucucuuuc F5 miR-200c uaauacugccggguaaugaugg
B6 miR-132 uaacagucuacagccauggucg F6 miR-202 agagguauagggcaugggaaaa
B7 miR-133a uugguccccuucaaccagcugu F7 miR-203 gugaaauguuuaggaccacuag
B8 miR-134 ugugacugguugaccagaggg F8 miR-204 uucccuuugucauccuaugccu
B9 miR-135b uauggcuuuucauuccuaugug F9 miR-205 uccuucauuccaccggagucug
B10 miR-136 acuccauuuguuuugaugaugga F10 miR-206 uggaauguaaggaagugugugg
B11 miR-137 uauugcuuaagaauacgcguag F11 miR-21 uagcuuaucagacugauguuga
B12 miR-140 agugguuuuacccuaugguag F12 miR-210 cugugcgugugacagcggcuga
C1 miR-141 uaacacugucugguaaagaugg G1 miR-214 acagcaggcacagacaggcag
C2 miR-142-3p uguaguguuuccuacuuuaugga G2 miR-215 augaccuaugaauugacagac
C3 miR-143 ugagaugaagcacuguagcuca G3 miR-372 aaagugcugcgacauuugagcgu
C4 miR-145 guccaguuuucccaggaaucccuu G4 miR-373 gaagugcuucgauuuuggggugu
C5 miR-146a ugagaacugaauuccauggguu G5 miR-218 uugugcuugaucuaaccaugu
C6 miR-149 ucuggcuccgugucuucacucc G6 miR-219 ugauuguccaaacgcaauucu
C7 miR-150 ucucccaacccuuguaccagug G7 miR-22 aagcugccaguugaagaacugu
C8 miR-151 acuagacugaagcuccuugagg G8 miR-488 cccagauaauggcacucucaa
C9 miR-153 uugcauagucacaaaaguga G9 miR-221 agcuacauugucugcuggguuuc
C10 miR-154 uagguuauccguguugccuucg G10 miR-222 agcuacaucuggcuacugggucuc
C11 miR-155 uuaaugcuaaucgugauagggg G11 miR-223 ugucaguuugucaaauacccc
C12 miR-15a uagcagcacauaaugguuugug G12 miR-224 caagucacuagugguuccguuua
D1 miR-15b uagcagcacaucaugguuuaca H1 miR-23a aucacauugccagggauuucc
D2 miR-16 uagcagcacguaaauauuggcg H2 miR-24 uggcucaguucagcaggaacag
D3 miR-17* acugcagugaaggcacuugu H3 miR-25 cauugcacuugucucggucuga
D4 miR-17 caaagugcuuacagugcagguagu H4 miR-26a uucaaguaauccaggauaggc
D5 miR-181a aacauucaacgcugucggugagu H5 miR-26b uucaaguaauucaggauagguu
D6 miR-181b aacauucauugcugucgguggg H6 miR-27a+b uucacaguggcuaaguuccgc, 
uucacaguggcuaaguucugc
D7 miR-181c aacauucaaccugucggugagu H7 miR-30c uguaaacauccuacacucucagc
D8 miR-181d aacauucauuguugucgguggguu H8 miR-29a+b+c uagcaccaucugaaaucgguu, 
uagcaccauuugaaaucaguguu, 
uagcaccauuugaaaucggu
D9 miR-183 uauggcacugguagaauucacug H9 miR-30a* cuuucagucggauguuugcagc
D10 miR-185 uggagagaaaggcaguuc H10 miR-30a uguaaacauccucgacuggaag
D11 miR-186 caaagaauucuccuuuugggcuu H11 miR-296 agggcccccccucaauccugu
D12 miR-188-5p caucccuugcaugguggaggg H12 U6 snRNA CGCAAGGAUGACACGCAAAUUC
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SBI QuantiMir Stem cell array 
Well MicroRNA MicroRNA assay Well MicroRNA MicroRNA assay
A1
miR-18a TAAGGTGCATCTAGTGCAGATA
E1
miR-101 TACAGTACTGTGATAACTGAAG
A2 miR-19a TGTGCAAATCTATGCAAAACTGA E2 miR-107 AGCAGCATTGTACAGGGCTATCA
A3 miR-19b TGTGCAAATCCATGCAAAACTGA E3 miR-126 CATTATTACTTTTGGTACGCG
A4 miR-24 TGGCTCAGTTCAGCAGGAACAG E4 miR-130a CAGTGCAATGTTAAAAGGGCAT
A5 miR-25 CATTGCACTTGTCTCGGTCTGA E5 miR-142-5p CATAAAGTAGAAAGCACTAC
A6 miR-17-5p CAAAGTGCTTACAGTGCAGGTAGT E6 miR-142-3p TGTAGTGTTTCCTACTTTATGGA
A7 miR-30c TGTAAACATCCTACACTCTCAGC E7 miR-146a TGAGAACTGAATTCCATGGGTT
A8 miR-34a TGGCAGTGTCTTAGCTGGTTGTT E8 miR-146b TGAGAACTGAATTCCATAGGCT
A9 miR-106a AAAAGTGCTTACAGTGCAGGTAGC E9 miR-155 TTAATGCTAATCGTGATAGGGG
A10
miR-106b TAAAGTGCTGACAGTGCAGAT
E10
miR-181a AACATTCAACGCTGTCGGTGAGT
A11 miR-130b CAGTGCAATGATGAAAGGGCAT E11 miR-181b AACATTCATTGCTGTCGGTGGG
A12 miR-141 TAACACTGTCTGGTAAAGATGG E12 miR-181c AACATTCAACCTGTCGGTGAGT
B1 miR-150 TCTCCCAACCCTTGTACCAGTG F1 miR-181d AACATTCATTGTTGTCGGTGGGTT
B2 miR-199a CCCAGTGTTCAGACTACCTGTTC F2 miR-191 CAACGGAATCCCAAAAGCAGCT
B3 miR-200b TAATACTGCCTGGTAATGATGAC F3 miR-193a AACTGGCCTACAAAGTCCCAG
B4 miR-200c TAATACTGCCGGGTAATGATGG F4 miR-193b AACTGGCCCTCAAAGTCCCGCTTT
B5 miR-301 CAGTGCAATAGTATTGTCAAAGC F5 miR-197 TTCACCACCTTCTCCACCCAGC
B6 miR-302a TAAACGTGGATGTACTTGCTTT F6 miR-221 AGCTACATTGTCTGCTGGGTTTC
B7 miR-302b ACTTTAACATGGAAGTGCTTTCT F7 miR-223 TGTCAGTTTGTCAAATACCCC
B8 miR-302c TTTAACATGGGGGTACCTGCTG F8 miR-339 TCCCTGTCCTCCAGGAGCTCA
B9 miR-302d TAAGTGCTTCCATGTTTGAGTGT F9 miR-9 TCTTTGGTTATCTAGCTGTATGA
B10 miR-367 AATTGCACTTTAGCAATGGTGA F10 miR-103 AGCAGCATTGTACAGGGCTATGA
B11 miR-368 ACATAGAGGAAATTCCACGTTT F11 miR-124a TTAAGGCACGCGGTGAATGCCA
B12 miR-369-5p AGATCGACCGTGTTATATTCGC F12 miR-125a TCCCTGAGACCCTTTAACCTGTG
C1 miR-369-3p AATAATACATGGTTGATCTTT G1 miR-125b TCCCTGAGACCCTAACTTGTGA
C2 miR-370 GCCTGCTGGGGTGGAACCTGG G2 miR-127 TCGGATCCGTCTGAGCTTGGCT
C3 miR-371 GTGCCGCCATCTTTTGAGTGT G3 miR-128a TCACAGTGAACCGGTCTCTTTT
C4 miR-372 AAAGTGCTGCGACATTTGAGCGT G4 miR-128b TCACAGTGAACCGGTCTCTTTC
C5 miR-373 ACTCAAAATGGGGGCGCTTTCC G5 miR-132 TAACAGTCTACAGCCATGGTCG
C6 let-7a TGAGGTAGTAGGTTGTATAGTT G6 miR-134 TGTGACTGGTTGACCAGAGGG
C7 let-7b TGAGGTAGTAGGTTGTGTGGTT G7 miR-135a TATGGCTTTTTATTCCTATGTGA
C8 miR-10a TACCCTGTAGATCCGAATTTGTG G8 miR-135b TATGGCTTTTCATTCCTATGTG
C9 miR-10b TACCCTGTAGAACCGAATTTGT G9 miR-136 ACTCCATTTGTTTTGATGATGGA
C10 miR-16 TAGCAGCACGTAAATATTGGCG G10 miR-138 AGCTGGTGTTGTGAATC
C11
miR-17-3p ACTGCAGTGAAGGCACTTGT
G11
miR-149 TCTGGCTCCGTGTCTTCACTCC
C12 miR-20a TAAAGTGCTTATAGTGCAGGTAG G12 miR-153 TTGCATAGTCACAAAAGTGA
D1
miR-20b CAAAGTGCTCATAGTGCAGGTAG
H1
miR-154 TAGGTTATCCGTGTTGCCTTCG
D2
miR-23a ATCACATTGCCAGGGATTTCC
H2
miR-183 TATGGCACTGGTAGAATTCACTG
D3
miR-23b ATCACATTGCCAGGGATTACC
H3
miR-218 TTGTGCTTGATCTAACCATGT
D4 miR-26a TTCAAGTAATCCAGGATAGGC H4 miR-219 TGATTGTCCAAACGCAATTCT
D5
miR-26b TTCAAGTAATTCAGGATAGGTT
H5
miR-222 AGCTACATCTGGCTACTGGGTCTC
D6
miR-30b TGTAAACATCCTACACTCAGCT
H6
miR-1 TGGAATGTAAAGAAGTATGTA
D7 miR-30d TGTAAACATCCCCGACTGGAAG H7 miR-122a TGGAGTGTGACAATGGTGTTTGT
D8
miR-32 TATTGCACATTACTAAGTTGC
H8
miR-133a TTGGTCCCCTTCAACCAGCTGT
D9 miR-33 GTGCATTGTAGTTGCATTG H9 miR-133b TTGGTCCCCTTCAACCAGCTA
D10 miR-92 TATTGCACTTGTCCCGGCCTG H10 miR-195 TAGCAGCACAGAAATATTGGC
D11 miR-93 AAAGTGCTGTTCGTGCAGGTAG H11 miR-206 TGGAATGTAAGGAAGTGTGTGG
D12 miR-99a AACCCGTAGATCCGATCTTGTG H12 U6 CGCAAGGAUGACACGCAAAUUC
154 
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Figure 8.1. wt THP1 resistance to various chemotherapeutics.  (A) wt THP1 cell 
were treated with amsacrine (0, 0.1, 0.5, 1, 5, 10 µM), DNR (0, 0.02, 0.05, 0.2, 0.5, 1 
μM) and etoposide (0, 0.1, 0.5, 1, 5, 10 μM).  Cells were stained with annexin-V and P1, 
number of viable cells was established using flow cytometry, (n = 1).  
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